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In recent years, the subsets of mammalian CD4+ T cells and their repertoire of 
effector cytokines has expanded beyond the original Th1/Th2 paradigm, to include 
natural (n) and inducible (i) regulatory T cells (Treg), Th17, Th9, Th22 and follicular 
T helper (Tfh) cells. Whilst Th1, Th2 and nTreg immune responses have been 
described in the chicken, the existence of other Th cell subsets is yet to be 
determined. To investigate Th17 immune responses in the chicken, the mammalian 
components of these responses currently unannotated in the chicken genome, IL-23 
p19 and the IL-23R, were identified and cDNAs cloned. A chicken IL-23 flexi-
construct, containing IL-23 p19 and p40 joined by a linker, was designed.  
Recombinant chicken IL-23 protein (rchIL-23) was expressed and purified. 
Bioactivity of rchIL-23 was demonstrated by increasd mRNA expression of chIL-
17F and chIL-22 in rchIL-23-stimulated splenocytes. Monoclonal antibodies which 
identify chIL-12/chIL-23 p40 also recognised purified rchIL-23. Further, chIL-23 
p19 mRNA levels were measured and detected in a wide range of tissues but was not 
up-regulated in stimulated splenocytes, thymocytes or bursal cells. 
Messenger RNA (mRNA) expression levels of Th17 cytokines (chIL-17A, chIL-17F, 
chIL-21, chIL-22 and chIL-23) were measured in a chicken tissue panel, in 
stimulated splenocytes, thymocytes and bursal cells, as well as during infections 
previously described as initiating typical Th1 or Th2 adaptive immune responses in 
the chicken. Chicken IL-17A mRNA expression levels were up-regulated in 
susceptible chickens during infection with Marek’s di ease virus (a disease which 
typically drives a Th1 immune response), but were down-regulated in resistant birds. 
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Chicken CD4+ T cells were sorted by fluorescence-activated cell sorting (FACS) and 
recombinant Th17-associated cytokines used to attemp  to drive the cells towards a 
Th17 phenotype, as measured by expression of mRNA for chIL-17A and chIL-23R. 
The sorted chicken CD4+ cells failed to proliferate or respond to Th17 cytokine 
stimulation. 
ChIL-23R was also correctly identified and cloned as cDNA, and its mRNA 
expression measured in a panel of unstimulated and stimulated tissues and cells. The 
chIL-23R mRNA levels were detected in a wide range of tissues as well as 
stimulated splenocytes, thymocytes and bursal cells. Future work would seek to 
positively identify Th17 cells in the chicken and determine the role of Th17 immune 
responses against avian diseases. 
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E. coli   Escherichia coli 
EDTA    Ethylenediaminetetraacetic acid 
eGFP   Enhanced Green Fluorescent Protein 
EID    Embryonic incubation day 
ELISA   Enzyme-linked immunosorbent assay 
EST   Expressed sequence tag 
ex-COS  Derived from COS-7 cells 
FACS   Fluorescence-activated cell sorting 
FAM   5- or 6-carboxyfluorescein 
FBS   Foetal bovine serum 
FITC   Fluorescein isothiocyanate 
FoxP3   Forkhead box P3 
FSC   Forward scatter 
γ   Gamma 
g   Gram 
g   Relative centrifugal force 
GATA3  trans-acting T-cell-specific transcription factor GATA-3 
G-CSF   Granulocyte -colony stimulating factor 
GALT   Gut-associated lymphoid tissues 
GI   Gastrointestinal 
GM-CSF  Granulocyte-macrophage colony-stimulating factor 
h   Hours 
H. meleagridis Histomonas meleagridis 
HEK   Human embryonic kidney  
HRP   Horseradish peroxidise 
hu   Human 
H2O   Water 
IBD   Inflammatory bowel disease  
IBDV   Infectious bursal disease virus 
IFN   Interferon  
Ig   Immunoglobulin  
IL   Interleukin 
ILC   Innate lymphoid cell 
IPTG   Isopropyl-beta-D-1-thiogalactopyranoside 
IRAK1  IL-1 receptor-associated kinase 
iTreg   Inducible Treg cells 
JAK   Janus kinase 
l   Litre 
LB   Lysogeny broth 
LPS   Lipopolysaccharide 
LRR   Leucine-rich repeats 
M   Molar 
mAbs   Monoclonal antibodies 
MACS   Magnetic-activated cell sorting 
MAD   Mothers against decapentaplegic protein 
MAPK   Mitogen-activated protein kinase 




MD   Marek’s disease 
MDV   Marek’s disease virus 
mg   Milligram 
MgCl2   Magnesium chloride 
MHC   Major histocompatibility complex  
min   Minute 
ml   Millilitre 
m   Mouse 
mRNA   Messenger ribonucleic acid 
MS   Multiple sclerosis 
NET   Neutrophil extracellular trap 
ng   Nanogram 
NK   Natural killer cells 
NKT   Natural killer T cells 
NLR   NOD-like receptor 
nm   Nanometre 
NOD   Nucleotide oligomerisation and binding domain 
NTC   No template control 
nt   Nucleotide 
nTreg   natural Treg cells 
°C   Degree (s) Celsius 
OD   Optical density 
ORF   Open reading frame 
p   Pico 
PAMP   Pathogen-associated molecular pattern 
PBMC   Peripheral blood mononuclear cell 
PBS   Phosphate-buffered saline 
PBST   Phosphate-buffered saline and Tween20 
PCR   Polymerase chain reaction 
PE   R-Phycoerythrin 
PHA   Phytohaemagglutinin 
PMA   Phorbol 12-myristate 13-acetate 
poly(A)  Polyadenylation 
Poly I:C  Polyinosinic:polycytidylic acid 
PRR   Pattern recognition receptor 
RT-qPCR  quantitative real-time RT-PCR 
r   Recombinant 
R   Receptor 
RACE   Rapid amplification of cDNA ends 
RAG   Recombination activating gene 
RAR   Retinoic-acid-related 
rch   Recombinant chicken protein 
RIG-I   Retinoic acid-inducible gene I 
RLR   RIG-I-like helicase receptor 
RNA   Ribonucleic acid  
RORγt   RAR-related orphan receptor gamma t 
ROS   Reactive oxygen species 




rRNA   ribosomal ribonucleic acid 
RT   Reverse transcriptase 
s   Second 
S. aureus  Staphylococcus aureus 
SOC   Super-optimal broth with catabolite repression 
SMA   Caenorhabditis elegans SMA protein 
SNP   Single nucleotide polymorphism 
SPF   Specific pathogen free 
STAT   Signal transducer and activator of transcription 
SV40   Simian virus 40 
TAE   Tris-acetate-EDTA 
TAMRA  Tetramethylrhodamine 
Taq   Thermus aquaticus 
TBE   Tris-borate-EDTA 
TCR   T cell receptor  
TGF   Transforming growth factor 
Th   T helper cell 
TIR   Toll/IL-1 receptor homology 
TLR   Toll-like receptor  
Tm   Melting temperature 
TNF   Tumour necrosis factor 
TR1   Type 1 regulatory T cells  
Treg   Regulatory T cell 
Tyk   Tyrosine kinase 
UTR   Untranslated region 
w/v   Weight per volume 
X-gal   5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside 
µ   Micro 
 
Chapter 1 Introduction 
1 
 
Chapter 1 Introduction 
Globally, chickens are one of the most important sources of protein, in the form of 
both meat and eggs, and are consequently a major res urce of food. Around 52 
billion chickens are reared per year and this immense supply and demand for poultry 
is increasing; approximately 91 million tonnes of chicken meat were consumed 
across the globe in 2012. In the UK alone there are ov r 850 million chickens 
produced for meat each year (Kaiser, 2010) and approximately 29 million laying 
hens generate over 1.1 billion eggs. As a result, poultry health and welfare are 
fundamental to the supply and safety of food. 
Poultry farming is carried out on an industrial scale nd birds are commonly farmed 
under very intensive conditions. In today’s world, it takes only 40 days for a broiler 
chicken to reach its target weight of 2 kg for slaughter. Layers have a longer lifespan 
and typically produce around 300 eggs per year. This level of poultry production is 
due to constant genetic selection for growth rates by chicken breeders, better 
understanding and quality of poultry nutrition and improved disease control 
programmes. Intensive rearing and processing techniques have also contributed to 
the massive increase in poultry production. With so many birds in close proximity to 
each other and under such growth pressure, the potential for disease outbreak is 
enormous. The financial implication of avian-specific disease in the poultry industry 
is great, despite routine vaccination against many different pathogens. More 
important is the zoonotic transmission of disease to humans via the food-chain. 
Zoonotic diseases such as salmonellosis and campylobacteriosis are well-recognised 
causes of food poisoning, mainly as a result of contaminated poultry products. 
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Understanding the pathogenesis of avian disease and the immunobiology of the 
chicken will improve food security. 
The nature of the infectious challenge to the poultry industry is constantly changing 
due to environmental change, changes in legislation and pathogen evolution. For 
example, legislation introduced nearly 10 years agoin the UK banned the use of 
antimicrobials as growth promoters in food-producing animals. Whilst effective at 
slowing evolution of antimicrobial drug resistance in humans, this increases the risk 
of disease in food-producing animals and consequently of disease transmission via 
the food chain to humans. With the increasing demand o  poultry production, 
strategies to preserve food security are vital. Oneof the keys to developing effective 
disease control measures for the future is a better understanding of the avian immune 
system and how to manipulate it. 
1.1 The mammalian immune system 
All living organisms have evolved mechanisms and strategies to defend themselves 
against disease. In concert, pathogens are continually evolving their own survival 
strategies to evade these immune defences. Healthy co-evolution is reached in some 
circumstances, e.g. commensal bacteria, but more commonly there is a continual 
“arms-race” between host and pathogen. The immune system is classically divided 
into two sub-systems: the innate immune response and the adaptive immune 
response. 
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1.1.1 The innate immune response 
The innate immune system is the first cellular line of defence against invading 
pathogens. It is an immediate, non-antigen-specific system. The innate immune 
response does not confer immunological memory, nor does it alter on repeated 
exposure to the same pathogen. It is an evolutionarily older defence mechanism than 
the adaptive immune system (section 1.1.2). 
The innate immune cells which orchestrate pathogen recognition and the host’s 
response include epithelial cells, mast cells, macrophages, dendritic cells (DCs), 
neutrophils, basophils, eosinophils, gamma delta (γδ) T cells and Natural Killer (NK) 
cells. The phagocytes (macrophages, DCs and neutrophils) identify, engulf and 
eliminate pathogens as well as presenting antigen to B and T cells to prime the 
adaptive immune response. Innate immune cells play key roles in effecting innate 
immune responses. Macrophages, DCs and epithelial cells “sense” pathogens by 
expression of pattern recognition receptors (PRRs) (di cussed in more detail below). 
They also express other receptors such as complement, mannose, glucan and 
scavenger receptors, which recognise many microbial ligands. Upon antigen 
stimulation, these cells secrete a range of inflammtory mediators, e.g. cytokines, to 
recruit other effector cells such as neutrophils. Neutrophils are potent killers of 
pathogens through the release of antimicrobial molecules and neutrophil extracellular 
traps (NETs), which reduce the spread of infection and inflammation by killing 
bacteria and neutralising bacterial virulence factors (Brinkmann et al., 2004). NK 
and γδ T cells are cytotoxic lymphocytes, which functionally sit at the interface 
between the innate and adaptive immune responses. They are capable of driving 
immune responses based on the expression of non-antigen-specific pleiotropic 
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receptors but their functions are only just being explored. γδ T cells can express high 
levels of cytokines and chemokines, such as interferon (IFN)-γ, tumour necrosis 
factor (TNF), interleukin (IL)-17 and CXCL13, as well as granzymes to lyse infected 
or stressed host cells. They also play roles in DC maturation, priming of αβ T cells 
via antigen presentation and helping B cells (Vantourout and Hayday, 2013). NK 
cells also do not directly attack invading microbes; they destroy pathogen-infected 
host cells with reduced major histocompatibility (MHC) class I expression to release 
pathogen components, facilitating clearance by phagocytes (Vivier, 2006). NK cells 
have recently been assigned as prototypical Group 1 innate lymphoid cell (ILC1) 
(Spits et al., 2013). ILC1s are developmentally related cells with important effector 
roles in innate immunity and tissue remodelling. They are defined by three main 
features: lack of recombination activating gene (RAG)-dependent rearranged antigen 
receptors, absence of myeloid cell and DC phenotypical markers and a lymphoid 
morphology (Spits and Cupedo, 2012). 
To recognise and respond to pathogens, innate cells must first distinguish between 
self and non-self. To this end, the cells use a limited number of soluble and cell-
associated receptors and proteins, encoded in the germline, which recognise common 
features of pathogens. Pathogens express several signature molecules, which are 
known as pathogen-associated molecular patterns (PAMPs). These tend to be 
indispensable components of microbes, which consequently are not readily altered by 
mutation or selection (Beutler, 2004). As mentioned previously, the receptors 
recognising invading pathogens, or PAMPs, are PRRs, which can also detect 
damage-associated molecular patterns (DAMPs). DAMPs are molecules produced by 
pathogen invasion or cell damage, such as reactive oxygen species (ROS) or 
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adenosine triphosphate (ATP) (Gombault et al., 2012). To date, there are four major 
classes of PRRs: toll-like receptors (TLRs), C-type lectin receptors (CLRs), retinoic 
acid-inducible gene I (RIG-I)-like helicase receptors (RLRs) and nucleotide 
oligomerisation and binding domain (NOD)-like receptors (NLRs) (Hardison and 
Brown, 2012; Lupfer and Kanneganti, 2013) . Upon activ tion, PRRs signal to the 
host the presence of infection and trigger pro-inflammatory and antimicrobial 
responses by activating a multitude of intracellular signalling pathways, adaptor 
molecules, kinases and transcription factors (Akira and Takeda, 2004). Therefore, 
PRR activation represents an important link between th  innate and adaptive immune 
responses. 
TLRs are the most well-characterised of the PRRs and they detect a wide range of 
microbial structures on the exterior of bacteria, viruses, protozoa and fungi (Kawai 
and Akira, 2010). They are expressed by many different cell types and structurally 
are glycoproteins characterised by an extracellular domain containing leucine-rich 
repeat (LRR) motifs and a cytoplasmic signalling Toll/IL-1 receptor homology (TIR) 
domain (O'Neill and Bowie, 2007). One way of grouping TLRs is on their cellular 
distribution. TLR1, 2, 4, 5, 6 and 10 are expressed on the cell surface whereas TLR3, 
7, 8 and 9 are located intracellularly (Iwasaki and Medzhitov, 2004). The TLRs 
expressed on the cell surface recognise products unique to bacteria, e.g. 
lipopolysaccharide (LPS) and flagellin, whereas theintracellular TLRs recognise 
pathogen-derived nucleic acids and discriminate self from non-self by the 
localisation of their ligands rather than a unique molecular structure different from 
the host (Mogensen, 2009).  
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In contrast, CLRs are essential for antifungal immunity. They are a heterogeneous 
superfamily of soluble and transmembrane proteins defined by a characteristic C-
type lectin domain (Zelensky and Gready, 2005) and recognise the major 
carbohydrate structures found in fungal cell walls. 
The RLRs sense viruses. These receptors are widely expressed cytosolic RNA 
helicase proteins, which lack a transmembrane domain and can identify viral 
ribonucleic acid (RNA). RLR activation leads to expression of anti-viral effector 
molecules such as type I IFN (Creagh and O'Neill, 2006; Ramos and Gale, 2011).  
Similar to RLRs, NLRs lack a transmembrane domain and are cytoplasmic sensors of 
intracellular pathogen invasion, sensing PAMPs and DAMPs. NLRs are a large 
receptor family with over 20 members, which have a wide range of effector and 
activation domains and consequently activate multiple signalling pathways (Lupfer 
and Kanneganti, 2013). One of the most studied and well-known roles of NLRs is in 
inflammasome activation. The inflammasome is a multi eric protein complex. 
These complexes are able to use an activated NLR to further activate pro-caspase-1, 
ultimately resulting in the generation of mature IL-1β and IL-18 pro-inflammatory 
cytokines (Latz et al., 2013). 
Following detection of invading pathogens, the innate immune response orchestrates 
neutralisation and removal of the pathogen as well as initiating the adaptive immune 
response should it fail to overcome the initial invasion. The same cells that detect 
foreign antigen, e.g. macrophages and neutrophils, also function to kill invading 
pathogens through several mechanisms touched on already such as phagocytosis, 
NETs and the release of effector molecules, e.g. cytokines, to activate other cells, 
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contributing to the developing immune response. Pathogen-activated innate immune 
cells produce cytokines to organise and drive the immune response to specific 
antigens. Cytokines are chemical messengers that include chemokines, IFNs, ILs and 
TNFs. Cytokines released by activated macrophages include the pro-inflammatory 
cytokines IL-1β, IL-6, IL-12 and TNF-α, which initiate early inflammatory 
responses, the chemokine CXCL8, which attracts neutrophils to sites of infection and 
the interferons IFN-α and IFN-β, which block viral replication. 
An additional effector component of innate immunity is the complement system. 
Plasma proteins, constitutively expressed by the liv r, react with one another to 
opsonize pathogens, which induces several inflammatory responses designed to aid 
innate cells in their removal. Three pathways of complement activation are defined 
differing in how they are triggered and in the first eactions in the cascade: the 
classical pathway, the lectin pathway and the alternative pathway (Zipfel and Skerka, 
2009). However, they all lead to the activation of the protein C3, deposition of C3b 
on the surface of the pathogen and the recruitment of effector mechanisms for 
pathogen destruction. 
The outcomes of the innate immune response and its effect on influencing the nature 
of the adaptive immune response depends on the initial signals sensed, e.g. activation 
of the PRR families, phagocytosis, pro-inflammatory c tokine secretion and 
complement activation (Mogensen, 2009). The innate immune response is activated 
immediately upon encountering a pathogen and continues for approximately 96 
hours, at which point infection is either effectively overcome or the adaptive immune 
response is triggered. 
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1.1.2 The adaptive immune response 
The adaptive immune response is recruited to combat inv ding pathogens able to 
evade or overcome the innate immune response and its activities are very antigen-
specific and modifiable. Further, a key feature of the adaptive immune response is 
the development of immunological memory, allowing a rapid and efficient response 
to subsequent encounters with a particular antigen. This secondary response is often 
stronger than the primary response to infection. It consists of antibody (Ab) 
responses mediated by B cells, also called humoral immunity, and cell-mediated 
responses predominantly orchestrated by T cells. Most effector B and T cells die 
when the host recovers from infection but a few cells persist as memory cells to 
provide long-term immunity. This ensures a rapid an protective immune response 
can be mounted if there is repeat exposure to the same antigen. Memory cells are 
more sensitive to infection, more easily activated an more abundant than naïve cells 
specific for the same pathogen. 
Both B and T cells have the capacity to respond to almost any antigen through their 
antigen-specific receptors (the B cell receptor (BCR) and the T cell receptor (TCR) 
respectively), with repertoires of specificity that expand and contract according to 
requirements. Where they differ is in the manifestation of this response. B cells 
produce antigen-specific immunoglobulin (Ig), while T cells primarily express 
cytokines to drive other cells (both immune and non-immune) in a developing 
immune response. Genetic rearrangement of both the BCR and TCR is very similar 
and drives huge diversity in the system, enabling recognition of almost any antigen. 
Another common feature shared by B and T lymphocyte development is for 
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apoptosis to be the default pathway unless a positive signal for survival and further 
differentiation is received. 
B cell development in humans begins in the bone marrow. Pluripotent 
haematopoietic stem cells give rise to common lymphoid progenitor cells, which 
have the potential to differentiate into B cells (a well as most other immune cell 
types). Once committed to the B cell lineage, B cell progenitors (pro-B cell) undergo 
rearrangement of the Ig heavy-chain and light-chain genes, which results in 
immature B cells expressing the membrane-bound Ig, IgM. The IgM further 
associates with Igα and Igβ signalling proteins to form a functional BCR complex. 
Non-lymphoid stromal cells provide the specialised nvironment for B cell 
maturation in the bone marrow. B cells undergo two ‘checkpoints’ in the bone 
marrow before migration to secondary lymphoid tissues. The first ensures only cells 
with a functional pre-B cell receptor are able to pr ceed in development, while the 
second checkpoint is assembly of a functional BCR. B cells that fail at either of the 
checkpoints undergo apoptosis in the bone marrow. In addition, before migrating to 
peripheral lymphoid organs to finish development, immature B cells must undergo 
negative selection to eliminate any self-reactive cells. These transitional B cells 
migrate to peripheral lymphoid organs, such as the spl en, lymph nodes and Peyer’s 
patches, under the guidance of chemokines, e.g. CCL21, expressed by stromal cells. 
These immature B cells are considered naïve (not yet exposed to antigen). Once 
inside the spleen or lymph node, B cells congregate in primary lymphoid follicles 
where they mature. In the absence of its specific antigen, a B cell will exit in the 
efferent lymph. A mature naïve B cell expresses both membrane-bound IgM and 
IgD. Activated B cells can express and secrete different classes of Ig. This Ig class-
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switching is orchestrated by cytokines. In mammals, there are five classes of Ig: IgA, 
IgD, IgE, IgG and IgM. Activation of a mature B cell occurs when it recognises 
antigen in conjunction with signals from Th cells. This process triggers proliferation 
and differentiation of the activated B cell into a pl sma cell, an antibody-producing 
cell or a memory cell, which survives for years and ‘remembers’ one specific 
antigen. Immunoglobulins from a single B cell have th same antigen specificity. 
The BCR, or Ig, is formed of a dimerised heavy and light chain, with constant (C) 
and variable (V) regions. The heavy and light chains are derived from somatic 
recombination of families of gene segments, called V and joining (J) genes, and, in 
the case of the heavy chain, diversity (D) genes. This V(D)J recombination produces 
incredible diversity in antigen recognition. Antigen recognition is further “fine-
tuned” in an immune response through point mutations ccurring in the V, D and J 
genes (somatic hypermutation) of the BCR during activ ted B cell expansion. The 
classification of the five Ab isotypes is based on the C region of the different heavy 
chains, which also defines specific functionality of the Ab. Secreted Ig can bind to 
pathogens, either neutralising or opsonising the pathogen, which aids in 
phagocytosis, or activates complement, ultimately clearing the pathogen from the 
host.  
T cell development also begins with lymphocyte progenitors in the bone marrow and 
has commonality with B cell development. T cells must also undergo gene 
rearrangement to produce a TCR, a process called somatic DNA recombination, 
which occurs after migration to the thymus. The stage of thymocyte development can 
be classified based on the expression of cluster of differentiation (CD) markers on 
the cell surface. Immature thymocytes are double-negative cells, they do not express 
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CD4 or CD8 (CD4-CD8-). Similarly to B cells, T cell development depends on 
signals received from thymic stromal cells. Activaton of Notch 1, a cell-surface 
receptor expressed by developing thymocytes, is crucial for T cell differentiation. 
Double-negative thymocytes begin developing into two functionally different 
lineages of T cells, which are distinguished by the expression of an αβ or γδ TCR. At 
this stage, γδ T cells leave the thymus and circulate in the blood as they are not 
subject to the stringent selection imposed on the αβ T cells. If a functional TCR is 
not generated, the T cell dies through apoptosis. When an immature αβ-expressing 
thymocyte loses dependence on Notch 1, it then differentiates into a CD4+CD8+ 
double-positive cell. Double-positive cells with a functional αβ TCR are exposed to 
endogenous peptides expressed on thymic cells and undergo further positive and 
negative selection processes. Like B cells, T cells undergo selection to quality 
control the recombination process. During positive selection, αβ T cells that are able 
to recognise peptides presented by self-MHC molecules are selected for (further 
discussion on the MHC is included below). This TCR interaction results in loss of 
either the CD4 or the CD8 co-receptor molecule, generating a single-positive cell 
(CD4+CD8- or CD4-CD8+). The cells then undergo negative selection, with αβ CD8+ 
or CD4+ T cells that recognise normal self-peptides presented by MHC complexes on 
healthy cells being eliminated. In this way, only T cells that recognise pathogen-
derived peptides presented by MHC class I or II isoforms are expressed. Following 
selection, surviving naïve T cells enter the circulation and migrate to peripheral 
lymphoid organs.  
There are three groups of cells in mammals considered to be antigen presenting cells 
(APCs): DCs, macrophages and B cells. Because DCs are unparalleled in their ability 
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to interact with T cells in peripheral lymphoid organs, they are considered to be the 
primary APC (Lewis et al., 2014). APCs are vital for bridging the innate and 
adaptive immune responses. They express numerous PRR to detect and phagocytose 
pathogens, including TLRs (see section 1.1.1). Activated DCs take up antigen in 
peripheral tissues before migrating to peripheral lymphoid organs to present the 
processed antigen to naïve T cells. APCs present antigen via MHC molecules, which 
are recognised by the TCR of a naïve T cell. MHC molecules are classed as either 
type I or type II depending on the antigen they present. MHC class I presents antigen 
from intracellular pathogens and is expressed by virtually all nucleated cells in the 
body. MHC class II is constitutively expressed by APCs and presents antigen from 
extracellular pathogens. 
As described before, single-positive CD8+ or CD4+ T cells develop in the thymus. 
CD8+ T cells are predominantly cytotoxic T lymphocytes (CTL) and are activated 
via MHC class I molecules. CD4+ T cells are helper Th cells, which are activated via 
MHC class II molecules. Ligation of the TCR with its specific antigen:MHC 
complex is necessary to activate a naïve T cell (signal 1) but is insufficient stimulus 
on its own. A co-stimulatory signal from the same APC (signal 2) is also required to 
initiate clonal expansion and further differentiation of a naïve T cell into an effector 
T cell. The co-stimulatory receptor on the cell surface of a naïve T cell is CD28, 
which is activated by co-stimulatory molecules called B7 molecules, which are 
expressed on the surface of APCs. 
The effector function of activated cytotoxic T cells is to kill cells that harbour 
intracellular infection. This is particularly important during viral infection. Binding 
of the CD8+ TCR with MHC class I provokes a cell-mediated response where CTLs 
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secrete cytotoxic granules, containing molecules such as perforin, to directly kill 
infected cells. Infected cells killed by CTLs undergo apoptosis, preventing further 
pathogen replication and release. CTLs are also capable of secreting cytokines to 
recruit more immune cells to the immune response. In contrast, activated CD4+ Th 
cells further differentiate into various effector sub ets, which orchestrate the adaptive 
immune response by secreting cytokines to direct other immune cells appropriate for 
the pathogen (outlined in section 1.1.3). 
1.1.3 T helper cells and immune responses 
The Th1 and Th2 paradigm proposed by Mosmann and Coffman (1989) has been 
universally used to explain how hosts elicit different adaptive immune responses to 
eradicate invading pathogens. Classically, effector CD4+ T cells have been divided 
into two distinct lineages on the basis of their cytokine profiles: IFN-γ-producing 
Th1 cells or IL-4-producing Th2 cells. It is the most studied model for Th subset 
differentiation. In the last few years, there has been further subdivision of the CD4+ 
T cell effector phenotypes beyond that encompassed by the Th1/Th2 paradigm 
(Harrington et al., 2006). The more recently defined effector CD4+ T cell subsets 
continue to be defined by the signature cytokines secreted, the transcription factors 
expressed and their surface phenotype. It is now apparent that CD4+ cells, upon 
encounter of specific antigen, are activated, expand and differentiate into various Th 
subsets expressing both distinct cytokine profiles and effector functions (Figure 1.1) 
(Korn et al., 2009).  




Figure 1.1. A simplified schematic tool of CD4+ T helper cell subsets.  Activated naïve CD4+ T 
cells differentiate into various T helper (Th) cell subsets driven by specific cytokines and 
transcription factors. The effector Th subsets express signature cytokines, which regulate 
immune responses to specific types of pathogen. The Th cell subsets exhibit considerable lineage 
plasticity, which cannot be fully demonstrated in this figure. Adapted from Boniface et al. 
(2013). 
The cytokine milieu present as a result of the early innate immune response is 
instrumental in the differentiation of CD4+ T cell subsets. In addition to cytokines 
and master transcription factors, Th cells utilise signalling molecules, such as signal 
transducer and activator of transcription factors (STATs), which couple cytokine 
receptors with gene expression (Adamson et al., 2009). IL-12 and IFN-γ signalling 
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through predominantly STAT1, and to a lesser extent STAT4, up-regulates the 
master transcription factor “T-box expressed in T cells” (T-bet) (Afkarian et al., 
2002), which in turn drives expression of IFN-γ in Th1 cells. Th1 cells mediate 
cytotoxic T cell responses against intracellular pathogens, such as viruses and some 
bacteria, by the secretion of IFN-γ. If IL-4 and IL-2 are expressed in the local 
environment, STAT6 and STAT5 signalling activates trans-acting T-cell-specific 
transcription factor GATA-3 (GATA3), the master regulator of Th2 cells (Kaplan et 
al., 1996). Th2 cells express the signature cytokines IL-4, IL-5 and IL-13, which 
activate B cells and drive Ab responses against extracellular pathogens such as 
parasitic worms. Th17 cells mediate acute inflammation at epithelial surfaces against 
extracellular bacteria and prokaryotes, and Treg cells inhibit T cell proliferation and 
autoimmune responses, dampening inflammatory responses (Wing et al., 2006). The 
newer T cell subsets that have been established in mammals in the last few years 
include Tregs (Sakaguchi et al., 1995), follicular helper T cells (Tfh) (Breitfeld et al., 
2000; Schaerli et al., 2000), Th17 cells (Harrington et al., 2005) and most recently, 
Th9 cells (Dardalhon et al., 2008; Veldhoen et al., 2008) and Th22 cells (Duhen et 
al., 2009). These subsets of T cells have specific effector or regulatory functions and, 
by expressing different cytokines, mediate their influence on other cells during the 
immune response (Figure 1.1). 
1.1.4 Cytokines 
Cytokines are key messenger molecules in cell-to-cell communication within the 
innate and adaptive immune system. They consist of the ILs, IFNs, TNFs, colony-
stimulating factors (CSFs), transforming growth factors (TGFs) and chemokines. 
During infection, a complex network of cytokines orchestrate the initiation, 
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maintenance and dampening of host defences.  They det rmine the type of response 
and the effector mechanisms initiated to eliminate  pathogen. Further, transiently 
and locally expressed cytokines control the size and duration of the immune 
response, playing a crucial role in regulating inflammation and immunity. The other 
side of the coin, disproportionate or inadequate production of cytokines, contributes 
significantly to the pathology of a disease (Ingrao et al., 2013). Typically, cytokines 
are secreted by a cell in response to stimulation and can exert their effect in an 
autocrine, paracrine or endocrine manner. Interleukins were originally defined as 
being produced and acting on white blood cells but are now recognised to have a 
much broader function and act on many different tissue . Interferons are named after 
their ability to ‘interfere’ with viral replication in a host cell, acting by stimulating 
innate cells to initiate anti-viral immune responses as well as recognising tumours. 
Tumour necrosis factors are pro-inflammatory and cause cell death by apoptosis. 
Colony stimulating factors direct haematopoietic stem cells to proliferate and 
differentiate. Transforming growth factors regulate c ll division and survival and 
also have an anti-inflammatory function. Chemokines are so-called because of their 
ability to induce directed chemotaxis in nearby responsive cells. They play a vital 
role in directing lymphocytes, particularly phagocytes, during the immune response. 
1.2 The avian immune system 
The chicken differs from mammals in its repertoire of lymphoid tissues, cells and 
molecules. The avian immune system, while similar to its mammalian counterparts in 
many aspects, differs from mammalian models sufficiently that to understand host-
pathogen interactions it is necessary to have a greter understanding of the elements 
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unique to birds. Birds and mammals evolved from a common ancestor over 300 
million years ago but have continued to occupy the same biological niche and 
consequently encounter a similar range of pathogens. In broad terms, chickens 
respond to pathogens in much the same way as man; they too have developed innate 
and adaptive immune responses to overcome a diverse range of pathogens. 
Nevertheless, the chicken immune system has a number of unique features. 
Similar to mammals, the chicken has both central and peripheral lymphoid tissues; 
however, the finer details differ. The central lymphoid tissues include the bone 
marrow, thymus and bursa of Fabricius (Figure 1.2). Peripheral lymphoid and 
myeloid cells originate from haematopoietic stem cells in the bone marrow. 
Immature chicken T cells migrate to the thymus to continue their development as in 
mammals. Chicken B cell development occurs in the bursa of Fabricius, which is 
strikingly different to B cell maturation in the bone marrow in mammals (section 
1.2.2). Like mammals, the peripheral lymphoid tissues include the spleen as a key 
lymphoid organ and mucosal-associated lymphoid tissue , such as Harderian glands, 
caecal tonsils, Meckel’s diverticulum and the oesophageal tonsil. However, the 
chicken lacks encapsulated lymph nodes and instead has diffuse mucosal-associated 
lymphoid tissues. Further, mammalian lymph node development is driven by two 
cytokines, the TNF superfamily members lymphotoxin α (LT-α) and LT-β 
(Alimzhanov et al., 1997; De Togni et al., 1994). These genes have not been found 
in the chicken genome to date (Kaiser, 2012), nor have their receptors, which may 
explain the lack of lymph nodes in the chicken. It is not yet clear where antigen 
presentation takes place in the chicken. 




Figure 1.2. The lymphoid organs of the chicken.  The central lymphoid organs include the bone 
marrow, thymus and bursa of Fabricius. The peripheral lymphoid tissues include the Harderian 
glands, spleen, bronchus-associated lymphoid tissues, Meckel’s diverticulum, caecal tonsils and 
Peyer’s patches. 
1.2.1 The avian innate immune system 
Many components of the human innate immune response do not have a recognised 
equivalent in the chicken or are not as well characterised. However, it is known that 
APCs recognise pathogen through PRRs, releasing cytokines and chemokines, which 
drive inflammatory responses and shape an appropriate adaptive response, as in 
mammals. 
Wu et al. (2010) first described bone marrow-derived DCs (BMDCs) in a non-
mammalian species. Identification of naturally deriv d DCs in the chicken has been 
attempted but progress is limited (reviewed by Kaiser, 2010). Relatively little is 
known about chicken DCs in vivo but it is assumed they function similarly to 
mammals and present antigen. BMDCs express PRRs, co- timulatory molecules, 
MHC class II, cytokines, chemokines and chemokine receptors (Wu et al., 2011; Wu 
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et al., 2010). Post-hatch, chicken macrophages differentiate from circulating bone 
marrow-derived precursors and complete their differentiation in peripheral tissues 
under the influence of CSFs (Garceau et al., 2010). Phenotypically, avian 
macrophages appear to be similar to mammals. As with their mammalian 
counterparts, chicken macrophages play an important ole in host defence against 
microbial infection. Chickens lack neutrophils; the functional equivalent in chicken 
is the heterophil (Harmon, 1998). Heterophils are also polymorphonuclear 
granulocytes that phagocytose microbial pathogens. Like neutrophils, heterophils 
migrate to sites of infection and form the first line of defence in early innate immune 
responses. Similar to neutrophil activation in mammals, activation of heterophils 
results in pro-inflammatory cytokine and chemokine rel ase (Kogut et al, 2005). The 
chicken also appears to lack functional eosinophils (Maxwell, 1987) and the eotaxins 
and eotaxin receptor, chemokines that control migration of eosinophils in mammals, 
are missing in the chicken genome (Kaiser, 2012). Eosinophils are recruited by Th2 
immune responses against parasitic infections and are a key component of allergy in 
mammals. 
DCs, macrophages and heterophils in the chicken express a different repertoire of 
PRRs compared to mammals. The TLRs are the most characterised of the PRRs in 
the chicken and are evolutionarily conserved compared to mammals. Ten different 
TLR genes have been identified in the chicken genome but the TLR repertoire is 
subtly different compared to mammals (Brownlie and Allan, 2011) (Table 1.1). 
Chicken TLR1, 2, 3, 4, 5 and 7 are orthologous to their mammalian counterparts but 
chickens lack TLR8 and 9. Chickens have two TLR1s (TLR1A and B) and two 
TLR2s (TLR2A and B) as a result of gene duplication. These variants dimerise to 
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form cell surface receptors which recognise the same PAMPs as human (hu) TLR2 
(Higuchi et al., 2008), which can dimerise with huTLR1, 6 and 10, thus suggesting 
chickens can recognise a similar range of PAMPs as m mmals, although using a 
different TLR repertoire (Kaiser, 2010). Chickens al o have two additional TLR 
genes, chicken (ch) TLR15 and chTLR21, which are absent in humans (Higgs et al., 
2006; Roach et al., 2005). Conversely, huTLR9 and huTLR11 orthologues are absent 
in the chicken. Chicken TLR21 is a direct functional equivalent of huTLR9 
(Brownlie et al., 2009). Recent study suggests chTLR15 may have evolved as a 
broad-spectrum TLR, with a specific role in defence against avian pathogens (Nerren 
et al., 2010). Finally, chTLR8 is a pseudogene (Philbin et al., 2005). RLRs and 
NLRs are cytoplasmic sensors of intracellular pathogen invasion. The chicken has a 
reduced repertoire of RLRs and NLRs compared to mamls, only NOD1 (not 
NOD2) being present in the chicken genome (Kaiser, 2010). 
Table 1.1. The human and chicken Toll-like receptor families. 
Location and PAMP of 
TLR Human Chicken Reference 
Cell surface TLRs that 





(Iqbal et al., 2005a; 




(Fukui et al., 2001) 
TLR4 TLR4 (Leveque et al., 2003) 
TLR5 TLR5 (Iqbal et al., 2005b) 




(Higgs et al., 2006; 
Nerren et al., 2010) 
Intracellular TLRs that 
recognise nucleic acid 
TLR3 TLR3 (Iqbal et al., 2005b) 
TLR7 TLR7 (Philbin et al., 2005) 





(Brownlie et al., 
2009; Roach et al., 
2005) 
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Compared to mice and humans, chickens possess a higher number of γδ T cells but 
with limited diversity of the variable regions of the TCR γ and δ genes (Su et al., 
1999). The highest numbers of γδ T cells are seen in the gut, specifically the caecum, 
following infection in the chicken (Pieper t al., 2011). Further, the number of γδ T 
cells in the chicken increases with age, constituting up to 50% of the circulating T 
cells in an adult bird. This is in contrast to chicken NK cells of which there are 
comparatively fewer numbers in the blood compared to mammals, up to 1% 
compared to 10% in mammals (Cooper et al., 2001; Gobel et al., 2001). Chicken NK 
cells have been described in the embryonic spleen but the most frequent population is 
the intestinal epithelial lymphocyte population in the intestinal mucosa (Gobel t al., 
2001). The role of chicken NK cells during disease remains unclear and is reviewed 
by Rogers et al. (2008). In conclusion, the exact roles of NK and γδ T cells in innate 
and adaptive immune responses in the chicken remain to be elucidated. Finally, the 
three complement pathways discussed in mammals (section 1.1.1) are present in the 
chicken, albeit with fewer components identified compared to mammals. When the 
avian innate immune response fails to neutralise an antigen, the adaptive immune 
response is triggered as in mammals. 
1.2.2 The avian adaptive immune system 
Chickens possess T and B cells, which generate a broadly similar adaptive immune 
response to infection, with a few prominent differenc s. B cells and Ab production 
are common to all vertebrates. B cells use their BCR as antigen receptors and 
differentiate into plasma cells capable of secreting a tibodies. The Ig genes in birds, 
which generate a diverse repertoire of BCR specificities, undergo Ig gene 
rearrangement like their mammalian counterparts; however, BCR/Ab diversity in 
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birds is primarily generated by gene conversion, which usually occurs after initial 
recombination of the single VJ or VH genes and surface expression of the canonical 
BCR. The chicken light chain and heavy chain gene loci are encoded by single 
copies of VL and JL genes and VH and JH respectively, limiting diversity and 
minimising V(D)J rearrangement (Ratcliffe and Jacobsen, 1994; Reynaud et al., 
1985) .  This is in contrast to humans whose heavy and light chains are encoded by 
families of gene segments. Diversity of the Ig V region is instead generated by 
recombination with clusters of pseudogenes upstream of the heavy and light chain 
loci, which donate sequence to the functionally rearranged JVL or VDJH genes 
(Reynaud et al., 1987; Reynaud et al., 1989). 
The primary site of BCR repertoire generation in the chicken is the bursa of 
Fabricius, which is unique to birds. B cell development in chickens begins in 
haematopoietic tissues, such as the bone marrow, similarly to mammals but then 
migrate to the bursa of Fabricius, colonising in a single wave during embryonic 
development. Gene conversion primarily occurs here as well. Post-hatch, the bursa of 
Fabricius begins to involute as cells die and completely disappears by 6 months. 
Peripheral blood levels of B cells are maintained an these B cells are thought to 
derive from the bone marrow (Schat et al., 2012). Chicken B cells express only three 
classes of Ab:  IgM, IgA and IgY. The latter is the functional equivalent of IgG in 
mammals but does not undergo subclass switching. Birds do not have equivalents of 
mammalian IgD or IgE (Ratcliffe, 2006). 
Chicken T cell precursors originate in the blood before migration to the thymus for 
further development. Here, the development of chicken T cells and the generation of 
TCR diversity through somatic DNA recombination areid ntical to the mechanisms 
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in mammals. Chicken T cell precursors differentiate into TCRγδ+ and TCRαβ+ T 
cells in the thymus. The antibody TCR1 (Sowder et al., 1988) recognises TCRγδ+ T 
cells, which constitute a large proportion of the total peripheral lymphocytes in birds. 
There are two subsets of αβ T cells in the chicken, which express αVβ1 or αVβ2 and 
can be distinguished by the antibodies TCR2 and TCR3 respectively (Davidson and 
Boyd, 1992). Similarly to their mammalian counterparts, thymic chicken αβ T cells 
are initially double-positive CD4+CD8+ cells, which undergo positive selection to 
become single-positive CD4+ or CD8+ T cells. Following selection, naïve T cells 
enter the circulation and migrate to the spleen. It is predicted that antigen 
presentation and signalling through the chicken TCR complex is similar to mammals 
based on the strong conservation of intracellular signalling motifs but this has not 
been fully investigated in the chicken. The MHC, genetic locus for the MHC class I 
and II molecules, of the chicken has a reduced number of genes compared to 
mammals and differs in its genomic organisation (Kaufman et al., 1999). Despite the 
chicken MHC being smaller than the mammalian MHC, nearly all of the chicken 
MHC genes have human MHC counterparts. There are many examples in the 
chicken of disease associations with the MHC (Bacon, 1987), e.g. chicken lines 
resistant and susceptible to MDV (Briles et al., 1977) and the concept of the 
“minimal essential MHC of the chicken” provides a molecular basis for this. The 
multigene families that make up the mammalian MHC confer protection against most 
pathogens, to a greater or lesser extent, whereas th  maller, simpler chicken MHC 
confers either resistance or susceptibility to a pathogen (Kaufman and Salomonsen, 
1997). 
Chapter 1 Introduction 
24 
 
Knowledge of the existence of the chicken equivalents of the mammalian CD4+ T 
cell subsets is slowly advancing. Despite the Th1/T2 paradigm being demonstrated 
almost a decade ago in the chicken (Degen et al., 2005), and the more recent 
identification of Tregs (Shanmugasundaram and Selvaraj, 2010; 2011), the presence 
of the newer Th subsets (Th17, Th9, Th22 and Tfh) has yet to be confirmed or 
dismissed in the chicken (Kaiser, 2010). Including the work in this thesis, all of the 
cytokines crucial to driving mammalian Th lineage dvelopment have now been 
identified in the chicken (Kaiser, 2012). However, the master regulators of 
transcription for Th17 and Tregs, retinoic-acid-relat d (RAR) orphan receptor 
gamma t (RORγt) and Forkhead box P3 (FoxP3) respectively, have not been 
identified in the chicken. Also, during a Th2 response in chickens, IL-4 and IL-13 are 
expressed, similarly to their mammalian counterparts (Degen et al., 2005; Powell et 
al., 2009) but IL-5 expression is switched off. In mammals, IgE production is 
dependent on IL-5 expression by Th2 cells and as discussed previously, IgE is not 
produced in birds. Given these significant differenc s between the mammalian and 
avian immune systems, and the importance of Th17 immune responses in mammals, 
it is fundamental to better understand if the Th17 system exists in chickens, if it is 
similar to mammals, and, if not, what the major differences are. 
1.2.3 Avian cytokines 
The repertoire of cytokines in mammals is extensive and considerably larger than 
that currently known in the chicken, consistent with the trend of minimalism in the 
avian immune system compared to the mammalian immune system (Kaiser, 2010). 
So far, the genes for 27 ILs, all the TGFs, all the CSFs, 10 type I IFNs, IFN-γ, a 
single IFN-λ, 12 TNFs and 24 chemokines have been identified (Kaiser, 2010). The 
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availability of the chicken genome sequence (Hillier et al., 2004) has aided in the 
discovery of new cytokine genes. However, progress in definitive identification is 
hindered by the lack of reagents and low sequence homology with mammalian 
orthologues. Typically, chicken cytokines have relatively low amino acid (aa) 
identities (18-40%) with human homologues but generally effector functions appear 
to be conserved. To date, the driving cytokines of Th17 cells, namely TGF-β4, IL-6, 
IL-1β, and IL-21, have been identified in the chicken. Further, it is known that the 
effector cytokines IL-17A, IL-17F, IL-21 and IL-22 are expressed in the chicken 
(Kim et al., 2012a; Kim et al., 2012b; Min and Lillehoj, 2002; Rothwell et al., 2012). 
Interestingly, until now, IL-23 and its receptor were crucially missing from the 
chicken genome (section 1.3). 
1.3 Th17 immune responses in mammals 
Th17 cells are one of the newer T helper cell subsets to be described in mammals. 
Aggarwal et al. (2003) first described the idea of an IL-23/IL-17 pro-inflammatory 
axis; however, it was Harrington et al.(2005) who described the Th17 cell, a distinct 
CD4+ T cell subset critically responsible for the production of IL-17. Th17 cells are 
characterised by the production of the cytokines IL-17A, IL-17F, IL-21 and IL-22 
(Korn et al., 2009), granulocyte-macrophage colony-stimulating factor (GM-CSF) 
and IFN-γ. Differentiated Th17 cells express the IL-23 receptor (IL-23R) (McGeachy 
et al., 2009). RORγt is only expressed by Th17 cells, and no other Th cell subsets, 
and its loss profoundly impairs the functionality of Th17 cells, which led to its 
characterisation as the master regulator of Th17 transcription (Ivanov et al., 2006). 
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Critically, the Th17 subset represents an arm of the adaptive immune system that 
functions to clear specific types of pathogen not effectively neutralised by Th1 or 
Th2 immune responses (Korn et al., 2009). Current data imply a specialised 
evolutionary function of Th17 cells to promote protective immunity at mucosal sites 
against a variety of pathogens (Kolls and Khader, 2010). Th17 is widely considered 
to be the main arsenal in host defence against extracellular bacteria but recent studies 
also suggest that the Th17 subset has evolved to confer protective immunity against 
intracellular pathogens (Khader and Gopal, 2010; Peck and Mellins, 2010). This 
duality is achieved by regulating and bridging the innate and adaptive immune 
responses (Kolls and Khader, 2010; Stockinger and Vel hoen, 2007). For example,  
IL-17 stimulates the mobilisation and e novo generation of neutrophils by 
granulocyte-colony stimulating factor (G-CSF) (Fossiez et al., 1998). Th17 cells can 
also promote multiple aspects of humoral immunity, ncluding germinal centre 
formation and antibody isotype switching, as well as v ccine-induced immunity by 
aiding Th1 cell recruitment (Khader et al., 2007; McAleer and Kolls, 2011; 
Mitsdoerffer et al., 2010). The Th17 subset provides a vital host defence function but 
it can also promote severe chronic inflammation. Experimental autoimmune 
encephalomyelitis (EAE), a mouse model for multiple sclerosis (MS) in humans, was 
pivotal in unravelling the role of Th17 cells in autoimmune disease (Figure 1.3). 
Ablation of EAE disease was seen in mice deficient in he p40 subunit of IL-12 
(Leonard et al., 1995); however, mice deficient in IFN-γ, the principle cytokine 
produced by Th1 cells, are susceptible to EAE (Ferber et al., 1996). With the 
discovery of IL-23, which is made up of p19 and p40, the latter of which it shares 
with IL-12 (Aggarwal et al., 2003), Cua et al. (2003) were able to show that mice 
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deficient in the p19 subunit of IL-23 were protected against EAE disease 
development and that IL-23, not IL-12, was responsible for EAE pathogenesis.  
 
Figure 1.3. The pathogenic role for IL-23, not IL-12, in mouse models of autoimmunity.  EAE 
disease development requires IL-23, but not IL-12. Compared with wild-type susceptible mice, mice 
deficient for IL-23 (IL-23 p19−/−) and both IL-23 and IL-12 (IL-12 p40−/−) failed to develop disease 
after antigenic challenge, whereas mice deficient for IL-12 (IL-12 p35−/−) developed more severe 
disease (Harrington et al., 2006). 
1.3.1 Differentiation 
The description of Th17 cells has caused a major paradigm shift in our understanding 
of T cell biology and immune regulation. The identification of this novel antigen-
dependent T cell subset has removed the dichotomous clas ification of Th1 and Th2, 
which had remained established for over 20 years. A further unexpected finding was 
the concept of T cell plasticity. Th17 cells are highly unstable in many experimental 
systems (Lee et al., 2009) and these initial observations raised the qu stion of 
whether or not Th17 cells represent a distinct T cell subset. It is generally accepted 
that because Th17 cells develop independently of STAT1, T-bet, STAT4 and STAT6 
and are the only Th subset to express RORγt that they are a distinct Th cell lineage 
(Harrington et al., 2005; Park et al., 2005). Networks of transcription factors regulate 
cytokine and effector gene expression and direct Th cell differentiation and 
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expression of effector phenotypes. The transcription factors STAT3, RORγt and 
RORα (Yang et al., 2008a; Yang et al., 2008b) all play a role in Th17 differentiation, 
as does activation of aryl hydrocarbon receptor (Ahr) but it remains unclear what 
features of Th17 differentiation are regulated by this latter transcription factor 
(Stockinger et al., 2011). The developmental pathway of naïve Th cells is determined 
at least in part by the cytokine milieu present when they are activated. The 
inflammatory cytokines TGF-β, IL-6, IL-1β (Veldhoen et al., 2006), IL-21 (Korn et 
al., 2007; Zhou et al., 2007) and IL-23 (Volpe et al., 2008) are required for the 
development of Th17 cells in mammals (Figure 1.4). IL-23 acts as a growth and 
stabilisation factor for Th17 cells (McGeachy et al., 2007; McGeachy et al., 2009; 
Veldhoen et al., 2006). 
 
Figure 1.4. Th17 cell differentiation. APCs present antigen using MHC molecules in the presence 
of TGF-β, IL-6, IL-21, IL-23 and IL-1β. This initial activation up-regulates STAT3 and ROγt 
expression to enhance IL-23 responsiveness and IL-17 production. Adapted from Cua and Tato 
(2010). 
Despite Th17 differentiation being extensively investigated, the exact in vivo 
differentiation requirements remain incompletely defin d. T cell activation in the 
presence of TGF-β and IL-6 primes the initial differentiation of naïve CD4+ T cells 
to IL-17-producing Th17 cells.  It is generally agreed that TGF-β, IL-6 and IL-1β are 
required. Confusion arises over whether the requirement of TGF-β because of 
differences between mice and humans and the requirement of TGF-β to induce 
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Tregs. It is now accepted that TGF-β is required but it is difficult to prove since 
removing it from tissue culture is extremely hard due to its expression from so many 
different cell types. The effect of TGF-β in a Th17 context is dependent on its 
concentration in the cytokine milieu: low levels promote Th17 differentiation by 
inhibiting T-bet whereas higher levels inhibit IL-23R expression and hinder Th17 
differentiation. Zhou et al. (2008) showed that lower levels of TGF-β with IL-6 
overcame FoxP3-mediated repression of RORγt to drive Th17 differentiation. FoxP3 
is the master regulator of transcription of naturally rising CD4+ regulatory T cells. 
Therefore, the concentration of TGF-β in the local cytokine milieu regulates Treg 
versus Th17 cell development. 
Veldhoen et al. (2006) showed that for Th17 cell differentiation, TGF-β and IL-6 
drive the coordinated activation of the transcription factors Caenorhabditis elegans 
SMA (SMA) and mothers against decapentaplegic (MAD) homolog 3 (SMAD3) and 
STAT3 to induce the transcription factors RORα and RORγt, which are necessary for 
Th17 cell differentiation. Th17 cell activation requires full activation of STAT3 by 
phosphorylation and IL-6 and IL-1β both play roles in this process: IL-6 via Janus 
kinase 2 (JAK2) and IL-1β via IL-1 receptor-associated kinase 1 (IRAK1) (Ivanov et 
al., 2006). STAT3, in turn, drives expression of RORγt, IL-17, IL-21 and IL-23R 
(Durant et al., 2010; Wei et al., 2007). The expression of IL-21, acting 
synergistically with TGF-β, is subsequently important in the induction and 
amplification of Th17 cells. IL-21 acts via an autocrine loop, inducing its own gene 
transcription in a STAT3-dependent manner, further enhancing expression of IL-21 
and IL-23R (Nurieva et al., 2007; Zhou et al., 2007). IL-23 is now understood to be 
required for full maturation and inflammatory function of Th17 cells. Addition of IL-
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23 also markedly enhances IL-23R gene expression by IL-23R+ ORγt+ Th17 cells, 
providing amplification of its own signalling via its own receptor. IL-23/IL-23R 
signalling induces RORγt, further up-regulating IL-23R expression. Therefo, IL-23 
is essential for full maturation of Th17 cells, including effector differentiation, 
acquisition of inflammatory phenotype and stabilisation of the lineage (Zuniga et al., 
2013). All of the cytokine pathways involved in Th17 cell differentiation result in 
up-regulation of RORγt expression, the master regulator of Th17 differentiation. 
In addition to the positive effects of cytokines on Th17 development, they are also 
able to exert an inhibitory effect. Specifically, Th17 development is inhibited by the 
Th1 and Th2 cytokines, IFN-γ and IL-4, as well as STAT1-activating cytokines, e.g. 
type I IFNs and IL-27. Th17 generation is also suppressed by IL-2, which activates 
STAT5, which in turn competitively binds at the same locus as STAT3 (Yang et al., 
2011). Further, TGF-β suppresses the transcription factors T-bet and GATA3, 
inhibiting CD4+ T cells from adopting Th1 or Th2 fates (Basu et al., 2013; 
Harrington et al., 2005). However, the developmental requirement of Th17 cells for 
TGF-β is shared with Tregs (Bettelli et al., 2006). Lee et al. (2009) have shown that 
Th17 cells can deviate towards a Th1 phenotype by expressing IFN-γ in response to 
further IL-23 or IL-12 signalling. This plasticity of Th17 cells initially clouded the 
issue of whether they were a genuine additional Th cell subset and consequently 
precisely what preserves phenotypic commitment of CD4+ T cells is currently 
intensely investigated. There is considerable heterogeneity and plasticity amongst the 
defined CD4+ T cell subsets, which has been extensively reviewed (Murphy and 
Stockinger, 2010; Nakayamada et al., 2012; O'Shea and Paul, 2010). TGF-β induces 
both Foxp3 and RORγt in naïve T cells but Foxp3 is dominant until IL-6 is present 
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(Zhou et al., 2008), indicating an inflammatory environment tips the balance 
between iTreg and Th17 differentiation. It is now evid nt that cytokine expression is 
also not as stable as initially thought. Th17 cells are able to acquire IFN-γ-producing 
potential and simultaneously produce IL-17 and IFN-γ (Wilson et al., 2007). Further, 
Th17 cells are able to extinguish expression of their signature cytokine and become 
selective IFN-γ-producers (Lee t al., 2009). 
1.3.2 Effector cytokines and functions 
Th17 cells can communicate with a broad range of cell types by inducing the 
production of pro-inflammatory cytokines and chemokines, resulting in protection 
from invading microbial pathogens (Korn et al., 2009). These effects are mediated by 
Th17 production of effector cytokines such as IL-17A, IL-17F, IL-21 and IL-22. In 
addition, Th17 cells produce the non-Th17-specific cytokines GM-CSF, IFN-γ and 
IL-10 (El-Behi et al., 2011; Ivanov et al., 2006; McGeachy et al., 2007) widening the 
spectrum of Th17 phenotypes by varying cytokine production and effector function. 
IL-17A and IL-17F belong to the IL-17 family of cytokines, which has four other 
members, designated IL-17A-F. IL-17A and IL-17F arep oduced by Th17 cells, IL-
17E, also known as IL-25, is produced by Th2 cells, whereas the other family 
members, IL-17B, IL-17C, IL-17D, are produced by non-T cell sources (Ouyang et 
al., 2008).  IL-17A and IL-17F can form homo or hetero-dimers, therefore giving rise 
to 3 forms of IL-17: IL-17A/A, IL-17F/F and IL-17A/F, which potentially have 
different biological activities. IL-17A/A appears to be most potent of the three in 
tissue inflammation. However, IL-17A/F is produced in the largest amounts by 
polarised Th17 cells (Liang et al., 2007). IL-17A, IL-17F and IL-17A/F heterodimers 
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signal through the receptor subunits IL-17RA and IL-17RC, which together form a 
heterodimeric complex to transduce downstream signall ng (Kuestner et al., 2007; 
Wright et al., 2008; Yao et al., 1995a). IL-17A and IL-17F cellular expression is 
tightly controlled. However, IL-17RA is expressed ubiquitously (Ishigame et al., 
2009; Yao et al., 1995a). In contrast to IL-17RA expression, IL-17RC is 
preferentially but lowly expressed on non-haematopoietic cells (Kuestner et al., 
2007). This differential expression may provide a mechanism for the tissue-specific 
functions of IL-17. 
Th17 cellular responses do not explain early IL-17-mediated immunity, which is 
vital during stress responses and host defence. Innate sources of IL-17 include γδ T 
cells (Ness-Schwickerath et al., 2010), natural killer T (NKT) cells (Michel et al., 
2008), LTi cells (Takatori et al., 2009), NK cells (Passos et al., 2010) macrophages, 
DCs, neutrophils, mast cells and myeloid cells (Figure 1.5) (reviewed by Cua and 
Tato, 2010). Thus IL-17A and IL-17F are produced by cells of the innate and 
adaptive immune systems, and activation of their receptors results in innate immune 
signalling, acting as a bridging function between in ate and adaptive immunity. The 
exact role of the innate cell populations expressing IL-17 in directing T cell effector 
and memory responses remains to be elucidated. However, it is notable that most IL-
17-producing cells are found in tissues which protect he host from the environment, 
e.g. lungs, intestinal mucosa and skin (Lochner et al., 2008). 




Figure 1.5. Activation of innate cells to produce IL-17.  Innate cells are activated by cytokines 
such as IL-1β and IL-23, alone or in combination with PAMPs or through their TCR when 
expressed. These cells constitutively express transcriptional regulators for IL-17 production so 
can produce IL-17 within hours of stimulation. Adapted from Cua and Tato (2010). 
Both IL-17A and IL-17F are pleiotropic cytokines, acting on a broad range of cell 
types to induce the expression of pro-inflammatory cytokines (IL-6, TNF-α, IL-1β, 
GM-CSF and G-CSF) (Fossiez t al., 1996; Jones and Chan, 2002; Jovanovic et al., 
1998) and chemokines (CXCL1, CXCL8 and CXCL10) (Witowski et al., 2000), 
which  potentially mediate IL-17 function by attracting neutrophils (Laan et al., 
1999), metalloproteinases (Prause et al., 2004) and anti-microbial peptides such as β-
defensins (Kao et al., 2004) in vivo. Accordingly, IL-17A and IL-17F are key 
cytokines in the recruitment, activation and migration of neutrophils to the site of 
inflammation (Aggarwal and Gurney, 2002).  
IL-21 is a member of the IL-2 family of cytokines and the IL-21R is mainly 
expressed on B cells but also on T cells and other myeloid cells (Parrish-Novak et 
al., 2000). It signals via the common γ-chain-receptor and an IL-21-specific receptor 
protein (IL-21R) to activate the JAK-STAT pathway, preferentially phosphorylating 
JAK1 and JAK3 to further activate STAT3 (Asao et al., 2001; Habib et al., 2002). It 
has pleiotropic effects on both innate and adaptive immune responses and its role in 
Th17 immunity is discussed in section 1.3.1. In addition to the differentiation of 
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Th17 cells, IL-21 stimulates proliferation and differentiation of CD8+ T cells 
(Kasaian et al., 2002), B cell differentiation and antibody class switching (Ozaki et 
al., 2004), and NK cell survival and cytotoxicity (Skak et al., 2008). 
IL-22 is a member of the IL-10 family of cytokines (Dumoutier et al., 2000). 
Originally designated a Th1-associated cytokine, it is most highly expressed by Th17 
cells in mice (Liang et al., 2006) and is additionally expressed by activated T cells 
(CD4+, CD8+, γδ and NKT cells), LTi and NK cells (Crellin et al., 2010; Doisne et 
al., 2011; Liu et al., 2011; Martin et al., 2009; Wolk et al., 2002). IL-22 signals 
through the heterodimeric receptor complex of the sp cific IL-22R and IL-10R2 
(Kotenko et al., 2001; Xie et al., 2000), with signal transduction through IL-22R 
activating STAT3. Expression of the IL-22R receptor chain is indicative of an IL-22 
target cell and expression is mostly found in cells from the skin, digestive and 
respiratory tracts (Trivella et al., 2010). Unlike many cytokines, IL-22 does not 
function to communicate between immune cells (Wolk et al., 2010) and acts 
exclusively on non-haematopoietic cells (Sonnenberg et al., 2011). In vivo, IL-22 
expression is critically dependent on IL-23 (Zheng et al., 2007) and in vitro 
production is optimal when IL-23 is present (Liang et al., 2006). 
IL-22 is important in anti-microbial defence, regeneration and protection against 
damage. Not only does it induce the expression of anti-microbial peptides, 
strengthening host defence directly but it also modulates tissue responses during 
inflammation and aids in tissue repair (Hirota et al., 2010). In the context of chronic 
inflammatory disorders, IL-22 may be either protective or highly pathogenic (Wolk 
et al., 2010). Its complex effects depend on the inflammatory context, e.g. on the 
duration and amount of IL-22 present, the surrounding cytokine milieu and the 
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tissues involved (Zenewicz and Flavell, 2011). Overall, IL-22 functions to promote 
barrier immunity by limiting bacterial replication. 
GM-CSF was originally discovered as a haematopoietic growth factor, capable of 
stimulating the proliferation of myeloid cells from bone-marrow progenitors 
(Burgess et al., 1977). It is a member of the common β-chain receptor family of 
haematopoietic cytokines and signals through a heterodimeric receptor composed of 
the ligand-specific CSF2Rα and a signal transducing β-chain, CSF2Rβ (Gearing et 
al., 1989; Hayashida et al., 1990). GM-CSF is now recognised to have a huge range 
of functions. On mature haematopoietic cells, GM-CSF enhances antigen 
presentation, polarisation of macrophages and induction of complement- and 
antibody-mediated phagocytosis as well as priming neutrophils. In addition, it is 
produced by a wide variety of cells including T cells, B cells, macrophages, 
endothelial cells and fibroblasts (reviewed by Fleetwood et al., 2005). It was first 
suggested by Hamilton et al. (1980) that GM-CSF should be viewed as a pro-
inflammatory cytokine and not simply a proliferation factor for macrophages. 
Codarri et al. (2011) and El-Behi et al. (2011) have all shown GM-CSF to be another 
Th17 cytokine, which contributes to the Th17 effector phenotype based on an EAE 
model, the mouse model for MS. GM-CSF, induced by IL-23, is indispensable for 
Th17-mediated EAE pathogenesis; GM-CSF-deficient mice are highly resistant to 
EAE (Ghoreschi et al., 2010). GM-CSF up-regulates IL-6 and IL-23 expression, 
further enhancing GM-CSF production in a positive fe dback loop and promoting de 
novo generation of Th17 cells (El-Behi et al., 2011). There are conflicting data as to 
whether the master regulator, RORγt, is the transcription factor, which drives GM-
CSF production in Th17 cells (Codarri et al., 2011; El-Behi et al., 2011). 
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IFN-γ is the signature cytokine expressed during a Th1 immune response and is 
under the control of the master transcription factor T-bet. It is a type II IFN that is 
critical in innate and adaptive immunity. It is predominantly expressed by APCs, NK 
cells, Th1 cells and CD8+ CTLs (Schroder et al., 2004). IFN-γ up-regulates the MHC 
class I and II presentation pathways on APCs, therefore promoting activation of 
CD8+ and CD4+ T cells. As a major product of Th1 cells, it skews the immune 
response towards a Th1 phenotype promoting cell-mediated immunity via activation 
of NK cells and macrophages. Th17 cells generated in vivo often co-produce IFN-γ 
(Abromson-Leeman et al., 2009; Acosta-Rodriguez et al., 2007a; Ivanov et al., 
2006). Until recently, there was much debate over whether these IL-17-IFN-γ 
double-producing T cells were derived from Th1 or Th17 cells. Hirota et al. (2011) 
settled the debate by generating a mouse that allowed for identification of all cells 
that have ever expressed IL-17, and demonstrated that the IL-17-IFN-γ double-
producing T cells were exclusively derived from Th17 cells. It has not been shown 
conclusively whether the production of IFN-γ by Th17 cells is protective or 
pathogenic (Peters et al., 2011) or what is the functional advantage for Th17 cells in 
demonstrating such plasticity. 
IL-10 was first described as cytokine synthesis inhibitory factor in mice (Fiorentino 
et al., 1989) and is almost certainly the most important anti-inflammatory cytokine in 
mammals. IL-10 is expressed by a huge number of cells including APCs, T and B 
cells, granulocytes, epithelial cells, keratinocytes and mast cells. It limits secretion of 
pro-inflammatory cytokines, deactivates macrophages and controls proliferation of 
many cell types including macrophages, T and B cells (reviewed by Moore et al., 
2001). IL-10 is the primary anti-inflammatory cytokine of the immune system that 
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protects against excessive immune responses and tissue damage, thus maintaining 
immune homeostasis. To exert its actions, IL-10 dimer ses and binds to its tetrameric 
cytokine receptor made up of two molecules of IL-10R  and two molecules of IL-
10R2 (Kotenko et al., 1997; Liu et al., 1994). Th17 cells produce variable amounts 
of IL-10 (McGeachy et al., 2007) as well as expressing the IL-10Rα (Huber et al., 
2011). IL-10-mediated Th17 suppression is brought about by the regulatory functions 
of Tregs but also by direct inhibition through IL-10 signalling (Huber et al., 2011). It 
is hypothesised that Th17 cells may produce IL-10 in order to restrain themselves 
and prevent unnecessary tissue destruction (Peters et al., 2011). 
1.3.3 Pathogenic effects 
Before the discovery of Th17 cells, experimental data from autoimmune disease 
studies could not be explained solely by the Th1/Th2 paradigm. The discovery of IL-
23 (Aggarwal et al., 2003), and its vital role in the development of central nervous 
system autoimmune inflammation (Cua et al., 2003), was the first step in 
understanding the pathogenesis of Th17 immune responses in autoimmunity. Since 
then, Th17 cells and their cytokines have been linked to several autoimmune and 
inflammatory diseases such as rheumatoid arthritis (RA), MS, psoriasis, systemic 
lupus erythematosus (SLE), inflammatory bowel disease (IBD), asthma and allergy 
(reviewed by Hu et al. (2011); Maddur et al. (2012); Ouyang et al. (2008); Qu et al. 
(2013)). The exact pathogenic mechanisms of autoimmune disease are poorly 
understood but the inflammatory cascades triggered by Th17 cells and the effector 
cytokines they express clearly have a role in the pathogenesis. 
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RA is a chronic inflammatory disease of the joints and is one of the most common 
autoimmune-related diseases. Increased levels of IL-17A are seen in sera and 
synovial fluid and increased levels of IL-22 and IL-23 are seen in the synovium of 
RA patients (Ikeuchi et al., 2005; Kim et al., 2007b; Ziolkowska et al., 2000). 
Interestingly, the increase in IL-17A and IL-23 is specific for RA and not 
osteoarthritis (Honorati et al., 2001; Kim et al., 2007a). These Th17 cytokines 
stimulate various cell types to produce cytokines, chemokines and destructive 
mediators which drive inflammation in the joints. 
As previously mentioned, IL-23 is critical for the induction of EAE in mice (Cua et 
al., 2003). In addition, in patients with MS, IL-17A expression is correlated with 
disease activity. IL-17A+ T cells, astrocytes and oligodendrocytes are increased in 
active, rather than inactive, MS lesions (Tzartos et al., 2008). Recently, Codarri et 
al., 2011) showed a critical non-redundant role of Th17-produced GM-CSF in the 
pathogenesis of EAE. GM-CSF drives APCs to secrete IL-23 in a positive feedback-
loop and absence of GM-CSF confers resistance to EAE in mice. However, the exact 
pathogenic role of Th17 cells, or their effector cytokines, in EAE/MS is not well 
understood. 
Psoriasis is a chronic immune-mediated skin disease in which therapeutic antibodies 
against IL-17A have shown promising results in late-stage clinical trials (Leonardi et 
al., 2012). Th17 cells are present in psoriatic lesions (Lowes et al., 2008) and IL-22 
expressed by infiltrating lymphocytes may have a role in the pathogenesis (Boniface 
et al., 2007). In terms of genetics, polymorphisms in IL-12/23 p40 and IL-23R have 
been associated with psoriasis (Nair et al., 2009). 
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In asthmatic patients, the number of Th17 cells in peripheral blood is enhanced (Li et 
al., 2013). IL-17 production induces a broad tissue response, including neutrophil 
trafficking to the site of inflammation and activation of airway smooth muscle cells 
and epithelial cells to produce pro-inflammatory mediators (Korn et al., 2009; Kudo 
et al., 2012). The exact role of Th17 cells in asthma remains elusive despite the 
important roles of IL-17A and IL-17F in airway neutrophilia in a mouse model of 
asthma (Hellings et al., 2003).  
There has been much research in mammals investigating Th17 immune responses, 
from the differentiation factors required, the effector cytokines expressed and the cell 
types upon which they act, to the detrimental effects of failure to control Th17 cells. 
To begin to establish if Th17 cells have a role in the avian immune system, the 
cytokine IL-23 and its receptor need to be identified and characterised in the chicken. 
1.4 Th17 immune responses in birds 
The Th17 cell subset has not yet been described in birds. Several components of 
Th17 immune responses have been identified in the chicken but a few key molecules 
are still currently “missing” from the chicken genome (Table 1.2), including IL-23, 
RORγt and IL-23R. 
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Table 1.2. Th17 immune response components in mammals and chicken. 
Mammalian Th17 
molecule 
Identified in chicken 
TGF-β TGF-β4 is orthologous to mammalian TGF-β1 
(Jakowlew et al., 1997) 
IL-1β (Weining et al., 1998) 
IL-6 (Schneider et al., 2001) 
IL-21 (Rothwell et al., 2012) 
IL-23 - 
RORγt - 
STAT3 (Wang et al., 2007) 
IL-23R - 
IL-17A (Min and Lillehoj, 2002) 
IL-17F (Kim et al., 2012b) 
IL-22 (Kim et al., 2012a) 
GM-CSF (Avery et al., 2004) 
1.4.1 IL-23 
IL-23 is a heterodimeric cytokine composed of a p19 subunit paired with a p40 
subunit, which is shared with IL-12. It is a member of the IL-12 family of cytokines 
(Oppmann et al., 2000). The p19 subunit, similarly to the p35 subunit of IL-12, has a 
four-alpha-helical bundle and is linked to the p40 rotein by disulphide bonds. IL-23 
and IL-12 are constitutively expressed as a binary complex of the p19 or p35 
subunits respectively and p40 (Lupardus and Garcia, 2008). This ensures the 
formation of biologically active protein (Langrish et al., 2004). IL-23 is mainly 
produced by cells of the innate immune system, such as DCs and tissue-resident 
macrophages, in peripheral tissues such as the skin, intestinal mucosa and lungs 
(Basso et al., 2009). Production is stimulated by activation of TLR ligands such as 
LPS, peptidoglycan, CpG deoxyribonucleic acid (DNA) and 
polyinosinic:polycytidylic acid (poly I:C) (Kastelein et al., 2007). Enhanced IL-23 
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production from APCs is also seen with CD40-CD40L interaction. However, the 
regulation of IL-23 expression remains incompletely understood. 
The full differentiation and maintenance of Th17 cells is dependent on IL-23 (Korn 
et al., 2009; McGeachy et al., 2009). However, after identification of the 
differentiation factors required for Th17 cells, it became clear that IL-23 was not 
involved in the initial differentiation stage (Korn et al., 2009) but is fundamental to 
maintain Th17 cells in vitro and in vivo (Chen et al., 2011). Naïve T cells do not 
express IL-23R; RORγt expression is required to control expression of IL-23R on 
newly primed T cells. This in turn expands their responsiveness to IL-23 by 
expression of IL-23R on activated/memory T cells (Aggarwal et al., 2003; Kastelein 
et al., 2007; Kolls and Khader, 2010), allowing Th17 cells to become responsive to 
IL-23 and subsequently allows IL-23 to serve as a survival factor for committed 
Th17 cells (Veldhoen et al., 2006). 
The supposition that the early role of mammalian IL-23 is only in the generation of 
Th17 cells has proven exceedingly over simplified, given the essential role for IL-23 
in several models of autoimmunity such as psoriasis, IBD and EAE has been 
established (Figure 1.6) (Becher t al., 2002; Hedrick et al., 2009; Uhlig et al., 
2006). It is clear that the pathogenic mechanism of IL-23 is not limited to Th17 cells 
and their expression of IL-17A. Multiple IL-23-responsive cell types, which express 
pro-inflammatory cytokines, are emerging. γδ T cells constitutively express the IL-
23R (Sutton et al., 2009) and the epithelium of the skin and gut are enriched with 
these cells. Group 3 ILCs (ILC3s) respond to IL-23 (Buonocore et al., 2010) and IL-
23R signalling drives expression of IFN-γ and IL-17. 




Figure 1.6. The divergent functions of IL-23 in diferent models of autoimmunity.  IL-23 is an 
essential messenger in different models of autoimmunity, including EAE, IBD, and psoriasis. IL-23 
not only acts on conventional αβ T cells but also on innate cells such as γδ T cells and ILCs. However, 
while the involvement of these cell types in the outlined autoimmune diseases has been clearly 
demonstrated in animal models, the relative contribu ion to disease progression in humans remains to 
be determined (Croxford et al., 2012). 
IL-23 may play a role in an early, immediate tissue inflammatory response, through 
the action of innate immune cells such as γδ T cells and ILC3s, as well as later on in 
an antigen-dependent fashion through the action of memory T cells (Croxford et al., 
2012). IL-23 p19 has been identified in many mammalian species (Chen et al., 2009; 
Gossner et al., 2012; Kokuho et al., 2012; Tompkins et al., 2010) and also in a non-
mammalian species, the zebrafish (Danio rerio) (Holt et al., 2011) but to date, it has 
not been identified in an avian species. 
1.4.2 IL-23R 
The receptor for IL-23 is made up of two subunits, IL-12Rβ1 and IL-23R, and is a 
member of the haemopoietin receptor superfamily (Parham et al., 2002). IL-23 and 
IL-12 also share a common subunit, IL-12Rβ1, in their receptor complex due to the 
common p40 subunit. The IL-23R subunit, which binds to the IL-23 p19 subunit, has 
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an extracellular NH2-terminal immunoglobulin-like domain and two cytokine 
receptor domains (Figure 1.7). It is the signalling component of the IL-23 receptor. 
The IL-12Rβ1 subunit contains three membrane-proximal fibronecti  type III and 
two cytokine receptor domains, which interact with IL-23/12 p40 (Langrish et al., 
2004; van de Vosse t al., 2003). Although structurally IL-23R belongs to the class I 
cytokine receptor family, it lacks the three membrane-proximal fibronectin type III-
like domains characteristic of the IL-12 receptor subunits (Kastelein et al., 2007). 




Figure 1.7. The different components of IL-23R, IL-12R and the common STAT3/STAT4 
activation pathway.  IL-12Rβ1 and IL-12Rβ2 each consists of three fibronectin type III (yellow) 
domains and two cytokine receptor (green) domains with an additional immunoglobulin-like domain 
(blue) on the latter. IL-23R closely resembles IL-12Rβ2 but without the fibronectin type III domains. 
The relative proportions of STAT3 or STAT4 activation dictate whether a cell responds to IL-12 or 
IL-23. Adapted from Tang et al. (2012). 
IL-23R is up-regulated on RORγt+ Th17 cells in an IL-6-dependent manner (Ivanov 
et al., 2006) and the generation of normal Th17 cell effector responses requires IL-
23R-dependent signalling (McGeachy et al., 2009). IL-23R expression on T cells at 
the site of inflammation suggests that IL-23R defins a population of infiltrating pro-
Chapter 1 Introduction 
45 
 
inflammatory Th17 cells in the target tissue (Awasthi et al., 2009). In humans, IL-
23R is expressed on activated and memory T cells and previously reported to be 
expressed at low levels on NK cells, monocytes, macrophages and DCs (Parham et 
al., 2002). However, recently, with the advent of RORγt-enhanced green fluorescent 
protein (eGFP) and IL-23R-eGFP reporter mice (Awasthi e  al., 2009), the majority 
of IL-23R expression has been localised to γδ T cells and cells of the innate immune 
system, such as γδ T cells and ILC3s (Chognard et al., 2014; Zuniga et al., 2013), as 
discussed in section 1.4.1. 
IL-23 induces signalling via IL-23R through the signalling chains JAK2 and tyrosine 
kinase 2 (Tyk2), leading to activation of STAT3 and STAT4 (Parham et al., 2002). 
Stimulation of the IL-23R complex induces tyrosine phosphorylation of JAK2 and 
Tyk2. Consequently, the STATs are phosphorylated, dimerised and translocated into 
the nucleus, which activates target genes. STAT3 is essential for development of 
Th17 cells and is required for expression of IL-17A, IL-17F and RORγt. The major 
difference between the signal transduction cascades of IL-23 and IL-12 is the level of 
STAT3 and STAT4 phosphorylation; IL-23 induces stronger phosphorylation of 
STAT3 versus STAT4 and the reverse is true for IL-12 (Oppmann et al., 2000). 
As mentioned previously, Th17 immune responses and IL-23 play a crucial role in 
mammalian autoimmune diseases. In humans, polymorphisms in IL-23R have been 
linked to genetic susceptibility to autoimmune diseas s such as psoriasis and IBD 
(Crohn’s disease and ulcerative colitis) (Cargill et al., 2007; Duerr et al., 2006). 
Development of IL-23R antagonists is a rapidly expanding area of autoimmunity 
therapy; fifteen IL-23R antagonists are now reported to be in pre-clinical or clinical 
development from twelve different companies (Tang et al., 2012). 
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The identification of IL-23 and its receptor in mammals (section 1.3) initiated the 
discovery of a third Th subset in mammals. Whilst IL-23 is not required for Th17 
differentiation, it is vital to the maintenance of Th17 cells in mammals and 
identifying this cytokine and its receptor in chicken is the first step towards 
confirming there are Th17 immune responses in birds. 
1.5 Infectious disease models 
Expression of Th17-related cytokines during infection n the chicken will shed light 
on the possible involvement of Th17 immune responses in diseases previously 
recognised as being controlled by Th1 or Th2 immune responses. To this end, 
archived samples from two Th1 infection models (Marek’s disease (MD) and 
infectious bursal disease and a Th2 infection model (histomoniasis) were 
investigated to see if Th17 cytokines were induced. As discussed in section 1.3, the 
Th17 immune response represents an arm of the adaptive immune system which 
functions to clear specific types of pathogen not effectively neutralised by Th1 or 
Th2 immunity (Korn et al., 2009). Current data imply a specialised evolutionary 
function of Th17 cells to promote protective immunity at mucosal sites against a 
variety of pathogens (Kolls and Khader, 2010) and i mammals Th17 cells are 
widely considered to be the main arsenal in host defenc  against extracellular 
bacteria (Peck and Mellins, 2010) such as Staphylococcus aureus. This is a disease 
model already established in the chicken at The Roslin Institute and it was used to 
outline the expression of Th17 cytokines during infection, to further compare avian 
Th17 immune responses to those in mammals. 
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1.5.1 Marek’s disease 
MD is a neuropathic and lymphoproliferative disease of birds caused by MD virus 
(MDV), which is a highly cell-associated, lymphotropic alphaherpes virus (Schat and 
Xing, 2000). It is a double-stranded DNA virus with molecular structure and 
genomic organisation similar to herpes simplex virus. There are three serotypes that 
differ at both the genome and biological level. Serotype 1 MDV includes all the 
oncogenic strains and their attenuated forms, serotype 2 MDV are non-oncogenic 
viruses isolated from chickens and serotype 3 MDV are non-oncogenic viruses 
isolated from turkeys (Gimeno, 2008). All chicken genotypes are susceptible to 
MDV infection but they differ greatly in their resistance or susceptibility to clinical 
disease, e.g. inbred line 61 is resistant, whereas line 72 is susceptible to clinical 
disease (Lee et al., 1981). Genes encoded in the chicken MHC locus contribute to 
MD resistance (Koch et al., 2007). The B21 haplotype is the most resistant and B19 
the most susceptible to disease. However, other genes also exert a strong influence 
on MD resistance. For example, lines 61 and 72 are MHC-congenic (Cole, 1968) and 
MD resistance in line 61 has been mapped to genetic loci outside the MHC locus 
(Bumstead, 1998; Smith et al., 2011). MDV vaccines are highly protective, often 
achieving close to 100% protection under commercial conditions. However, there is 
growing evidence that virulence of MDV is increasing due to the intensive use of 
vaccines (Witter, 1997). 
MDV is not vertically transmitted through infected ggs; however, chicks become 
infected after hatching via a heavily contaminated environment. The natural route of 
MDV infection is via the respiratory tract following inhalation of infectious cell-free 
MDV present in dander shed from feather follicles. The virus is incredibly stable in 
Chapter 1 Introduction 
48 
 
the environment. Various factors such as virus strain and dosage, gender and genetic 
resistance of the host, presence of maternal antibodies and environmental factors 
affect the clinical outcome (Nair, 2014).  
Based on the ‘Cornell Model’ (Calnek, 1986), there are four phases of MDV 
pathogenesis (Figure 1.8). MDV is inhaled and infects macrophages in the lung. 
During the early cytolytic phase, B cells become infected as a result of infected 
macrophages tracking to the spleen. T cells are activated by infected B cells and 
subsequently are also infected with MDV. At this stage, the virus is able to enter a 
latent phase, where depending on the pathotype of the virus and the genotype of the 
host, T cells are transformed and proliferate to form malignant tumours. MDV is 
shed into the environment in the feather follicle epithelium. 
 
Figure 1.8. The infection cycle of MDV. The virus enters the chicken and infects phagocytes.  B 
cells and T cells are subsequently infected and some T cells enter a state of latency.  The T cells can 
then transform and cause tumours in the bird.  The virus is shed within the feather follicle epithelial 
cells (Davison and Nair, 2008). 
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The immune response to MDV infection involves CTL responses and antibody 
production. The defining role of cytokines in MDV pathogenesis and immunity 
remains unclear (Heidari et al., 2008), it has been established that IFN-γ expression 
is up-regulated during MDV infection and a predominantly Th1-type immune 
response is seen in chickens infected with MDV (Volpini et al., 1995; Xing and 
Schat, 2000). Our group also showed increased IFN-γ mRNA levels in both 
susceptible and resistant genotypes infected with MDV. Further, increased mRNA 
expression of IL-6 and IL-18 was detected in MDV infected susceptible genotypes 
compared to resistant genotypes (Kaiser et al., 2003). Th17 cytokines have yet to be 
measured during MD. 
1.5.2 Infectious bursal disease 
Infectious bursal disease virus (IBDV) is a non-enveloped double-stranded RNA 
virus of the family Birnaviridae.  Its simple structure makes the virus highly resistant 
in the environment and this is an important issue in the control of the disease. There 
are two serotypes recognised: serotype 1, which only causes disease in chickens and 
serotype 2, which was isolated from turkeys and is considered non-pathogenic in 
chickens (McFerran et al., 1980). Based on virulence, serotype 1 strains are 
classified as classical, intermediate, virulent andvery virulent (van den Berg et al., 
2000). 
IBDV causes immunosuppression in chickens as a result of aggressive destruction of 
B cells in the lymphoid organs, particularly the bursa of Fabricius. In the acute form, 
birds show signs of depression and dehydration. In vitro studies have shown that 
IBDV replicates in proliferating B cells (Muller, 1986) and the severity of the disease 
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is directly related to the number of susceptible B cells present in the bursa of 
Fabricius. Consequently, chicks between 3-6 weeks of age are most susceptible to 
disease (Ingrao et al., 2013). Bursectomised chickens survive infection with IBDV 
(Okoye and Uzoukwu, 1990).  
It is hypothesised that IBDV enters the host via the oral route and gut-associated 
macrophages transport the virus from the digestive tract to the bursa of Fabricius and 
other peripheral organs (Kaufer and Weiss, 1976). All parts of the chicken immune 
system are affected during infection with IBDV (Figure 1.9). The virus destroys B 
cells, attracts T cells and activates macrophages but the molecular basis for IBDV 
pathogenicity is still poorly understood (Ingrao et al., 2013). What is known is that 
bursal T cells are activated and gene transcription of pro-inflammatory cytokines, 
e.g. chIL-1β, chIL-6, CXCi2 and chIFN-γ, is up-regulated during the acute phase of 
IBDV infection (Eldaghayes et al., 2006). Further, Liu et al. (2010) demonstrated up-
regulation of Th1 and Th2 cytokines during IBDV infection, indicating that the 
primary immune response is likely to be cell-mediated. Th17 cytokines have yet to 
be measured in Infectious bursal disease. 




Figure 1.9. Interactions between IBDV and the host immune cells (Ingrao et al., 2013). 
1.5.3 Histomoniasis 
The trichomonad Histomonas meleagridis (H. meleagridis) is a flagellate, amoeboid, 
extracellular protozoan parasite that causes the dis ase histomoniasis in galliform 
birds (formerly known as enterohepatitis or ‘blackhead’ disease). Typically, birds 
show signs of anorexia and depression due to enterohepatitis. It can infect all species 
of galliform birds but its pathogenicity varies markedly between species. The most 
prominent lesions are seen in the caeca. Chickens rcover quickly but become 
healthy carriers of the protozoan whereas turkeys show more severe caecal lesions as 
well as liver lesions and mortality can be very high, approaching nearly 100%. Birds 
become infected with H. meleagridis by ingesting infected embryonated eggs of 
Heterakis gallinarum (H. gallinarum), which is a caecal worm.  
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The importance of the caecal worm as a H. meleagridis vector was discovered by 
Graybill (1921) and the chicken was identified as the best host for caecal worms and 
a reservoir of infection (Lund and Chute, 1974). In turkeys, bird-to-bird transmission 
of H. meleagridis is possible by ‘cloacal drinking’, where protozoa shed in the faeces 
are taken up by the cloaca and transported by retrograde peristalsis to the caeca (Hu 
and McDougald, 2003). The ‘cloacal drinking’ phenomena is also well-known in 
chickens but bird-to-bird transmission of H. meleagridis infection has not been 
shown (Hu et al., 2006). Under experimental conditions, intra-cloacal infection with 
infected caeca and liver tissues eliminates the need for the vector thus avoiding any 
immune response to H. gallinarum complicating the immune response to H.
meleagridis (Powell et al., 2009). This is important when investigating cytokine 
expression in response to H. meleagridis infection so that any immune response 
measured can be more confidently attributed to this infection and not to the vector H. 
gallinarum as well. 
The chicken mounts a typical Th2-type immune respone to H. meleagridis infection, 
with increased expression of IL-13 (Powell t al., 2009). Further, Powell et al. 
(2009) also showed the chicken mounts an earlier innate immune response in the 
caecal tonsil compared to the turkey when infected with H. meleagridis, possibly 
limiting the movement of protozoa from the caeca to the liver in the chicken. The 
expression of Th17 cytokines in H. meleagridis infection in chicken has not been 
investigated to-date. 
Chapter 1 Introduction 
53 
 
1.5.4 Staphylococcus aureus infection 
Staphylococcus aureus (S. aureus) is a Gram-positive, catalase-positive, coccoid 
bacteria. It is a commensal bacteria of the skin and mucosal surfaces and an 
opportunistic pathogen. S. aureus is associated with several infections of poultry 
including septic arthritis, subdermal abscesses (‘bum le foot’) and gangrenous 
dermatitis.  S. aureus is a ubiquitous organism in the poultry house environment and 
can be isolated from the litter, dust and feathers (Skeeles, 1997). Bacterial 
chondronecrosis with osteomyelitis (BCO) was first reported as a cause of lameness 
in commercial broiler chickens in 1972 (Nairn and Watson). It is now recognised as 
the most common cause of lameness in commercial birds (Dinev, 2009; McNamee, 
1999; McNamee and Smyth, 2000) with S. aureus being the most common cause of 
BCO in commercial chickens (McNamee and Smyth, 2000).  
The exact pathogenesis of BCO remains unclear. S. aureus must enter the circulatory 
system in order for bacteraemia to develop. Injury, an open naval post-hatching and 
the respiratory system have all been implicated as possible routes of entry into the 
bloodstream (reviewed by McNamee and Smyth (2000)). Once in the circulation, 
staphylococci have a high affinity for collagen-rich surfaces (Nade and Speers, 1987) 
and tend to localise in the growth plate of actively growing bones (Speers and Nade, 
1985), explaining the higher incidence of BCO in young chickens. Since bacteraemia 
is required for BCO development, development of the disease has been studied by 
injecting S. aureus intravenously. An established experimental BCO model, this has 
also been used extensively as a model for acute haematogenous staphylococcal 
osteomyelitis of human infants (Daum et al., 1990; Emslie et al., 1983).  
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The strong relationship of Th17 cells with the mammalian immune response to S. 
aureus infection is well established (Cho et al., 2010; Frodermann et al., 2011; 
Henningsson et al., 2010). Early innate signalling, which drives the appropriate 
adaptive response to a pathogen, in response to S. aureus infection, results in 
production of IL-23 (Volz et al., 2010). Also, humans and mice lacking Th17 
immune responses show increased susceptibility to S. aureus infections (Ma et al., 
2008; Renner et al., 2008). Of the pathogens in mammals known to drive Th17 
immune responses and, therefore, require a Th17 adaptive response to overcome 
infection, S. aureus infection is currently the only disease model established in 
poultry. 
The theory is the disease models, MDV and IBDV, typically inducing Th1-type 
immune responses in the chicken, the Th2-inducing infection, H. meleagridis in 
chicken and the mammalian Th17-inducing immune respon es of S. aureus, would 
provide a fundamental basis to further investigations f Th17 immune responses in 
birds.
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1.6 Hypothesis and aims of the project 
As previously discussed, there are both similarities and significant differences 
between the avian and mammalian immune system. The evolutionary distance 
between birds and mammals, and the speed of orthologous sequence divergence 
under selective pressure from pathogens, has resulted in relatively slow progress in 
cloning and characterising avian cytokines. Mammalian reagents and bioassays often 
do not cross-react with avian molecules as aa sequence identities are often as low as 
25% (Kaiser et al., 2005). This project aims to establish whether Th17 and associated 
immune responses exist in the chicken. The hypothesis was that chickens have Th17 
cells, are able to mount Th17-associated immune responses and that the driving 
cytokine IL-23 has a similar biological role to tha seen in mammals. 
To test the hypothesis, the aim will be to clone and characterise IL-17F, IL-23, IL-
23R and RORγt, and to investigate of the expression and effects of chicken Th17 
cytokines in vitro on chicken-derived tissues and during infection in the chicken. The 
biological activity and effects of IL-23 on immune c lls in the chicken will also be 
investigated. Additionally, the biological activity and effects of IL-23 on immune 
cells in the chicken will be investigated. Finally, attempts will be made to drive 
CD4+ T cells to a Th17 phenotype, using the chicken orthologues of the cytokines 
that drive such differentiation in mammals. 
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Chapter 2 Materials and methods 
2.1 In silico  software packages 
2.1.1 ClustalX 
ClustalX allows multiple alignments of nucleotide (nt) or aa sequences (Thompson et 
al., 1994). ClustalX is currently maintained at the Conway Institute, University 
College Dublin, Dublin. 
2.1.2 Multalin 
Multalin allows multiple alignments of nt or aa sequ nces (Corpet, 1988).  
2.1.3 GeneDoc 
GeneDoc is a multiple sequence alignment software tool, which allows editing, 
analysing and a shading utility for use in Windows (Nicholas et al., 1997). GeneDoc 
was used to produce highly configurable exported figures of ClustalX aa alignments. 
Further information on the software can be found at: 
http://www.psc.edu/biomed/genedoc 
2.1.4 SignalP3.0 
SignalP3.0 (Centre for Biological Sequence Analysis, Technical University of 
Denmark DTU; http://www.cbs.dtu.dk/services/SignalP/) is an online server, which 
predicts the existence and position of signal peptid s as well as the exact residues 
where cleavage will occur in an aa sequence (Bendts e  al., 2004). 
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2.2 Sources of chicken tissues and cells 
2.2.1 J line birds 
All tissue samples were extracted from vaccinated 4-9-week-old J line birds, from a 
flock maintained in The Roslin Institute Poultry Unit. All birds were vaccinated 
against MDV, coccidiosis, Newcastle Disease virus, infectious bronchitis virus, 
IBDV, chicken anaemia virus, avian encephalomyelitis virus and infectious 
laryngotracheitis virus. 
2.2.2 MDV challenged line 6 1 and line 7 2 birds 
Two-week-old White Leghorn specific pathogen free (SPF) chickens of the inbred 
lines 61 (MDV resistant) and 72 (MDV susceptible) were challenged with MDV 
strain RB1B as described by Smith et al. (2011). Archived RNA samples from spleen 
at 2, 3 and 4 days post-infection (dpi) from 2 uninfected control birds and 3 infected 
birds were used. 
2.2.3 IBDV challenged birds 
Four-week-old out-bred Rhode Island Red chickens reared from the SPF flock 
maintained at the Institute of Animal Health, Compton, United Kingdom were 
challenged with a very virulent strain of IBDV as described by Maghoub (2010). 
Archived RNA samples from caecal tonsil at 1, 3 and4 dpi from 1 uninfected control 
bird and 3 infected birds were used. 
2.2.4 Histomonas meleagridis challenged birds 
Breeder cockerels at 4-weeks of age were challenged with H. meleagridis as 
described in the second chicken study by Powell et al. (2009). Archived RNA 
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samples from caecal tonsil at 1, 2, 3, 4, 6, 8, 10, 12, 18, 24 and 30 dpi from 2 
uninfected control birds and 3 infected birds were us d. 
2.2.5 Staphylococcus aureus challenged birds (pilot  study) 
This study was carried out in collaboration with Prof. Ross Fitzgerald and Dr 
Andreas Lengeling. Four-week-old female Cobb-Vantress broilers, obtained as eggs 
from Cobb-Vantress, were hatched and reared in The Roslin Poultry Unit, University 
of Edinburgh, United Kingdom, before being transferred to the high security unit, 
Moredun Research Institute, Penecuik, United Kingdom. Bacterial virulence of the 
wild-type S. aureus CIX2 strain was compared to an isogenic mutant strain of S. 
aureus in which a β-converting phage (ϕAvβ) had been deleted from the bacterial 
genome. Twenty-five 29 day-old female Cobb broilers were divided into 4 groups: 
wild-type (7 birds), mutant (7 birds), co-infected (6 birds) and control (5 birds). Each 
bird was infected intravenously with the same volume (200 μl) and number of 
bacteria (4 x 104 colony forming units (CFU)/ml) of either the wild-type or mutant S. 
aureus strains, or co-infected with equal numbers of both bacterial strains in the 
same volume of inocula (total 8 x 104 CFU/ml). The control group was administered 
phosphate buffered saline (PBS) (Central Services Unit, The Roslin Institute) 
intravenously. The birds were housed in pens on the floor in the same room and 
monitored for disease phenotypes over a period of 11 days. Half of the birds were 
culled and sampled 6 dpi and the remaining birds were culled and sampled 11 dpi. 
Tissues sampled (spleen, bursa, thymus, liver and bo e marrow from the femur) were 
placed in RNAlater for RNA extraction (section 2.3.2) and Th17 cytokine mRNA 
expression by TaqMan® RT-qPCR assay as described in sections 1.1.1.1 and 2.4.3.6. 
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2.2.6 Chicken tissue panel 
Tissues (brain, muscle, heart, liver, kidney, lung, skin, crop, gizzard, upper gut, 
caecum, mid-gut, caecal tonsil, Meckel’s diverticulum, Harderian gland, bursa of 
Fabricius, femurs for bone marrow, spleen and thymus) were harvested from J line 
birds at 4-9 weeks of age. Tissues were collected and stored in RNAlater (Ambion®) 
at -20°C until RNA was purified. 
2.3 Plasmid purification 
2.3.1 DNA isolation 
2.3.1.1 Minipreps (small scale) 
Bacterial colonies were picked from LB plates and ioculated into 5 ml of LB 
containing 100 µg/ml of ampicillin. These were cultured overnight at 37°C with 
shaking at 200 rpm. These cells were pelleted with centrifugation at 1800 x g for 15 
min at 4°C and the supernatant discarded. Minipreps were carried out using the 
QIAprep Spin Miniprep kit (Qiagen) following the manufacturer’s protocol. DNA 
concentration was determined using a Nanodrop ND 1000 spectrophotometer. 
2.3.1.2 Maxipreps (large scale) 
Bacterial colonies were picked from LB plates and ioculated into 5 ml of LB broth 
containing 100 µg/ml of ampicillin. These were cultured for 6 h at 37°C with shaking 
at 200 rpm. Day culture (2.5 ml) were used to inoculate 200 ml of LB broth 
containing 100 µg/ml of ampicillin in a 1 l flask and cultured overnight at 37°C with 
shaking at 200 rpm. These cells were pelleted with centrifugation at 6000 x g for 15 
min at 4°C and the supernatant discarded. Maxipreps were carried out using an 
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Endofree Plasmid Maxi kit (Qiagen) following the manufacturer’s protocol. DNA 
concentration was determined using a Nanodrop ND 1000 spectrophotometer. 
2.3.2 RNA isolation 
2.3.2.1 Isolation of total RNA from chicken tissue 
Total RNA was purified from chicken tissue using the RNeasy® Mini Kit (Qiagen) 
following the manufacturers’ protocol for purification of total RNA from animal 
tissues. Fresh tissues were stabilised in RNAlater® (Ambion®) and frozen at -20°C 
until processed. After thawing, 30 mg of tissue was lysed and homogenised using a 
rotor-stator homogeniser in 600 µl of buffer RLT with β-mercaptoethanol (1/100) in 
a lysing matrix tube (MP Biomedicals). All samples were homogenised for 40 s. 
Following homogenisation, samples were centrifuged at 13,000 x g for 3 min. The 
supernatant was pipetted off and 1 volume of 70% ethanol (RNase-free) was added. 
Samples were applied to RNeasy® mini columns and centrifuged at 8,000 x g for 15 
s. Residual fluids were discarded before the addition of 700 μl of buffer RW1 and 
centrifugation again at 8,000 x g for 15 s. Residual fluids were discarded and 500 μl 
of buffer RPE was added, followed by centrifugation at 8,000 x g for 15 s. This step 
was repeated a second time before the RNeasy® mini column was placed in a new 
collection tube and centrifuged at 8,000 x g for 1 min. RNA was eluted into a clean 
1.5 ml tube with 50 µl nuclease-treated H2O (Ambion®) by centrifugation at 8,000 x 
g for 1 min. RNA was stored at -20°C prior to use. 
2.3.2.2 DNase treatment of RNA samples 
DNase digestion is generally not required with RNeasy® Kits since RNeasy® silica 
membrane technology efficiently removes most of theDNA without DNase 
Chapter 2 Materials and methods 
61 
 
treatment. However, further DNA removal may be necessary for certain RNA 
applications that are sensitive to very small amounts of DNA. DNA can also be 
removed by DNase digestion following RNA isolation. 
2.3.2.2.1 On-column DNase treatment during RNA extraction 
RNA samples from the S. aureus pilot study were on-column DNase treated during 
RNA extraction. An RNase-Free DNase Set (Qiagen) was used according to the 
manufacturer’s protocol to digest DNA on-column during RNA purification as in 
section 2.3.2.1. Briefly, the sample was applied to an RNeasy® mini column, 
centrifuged at 8,000 x g for 15 s and the residual fluid discarded. Buffer RW1 (350 
μl) were applied to the RNeasy® mini column and centrifuged again at 8,000 x g for 
15 s. The residual fluid was discarded. DNase I stock solution (10 μl) was added to 
70 μl buffer RDD and mixed gently by inversion. DNase I incubation mix (80 μl) 
was added directly to the RNeasy® mini column and incubated at RT for 15 min. 
Buffer RW1 (350 μl) was added to the RNeasy® mini column and centrifuged at 
8,000 x g for 15 s. The residual fluid was discarded. The protocol was continued as 
described in section 2.3.2.1 with the addition of 500 μl buffer RPE. 
2.3.2.2.2 Removal of contaminating DNA from RNA preparations 
To compare mRNA detection by TaqMan® in DNase-treated versus non-DNase-
treated RNA samples, a TURBO DNA-free™ kit (Ambion®) was used according to 
the manufacturers’ protocol. In brief, 0.1 volumes of 10X TURBO DNase buffer and 
1 μl TURBO DNase were added to 20 μl RNA and incubated at 37°C for 30 min. 
Two microlitres re-suspended DNase inactivation reagent were added, mixed well 
and incubated at RT for 5 min, mixing occasionally. The sample was centrifuged at 
Chapter 2 Materials and methods 
62 
 
10,000 x g for 1.5 min to pellet DNA and DNase enzymes. The RNA in the 
supernatant was carefully pipetted off and transferred to a clean Eppendorf tube for 
storage at -20°C prior to use. 
2.3.3 Agarose gel electrophoresis of DNA 
Products (5 µl) from all PCR and restriction enzyme digests were analysed by gel  
electrophoresis. The products were combined with 6X loading buffer (Invitrogen) 
and loaded into a 0.7% (products larger than 500 nt) or 1.5% (products smaller than 
500 nt) gel, composed of agarose dissolved in Tris-acetate- 
ethylenediaminetetraacetic acid (EDTA) (TAE) buffer. 1X SYBR® Safe (Life 
Technologies) was incorporated into the gel to allow DNA to be visualised under an 
ultraviolet illuminator. Five microlitres of DNA marker ladder (Invitrogen TrackIt 
100 bp ladder or Thermo Scientific GeneRuler™ DNA Ladder Mix) was used to 
estimate product size. 
2.3.4 PCR purification 
Single PCR products of interest were purified using a QIAquick PCR Purification kit 
(Qiagen) following the manufacturer’s protocol. Five olumes of buffer PB were 
added to 1 volume PCR reaction, mixed, and added to a QIAquick spin column in a 2 
ml collection tube. Centrifugation was carried out at 13,000 x g for 1 min. The flow-
through was discarded and the column washed with 750 μl buffer PE. Residual fluids 
were discarded following centrifugation at 13,000 x g for 1 min. A further 
centrifugation at 13,000 x g for 1 min eliminated possible carryover of ethanol. 
Elution was carried out in a clean 1.5 ml tube with 30 µl of buffer EB by 
centrifugation at 13,000 x g for 1 min following 1 min incubation at RT. 
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2.3.5 Gel purification 
Where multiple products of interest were present in one reaction, the cDNA was 
electrophoresed on an agarose gel. The fragments of interest were excised with a 
clean scalpel and purified using a QIAquick Gel Extrac ion kit (Qiagen), following 
the manufacturers' protocol. Briefly, buffer QG was added at 3 times the volume of 
the gel and incubated at 50°C. One gel volume of ispropanol was added to the 
sample, mixed and added to a QIAquick spin column in a 2 ml collection tube. The 
tube was centrifuged at 13,000 x g for 1 min. Residual fluid was discarded, the 
column washed with 500 μl of buffer QG and centrifuged at 13,000 x g for 1 min. 
Residual fluid was discarded, the column washed with 750 µl buffer PE and 
centrifuged at 13,000 x g for 1 min. Contaminants were discarded in the flow-
through and the column centrifuged for a further 1 min at 13,000 x g. Elution was 
carried out in a clean tube with 30 µl of buffer EBand centrifuged at 13,000 x g for 1 
min following 1 min incubation at RT. 
2.4 DNA and RNA amplification 
2.4.1 Oligonucleotide primer design 
Oligonucleotide primers were used to generate cDNA templates, amplify cDNA in 
PCR and RACE-PCR, measure expression of mRNA by TaqMan® and SBYR® 
Green assays and for sequencing of PCR products (Table 2.1, Table 2.2, Table 2.3, 
Table 2.4 and Table 2.5). Primers and probes were dsigned manually with the 
exception of TaqMan® primers and probe sets, which were designed using Primer 
Express v3 (Applied Biosystems). IL-23 p19 TaqMan® primers and probe were 
custom-designed by Applied Biosystems. 
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Table 2.1. Primer sequences for PCR 
Primer name Target for amplification Sequence (5’ – 3’) 
OligodT_20 mRNA transcripts TTTTTTTTTTTTTTTTTTTT 
IL-17A_F1 IL-17A cDNA ATGTCTCCGATCCCTTGTTC 
IL-17A_R1 IL-17A cDNA TTAAGCCTGGTGCTGGATCA 
IL-17F_F3 IL-17F cDNA ATGGCTTTTGCTAGCTGTGCTGC 
IL-17F_R2 IL-17F cDNA CTAGGACTGGTGCTGGATGACC 
IL-23_F1 IL-23 EST cDNA GCACGAGGAGGACATGGA 
IL-23_R1 IL-23 EST cDNA GGAACGCATGGGGACCTG 
IL-23_F2 IL-23 p19 cDNA ATGGCCCCGCTCCGCCGC 
IL-23_R3 IL-23 p19 cDNA TCAGCGGGTGCTGGCGCC 
IL-23R_F10 IL-23R cDNA ATGAACGCTTTCACTGTGCTTGAA 
IL-23R_R1b IL-23R cDNA TCAAAACAATCTTCCGATGCTCTG 
Table 2.2. Primer sequences for 5’ and 3’ RACE-PCR 
Primer name Sequence (5’ – 3’) 
IL-23_GSP_F1 GACATCTTCGCCACACACCCACA 
IL-23_GSP_RC1 CAGAGCGTGCTGTTCGTGTCCAGC 
IL-23 GSP NF1 GCTGAAGGCGGTGCTGGAGGAGC 
IL-23 GSP NRC1 TCGCAGGCGTCGCTGCAGCGGATG 
IL-23R GSP F1 GCACCTCCCCATAACACGGCCAC 
IL-23R GSP RC1 GCTGTTTGTGAATTCACTCTTCTCC 
IL-23R GSP NF1 GAGGACGTCAGTGACTACAAACCC 
IL-23R GSP NRC1 GGAAGGACTTTATCACCTTGCTG 
Table 2.3. Primer sequences for SYBR® Green. 
Primer Name Sequence (5’ – 3’) 
p19_F1 GTGGAGAGGAGGACATGGAG  
p19_F2 CTGGGGACAATGAAGGAGTC  
p19_F3 GGGACAATGAAGGAGTCGCA  
p19_F4 ATGGAGGGGGAGTG GCC  
p19_F5 GAGCGGGGTCCGTC  
p19_F6 GTCCGTCTGGGTGGAG  
p19_R1 GGTGTGTGGCGAAGATGTC  
p19_R2 AGAGCGTGCTGTTCGTGT C  
p19_R3 GGCACACTCCCCCTCCAT  
p19_R4 GTGTGGCGAAGATGTCGG AG  
p19_R5 CGAGGCTCAGCAGCTC 
p19_R6 CGAGTGTGCCGTGCTG  
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Table 2.4. Primer and probe sequences for TaqMan®.  a indicates MGB probe. F = forward 
primer; R = reverse primer; P = probe; ex-COS = RNA for standards expressed in COS-7 cells. 
















































P: AGGAATCGCACCTACACCTTGGCTGA  
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IFNγ ex-COS 0.6 
Table 2.5. Primer sequences for sequencing vector inserts. 
Primer Name Sequence (5’ – 3’) 
T7 TAATACGACTCACTATAGG 
SP6 ATTTAGGTGACACTATAG 
pcDNA3.1 reverse TAGAAGGCACAGTCGAGG 
pTargeT_Rev TTACGCCAAGTTATTTAGGTGACA 
IL-23R_F9 TGGCATGTGACAGCATGGGAC 
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2.4.2 cDNA synthesis 
Reverse transcription was carried out with 5 µl total RNA as a template in a standard 
20 µl reaction, which contained 5X First Strand buffer (Invitrogen) (4 µl) mixed with 
1 µl of 0.1 M dithiothreitol (DTT), 1 µl PCR Grade Nucleotide Mix (Roche), 1 µl of 
oligo(dT)20 (50 µM) or 2 pmol gene-specific reverse primer (Table 2.6) 1 µl 
RNAsin (Promega), 1 µl SuperScript III (Invitrogen) and 6 µl nuclease-treated H2O 
(Ambion®). First strand synthesis was carried out for 1 h at 50°C if using 
oligo(dT)20 primer or 1 h at 55°C if using a gene-sp cific reverse primer, followed 
by incubation at 70°C for 15 min to inactivate the reaction. The cDNA products were 
used as a template to carry out PCR. If the cDNA product was to be used for SYBR® 
Green quantitative RT-PCR (section 2.4.3.8) then complementary RNA was 
removed by the addition of 1 μl RNase H (Life Technologies) and further incubation 
at 37°C for 20 min.  
Table 2.6. Primers used for reverse transcription. 




2.4.3 PCR amplification of DNA 
2.4.3.1 Standard PCR 
PCR reactions were performed in a standard 30 µl reaction containing 1 µl of cDNA 
template, 1X final volume of PCR buffer (Promega), 1.5 mM magnesium chloride 
(MgCl2) (Promega), 0.4 mM PCR Grade Nucleotide Mix, 12 µMof each primer 
(Table 2.1) and 0.5 units of Go Taq® DNA polymerase (Promega). Thermal cycling 
was performed as described in Table 2.7. 
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Table 2.7. Cycling conditions for standard PCR. 
Step IL-17F Cycles 
Initial denaturation 95°C, 3 min 1 x 
Denaturation 95°C, 1 min 
30 x Annealing 65°C, 2 min 
Extension 72°C, 2 min 
Final extension 72°C, 10 min 1 x 
Cooling 12°C, hold  
2.4.3.2 IL-23 PCR 
The Expand High Fidelity PCR system (Roche) was used to clone chIL-23 p19.  A 
30 µl reaction contained 0.6 µl of cDNA template, 3 µl 10X Expand High Fidelity 
buffer, 0.2 mM dNTPs, final concentration 0.3 µM of each primer (Table 2.1) and 
1.6 U of Expand High Fidelity enzyme mix. Thermal cycling was performed as 
described in Table 2.8. 
Table 2.8. Cycling conditions for Expand High Fidelity PCR System (Roche). 
Step Temperature (°C) Time Cycles 
Initial denaturation 95 2 min 1 x 
Denaturation 95 40 s 
8 x Annealing 64 40 s 
Extension 72 1 min 
Denaturation 95 40 s 
8 x Annealing 63 40 s 
Extension 72 1 min 
Denaturation 95 40 s 
25 x Annealing 62 40 s 
Extension 72 1 min 
Final extension 72 10 min 1 x 
Cooling 12 Hold  
2.4.3.3 IL-23R PCR 
The GC-Rich PCR System, dNTPack (Roche) was used to clone chIL-23R. A 30 µl 
reaction contained 1 µl of cDNA template, 6 µl 5X GC-RICH PCR reaction buffer, 1 
µl PCR Grade Nucleotide Mix, final reaction concentration 0.2 µM of each primer 
(Table 2.1), 4 mM of MgCl2, and 0.5 M Resolution Solution and 1.25 U GC-RICH 
PCR system enzyme mix. Thermal cycling was performed as described in Table 2.9. 
Chapter 2 Materials and methods 
68 
 
Table 2.9. Cycling conditions for GC-Rich PCR System, dNTPack (Roche). 
Step Temperature (°C) Time Cycles 
Initial denaturation 95 3 min 1 x 
Denaturation 95 30 s 
8 x Annealing 62 30 s 
Extension 72 2.5 min 
Denaturation 94 30 s 
8 x Annealing 
62 30 s 
Extension 72 3 min + 5 s cycle elongation 
for each successive cycle 
Final extension 72 7 min 1 x 
Cooling 12 Hold  
2.4.3.4 5’ and 3’ Rapid amplification of cDNA ends (RACE) 
5’ and 3’ RACE were performed using a SMARTer™ RACE cDNA amplification 
kit (Clontech) and an Advantage PCR 2 kit (Clontech).  The manufacturer’s 
instructions were followed and primers (Table 2.2) were designed according to the 
instructions (a melting temperature (Tm) of more than 70°C).  RNA from stimulated 
splenocytes, thymocytes and DCs were used as templates for cDNA.  Thermal 
cycling conditions were performed as in Table 2.10. 
Table 2.10. Cycling conditions for 5’ and 3’ RACE-PCR. 
Step Temperature (°C) Time Cycles 
Denaturation 94 30 s 
5 x 
Extension 72 3 min 
Denaturation 94 30 s 
5 x Annealing 70 30 s 
Extension 72 3 min 
Denaturation 94 30 s 
25 x Annealing 68 30 s 
Extension 72 3 min 
Final extension 72 8 min 1 x 
Cooling 12 Hold  
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2.4.3.5 Real-time quantitative RT-PCR (TaqMan ®) 
A master mix was prepared using 5 µl Fast Universal PCR master mix (2X) (Applied 
Biosystems), 0.125 µl MultiScribe™ and RNase inhibitor, 2.5 µl RNA (diluted 1/5), 
0.5 µl of the optimal primer dilution and 0.25 µl (5 µM) of probe (Table 2.4) and 
made up to 10 μl with nuclease-treated H2O (Ambion®). 
COS-7 cell RNA (for transfection and RNA isolation see sections 2.8.3 and 2.3.2.1 
respectively) containing the gene of interest was used to set up a standard curve for 
the TaqMan® assays, using 10-fold serial dilutions. The test RNA was diluted 1/5 for 
cytokine mRNA expression analysis. 
28S ribosomal RNA (rRNA) expression was used as a reference gene for 
standardisation of mRNA levels. The RNA samples were assayed at a dilution of 
1/500. A standard curve was also set up for this assay using stimulated HD11 RNA 
(kindly supplied by Lisa Rothwell) (HD11 cells stimulated with 200 ng/ml 
lipopolysaccharide (LPS) (Sigma) for 6 h) at a starting dilution of 1/10. 
MicroAmp FAST 96-well plates were loaded with 7.5 µl master mix per well. 2.5 µl 
of nuclease-treated water were loaded into no template control (NTC) wells and 2.5 
µl of RNA loaded in triplicate. An optical adhesive cover was then applied and the 
plate briefly centrifuged. The plate was then placed on the ABI 7500 FAST sequence 
detection system (Applied Biosystems). The amplification conditions used are 
outlined in Table 2.11. Data were collected during the 60°C step.
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Table 2.11. Cycling conditions for TaqMan®. 
Step Temperature (°C) Time Cycles 
RT 48 30 min 1 x 
Denaturation 95 20 s 1 x 
Denaturation 95 3 s 
40 x 
Annealing/extension 60 30 s 
2.4.3.6 IL-23 custom TaqMan ® assay 
A master mix was prepared using 5 μl Fast Universal PCR master mix (2X) (Applied 
Biosystems), 0.125 μl MultiScribe ™ and RNase inhibitor, 2.5 μl RNA (diluted 1/5), 
0.5 μl of IL-23 Custom TaqMan Assay Mix (20X) (Table 2.4) and 1.75 μl nuclease-
treated H2O. 
For the standard curve, reference gene and cycling onditions used see section 
1.1.1.1. 
2.4.3.7 Analysis of TaqMan ® 
The data output were expressed as cycle threshold (Ct), the cycle at which the 
fluorescence from the reporter dye passed a set thrshold. The threshold was 
appropriately set for each target gene by the 7500 Software v2.0.6 (Applied 
Biosystems). 
The efficiency of the reaction was examined using the standard curves created by 
serially diluting samples which contain the target s quence. The slope of the line was 
used to examine the efficiency of the reaction: 
y = mx + c 
The reaction efficiency E was calculated as follows: 
E = (10(-1/slope))-1 
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If the slope of the standard curve was -3.2 then th PCR was 100% efficient. With 
100% efficiency, a 10X dilution gave a ∆Ct of 3.2 values between each dilution 
(every 3.2 cycles the amount of amplification was 10-fold higher). 
The corrected Ct value was calculated using the equation: 
Corrected Ct = Ct + (Nt – Ct’) x E/E’ 
Where Ct = sample (target gene) mean from triplicate, Nt = total reference gene 
mean from triplicate, Ct’ = sample reference gene man, E = target reaction 
efficiency and E’ = reference reaction efficiency. 
Corrected 40-Ct is the total number of PCR cycles (40) minus the corrected Ct value. 
Analysis of TaqMan® results was performed using Windows Excel. 
2.4.3.8 SYBR® Green assay 
2.4.3.8.1 Optimisation of 1-step RT-qPCR (SYBR® Green) 
This RT-qPCR assay was performed using a Power SYBR® Green RNA-to-CT™ 1-
Step kit (Applied Biosystems) according to the manufacturer’s protocol. A 20 μl 
reaction contained 10 µl Power SYBR® Green PCR Master Mix (2X), 0.4 μl primer 
dilution (100-1000 nM final concentration) (Table 2.3), 0.16 μl RT Enzyme Mix 
(125X), 5 μl RNA template and 4.4 μl nuclease-treated H2O. Thermal cycling on the 
ABI 7500 FAST sequence detection system (Applied Biosystems) using Standard 
Mode was performed as outlined in Table 2.12 
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Table 2.12. Cycling conditions for 1-step RT-qPCR (SYBR® Green). 
Stage Step Temperature (°C) Time 
Holding Reverse transcription 48 30 min 
Holding Activation of Taq polymerase 95 10 min 
Cycling (x40) 
Denature 95 15 s 
Anneal/Extend 60 1 min 
Melt Curve 
Denature 95 15 s 
Anneal 60 15 s 
Denature 95 15 s 
2.4.3.8.2 Optimisation of 2-step RT-qPCR (SYBR® green) 
A cDNA template was generated as described in section 2.4.2 using RNA from DCs 
stimulated with LPS (200 ng/ml) for 3 h and splenocytes stimulated with 
Concanavalin A (ConA) (Sigma) (1 μg/ml) for 4 h from 6-week-old J line birds. 
This RT-qPCR was performed using the Power SYBR® Green PCR Master Mix 
(Applied Biosystems). A 20 μl reaction contained 10 µl Power SYBR® Green PCR 
Master Mix (2X), 2 μl primer dilution (50-900 nM final concentration) (Table 2.3), 2 
μl cDNA template and 6 μl nuclease-treated H2O. Thermal cycling on the ABI 7500 
FAST sequence detection system (Applied Biosystems) using Standard Mode was 
performed as outline in Table 2.13. 
Table 2.13. Cycling conditions for 2-step RT-qPCR (SYBR®Green). 
Stage Step Temperature (°C) Time 
Holding Activation of Taq polymerase 95 10 min 
Cycling (x40) 
Denature 95 15 s 
Anneal/Extend 60 1 min 
Melt Curve 
Denature 95 15 s 
Anneal 60 15 s 
Denature 95 15 s 




2.5.1 A-tailing PCR products 
Purified PCR products were A-tailed using Taq polymerase (Invitrogen). The 10 µl 
reaction contained 1 µl 10X PCR buffer, 0.3 µl 50 mM MgCl2, 10 mM dATP, 7.2 µl 
PCR product and 0.5 U Taq polymerase. The reaction was incubated at 72°C for 5 
min and inactivated by incubation on ice. 
A-tailed PCR products were ligated into the TA cloning vectors pGEM®-T Easy and 
pTargeT™ (Promega) (Appendix 2). The 10 µl reaction mixture contained 
approximately 50 ng (7.2 μl) of vector, 3 µl DNA, 1 U of T4 DNA ligase and 1X T4 
DNA ligase buffer and was incubated at RT for 2 h. 
2.5.2 TA cloning RT-PCR products 
Purified and A-tailed RT-PCR products were ligated into pGEM®-T Easy vector  for 
sequencing or pTargeT™ (Appendix 2) for transient rcombinant protein expression 
in COS-7 cells. The ligation reaction contained 1 μl vector, 3 μl of the DNA to be 
cloned, 3 U (1 µl) of T4 DNA ligase and 5 μl 2X Rapid Ligation Buffer and was 
incubated at RT for 2 h. 
2.5.3 Transformation and screening 
E. coli JM109 competent cells (Appendix 3) were placed on ice to thaw for 
approximately 5 min. Aliquots of cells (100 µl) were added to pre-chilled tubes 
containing 5 µl of ligation reaction and gently flicked to mix. The ligation/cell 
mixture was incubated on ice for 20 min and then heat-shocked for 45 s exactly at 
42°C before a further 2 min incubation on ice. Room te perature super-optimal 
broth with catabolite repression (SOC) was then added to give a total of 1 ml per 
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transformation reaction. The tubes were incubated with shaking at 200 rpm  at 37°C 
for 1 h. Cells were gently agitated to mix and 200 µl of each reaction in duplicate (2 
x 200 µl) were plated onto LB plates containing 100 µg/ml ampicillin/0.5 mM 
isopropyl-beta-D-thiogalactopyranoside (IPTG)/80 µg/ml X-gal and incubated 
inverted overnight at 37°C. White coloured colonies are indicative of vector (ampr) 
containing an insert, while blue colonies contain empty vector. 
2.5.4 Restriction digestion 
Restriction digests were carried out using restriction enzymes and buffers (Table 
2.14) to release DNA inserts from cloning vectors for positive confirmation of 
successful TA cloning. DNA digests were performed un er conditions recommended 
by the manufacturer. Standard 10 µl reactions contained 1X final volume buffer (1 
µl), 1 µl of DNA, 1 µl of enzyme and 7 µl of nucleas -free H2O and were incubated 
at 37°C for 1.5 h. 
Table 2.14. Restriction enzymes used in this study. 
Restriction Enzyme Cut Site Reaction Buffer Manufacturer 
NotI GC/GGCCGC React 3 Invitrogen 
EcoRI G/AATTC Buffer H Promega 
2.6 DNA sequencing 
Sequencing was performed by either DNA Sequencing and Services at the University 
of Dundee on an Applied Biosystems 3730 DNA analyser or GATC Biotech AG, 
Cologne, Germany on an Applied Biosystems 3730xl ana yser. 
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2.7 Isolation and stimulation of primary cells 
Cells were isolated from the spleen, thymus, bursa of Fabricius and bone marrow 
from the femurs and tibias of chickens for stimulation or differentiation and 
subsequent RNA extraction. Tissues were removed and stored in PBS on ice.  
2.7.1 Splenocytes 
A single cell suspension was prepared in a 50 ml Falcon tube containing 15 ml cold 
PBS. The relevant tissue was cut in half with scissors, and mashed through a 70 μm 
cell strainer using the end of a syringe plunger. Eight millilitres Histopaque 1.077 
(Sigma) were underlaid beneath the single cell suspen ion using a 10 ml pipette and 
centrifuged at 400 x g for 20 min at RT with the centrifuge brakes off. Lymphocytes 
were drawn off the density gradient interface with a wide mouth pipette and washed 
with 20 ml PBS before centrifugation at 300 x g for 10 min at 4°C. The wash step 
was repeated and the cells re-suspended in complete Dulbecco’s modified eagle 
medium (DMEM) (Appendix 1) at 5 x 106 cells/ml following a viable cell count with 
Trypan blue (Life Technologies) and a haemocytometer. C lls (5 x 105) were added 
to each well of a U-bottomed 96-well plate. The splenocytes were stimulated with 
ConA at 1 µg/ml, for 2, 4, 6, 12, 18 and 24 h. Cells were harvested post-stimulation 
by centrifugation at 250 x g for 10 min, media were removed with a pipette and 
triplicate wells of cells re-suspended in 350 μl of buffer RLT. RNA was isolated 
from cell lysates using the method described in section 2.3.2.1. 
2.7.2 Thymocytes 
A single cell suspension was prepared by mashing the tissue through a cell strainer as 
in section 1.3.10.1. Cells were pelleted by centrifugation at 250 x g for 10 min at RT. 
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The supernatant was poured off and the cell pellet re-suspended in 20 ml of complete 
DMEM. A viable cell count using Trypan blue and a haemocytometer was performed 
and cells re-suspended at 5 x 106 cells/ml. Cells (5 x 105) were added to each well of 
a U-bottomed 96-well plate. Thymocytes were stimulated with phytohaemagglutinin 
(PHA-P) (Sigma) at 25 µg/ml for 2, 4, 6, 12, 18 and 24 h. The cells were harvested 
as described in section 1.3.10.1. RNA was isolated s in section 2.3.2.1. 
2.7.3 Bursal Cells 
Bursal cells were prepared as described in section 1.3.10.2 and stimulated with 
phorbol 12-myristate 13-acetate (PMA) (Sigma) and ionomycin (Sigma) at 800 
ng/ml and 100 ng/ml respectively for 2, 4, 6, 12, 18 and 24 h. Bursal cells were also 
harvested as described in section 1.3.10.1 and RNA isolated as in section 2.3.2. 
2.7.4 Isolation and differentiation of bone marrow- derived dendritic 
cells 
Isolation and differentiation of bone marrow-derived dendritic cells (BMDCs) was 
based on the method described by Wu et al. (2010). 
Both ends of the femur and tibia bones were cut off and the bone marrow flushed out 
into a Petri dish using a 21G needle, 10 ml syringe and sterile PBS. A cell suspension 
was created by gently mixing up and down using a pipette. A single cell suspension 
was created by passing the cells through a 70 μm cell strainer into a 50 ml Falcon 
tube. Cells were pelleted by centrifugation at 500 x g for 10 min at RT. The 
supernatant was discarded and the cell pellet re-suspended in 15 ml sterile PBS. 
Fifteen millilitres Histopaque 1.077 were underlaid beneath the single cell 
suspension using a 20 ml pipette and centrifuged at 1200 x g for 20 min at RT with 
the centrifuge brakes off. Cells were drawn off thedensity gradient interface with a 
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wide-mouthed pipette, transferred to a Universal and washed with 20 ml PBS before 
centrifugation at 300 x g for 10 min at 4°C. The supernatant was discarded and cells 
re-suspended in 10 ml pre-warmed complete Roswell Park Memorial Institute 
(RPMI) medium (Appendix 1). A viable cell count was performed using Trypan blue 
and a haemocytometer and the concentration of cells adjusted to 2 x 106 cells/ml. 
Recombinant chIL-4 and rchGM-CSF were transiently expr ssed from COS-7 cells 
as described in section 2.8.4. Three millilitres of cell suspension supplemented with 
7.5 μl rchGM-CSF (1/400) and 15 μl rchIL-4 (1/200) were added to each well of 6-
well plates and incubated at 41°C, 5% CO2 for 6 d. Fresh complete RPMI medium 
supplemented with rchGM-CSF and rchIL-4 replaced 75% of the old media every 2 
days. 
2.7.5 Stimulation of bone marrow-derived dendritic cells 
Chicken BMDCs were isolated and differentiated as de cribed in sections 2.7.4. On 
day 6 of differentiation, all media were carefully removed from each well with a 
pipette without disrupting the adherent cells, and was replaced with 3 ml of complete 
RPMI media supplemented with ex-COS rchIL-23 (1:100 or 1:250), LPS (25-200 
ng/ml) or recombinant chicken pcDNA3 protein (1:100 or 1:250) for 3, 6 and 24 h. 
Cells were harvested by adding 5 drops of 0.5 M EDTA from a pastette to each well. 
The plate was gently agitated and incubated at RT for 3-5 min. The cells were 
pipetted up and down to ensure all adherent cells were removed and transferred to a 
Universal. The cells were pelleted by centrifugation at 300 x g for 5 min and the 
supernatant discarded. The cell pellet was re-suspended in 700 μl buffer RLT and 
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transferred to a 1.5 ml Eppendorf tube for storage t -20°C. RNA was isolated from 
cell lysates as described in section 2.3.2.1. 
2.8 Cell culture 
2.8.1 Resurrection of cryopreserved COS-7 cell line  
Cells (Appendix 3) were retrieved from liquid nitrogen and thawed in a 37°C water 
bath. Cells were washed with 20 ml of warmed growth DMEM (Appendix 1), 
pelleted by centrifugation at 216 x g for 5 min and re-suspended in growth DMEM. 
A T75 culture flask was seeded with 7.5 x 105 COS-7 cells. The cells were incubated 
at 37°C, 5% CO2 and checked regularly. 
2.8.2 General maintenance of COS-7 cell line 
COS-7 cells were grown adherently until 90% confluent and then passaged, 
typically, every 2-3 days. Trypsin/versene solution (Gibco) at a 1/10 dilution was 
prepared. Old media were removed and cells washed twice with 15 ml pre-warmed 
PBS. Five ml of trypsin/versene solution was added an discarded. Another 5 ml of 
trypsin/versene solution was added and the flask incubated at 37°C, 5% CO2 for 5 
min. The flask was tapped on the bench and 15 ml of gr wth DMEM added to 
inactivate the enzyme. The cells were pelleted by centrifugation at 216 x g for 5 min 
and the supernatant discarded. The cells were counted using Trypan blue and a 
haemocytometer. T75 flasks were re-seeded with 7.5 x 105 COS-7 cells. The cells 
were checked regularly and passaged every 3-4 days.
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2.8.3 Transfection of COS-7 cells 
Twenty-four hours prior to transfection, COS-7 cells were seeded at 6 x 106 cells per 
T75 flask and incubated overnight at 37°C, 5% CO2. Fifteen ml of serum-free growth 
DMEM containing 112.5 µg of endotoxin-free plasmid DNA, 150 µl 10 M 
chloroquine (Sigma) and 90 µl of 100 mg/ml DEAE/Dextran (Sigma) were used per 
transfection. The cell layer was washed twice with PBS and the DNA/DEAE 
complex added. The cells were incubated at 37°C, 5% CO2 for 3 h. The DNA/DEAE 
complex was removed and the cell layer washed with PBS. Ten percent dimethyl 
sulfoxide (DMSO) (Sigma) in PBS was added for 2 min, a d then replaced with 5 ml 
of growth DMEM. The cells were incubated at 37°C, 5% CO2 overnight. The 
medium was changed for 15 ml serum-free growth DMEM. The supernatant was 
harvested after 3 d, centrifuged at 216 x g for 5 min and stored at 4°C. The cells were 
harvested after 3 d using trypsin/versene and re-suspended in appropriate amount of 
buffer RLT (Qiagen) for RNA isolation (section 2.3.2.1). 
2.8.4 Transient recombinant protein expression in C OS-7 cells 
COS-7 cells were transiently transfected with chicken cDNA clones (Appendix 3) by 
the DEAE/dextran method. COS-7 cells were trypsinised, counted and re-seeded at 6 
x 106 cells/75 cm² flask. Cells were then cultured for 18-24 h at 37ºC, 5% CO2. For 
each separate cDNA, a transfection mix for a 75 cm² flask was made containing 15 
ml serum-free growth DMEM (Appendix 1), 112.5 µg DNA, 258 µg/ml chloroquine 
and 600 µg/ml DEAE/dextran. Cells were washed with 2 x 10 ml warm PBS, 
followed by the addition of the transfection mix. Cells were incubated for 3 h at 
37ºC, 5% CO2 to facilitate DNA uptake. The transfection mix was di carded and 
cells were washed with another 10 ml warm PBS. Next, a solution of PBS containing 
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10% DMSO was added for 2 min to shock the cells, increasing the efficiency of the 
transfection. The PBS/DMSO was then discarded and replaced with 15 ml growth 
DMEM. After incubating the cells for 16-24 h at 37ºC, 5% CO2, growth DMEM was 
changed for serum-free growth DMEM. Cell supernatants were harvested 72 h later.  
2.9 IL-23 bioassay 
2.9.1 Optimising the IL-23 bioassay 
Preliminary assays were carried out to determine the optimal conditions and methods 
to quantify the bioactivity of rchIL-23, as described by Aggarwal et al. (2003). 
Lymphocytes were isolated over Histopaque 1.077 from the spleen of 6-week-old J 
line birds, washed and re-suspended at 5-10 x 106 cells/ml in complete DMEM, as 
described in section 2.7.1. The cell suspension was added to 96-well flat-bottomed 
plates (100 µl/well) containing different dilutions of ex-COS rchIL-23 (1/10-1/500) 
and ex-COS rchIL-2 (1/100-1/500) or purified rchIL-23 (Dundee Cell Products) (0.1-
1000 ng/ml) in a final volume of 200 µl/well. ConA (1 μg/ml) was used as a positive 
control and medium alone was used as a negative control. Assays were conducted in 
triplicate. Cells were incubated at 41°C in 5% CO2 for 6 h, 1, 2, 3 and 4 d with ex-
COS rchIL-23 and rchIL-2 and 1, 2 and 3 d with purified rchIL-23 alone (Dundee 
Cell Products). RNA was isolated as described in section 2.3.2.1 to measure 
expression of chIL-17A, chIFNγ and chIL-2 transcripts by TaqMan®. 
2.9.2 Optimised IL-23 bioassay conditions 
Lymphocytes were isolated over Histopaque 1.077 from the spleen of 6-week-old J 
line birds, washed and re-suspended at 5 x 106 cells/ml in complete DMEM, as 
described in section 2.7.1. The cell suspension was added to 96-well U-bottomed 
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plates (100 µl/well) containing purified rchIL-23 (Dundee Cell Products) (0.1-1000 
ng/ml) and ex-COS rchIL-2 (1/250) in a final volume of 200 µl/well. ConA (1 
μg/ml) was used as a positive control and medium alone was used as a negative 
control. Assays were conducted in triplicate. Cells were incubated at 41°C in 5% 
CO2 for 6 h, 1, 2, 3, 4 and 6 d. RNA was isolated as de cribed in section 2.3.2.1 to 
measure expression of cytokine transcripts by TaqMan® assay. 
2.10 Dot-blot assay 
Dot-blot assays were used to investigate if mouse anti-chicken IL-12 p40 Abs 
(Appendix 3) recognise rchIL-23. A Hibri-Dot 96 device (Whatman) was used to 
isolate protein on nitrocellulose membrane. The device was assembled by laying a 
membrane-support plate on a waste-reservoir plate, followed by a sheet of 
nitrocellulose membrane to cover every hole on the support plate. Finally, a cover 
plate with 96 wells and a sample reservoir were carfully placed on the membrane. 
With all three plates in the correct position, they were tightened by 8 screws.  
Protein samples (50 µl) were added to the wells on the cover plate of the Hibri-Dot 
96 and drawn onto the membrane by vacuum. The membrane was removed, washed 
in buffer PBS and Tween20 (PBST) for 5 min and blocked in 0.2% casein/PBS 
solution for 1 h. The membrane was washed twice more in PBST for 2 min. The 
membrane was then transferred into a mouse anti-chicken IL-12 p40 Ab solution 
(AV134, AV135 or AV136), 1/500 dilution in 0.2% casein/PBS, and incubated for 1 
h at room temperature. After three washes with PBST, 5 min per wash, the secondary 
antibody, goat anti-mouse IgG1-HRP, diluted 1/1000 in .2% casein/PBS, was added 
to the membrane and incubated for 1 h. The membrane w s washed 3 times as before 
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and then additionally for 2 further washes in PBST for 10 min each. The 
nitrocellulose membrane was then washed for 1 min in Milli-Q water and dried with 
tissue paper. All wash and incubation steps were carried out on a rocking shaker. 
The binding secondary Ab was detected using enhanced ch miluminescence (ECL) 
Western Blotting Detection Reagents (GE Healthcare), as per the manufacturer’s 
protocol. Equal volumes of luminol substrate and peroxide solution from the ECL kit 
were directly mixed before use, homogeneously distributed on the membrane, 
incubated for 5 min and dried with tissue paper. The membrane was visualised and a 
digital image captured on a G:Box (Syngene). 
2.11 Differentiation of CD4 + T cells 
2.11.1 Fluorescence-activated cell sorting (FACS) 
Cells were analysed and sorted by flow cytometry using a FacsAria III instrument 
(BD Becton Dickinson) by Bob Fleming (The Roslin Institute). 
Lymphocytes from the spleens of 7-9-week-old J linebirds, processed as described 
in section 2.7.1, were adjusted to 1 x 108 cells/ml. For immunostaining, cells were 
aliquoted into 5 x 1 ml aliquots in 15 ml Falcon tubes. All Abs were used at a 1/200 
dilution, therefore 5 μl of each Ab were added to each 1 ml aliquot of cells. For 
negative cell sorting, cells were stained with the following combinations of cell 
surface marker Abs and fluorochromes: TCR-1-FITC (fluorescein isothiocyanate), 
KUL01-FITC, CD8α-PE (phycoerythrin) and Bu-1-A647 (Alexa Fluor 647) (all 
Southern Biotech). For positive cell sorting, cells were stained with CD4-PE 
(Southern Biotech). Sytox® blue dead cell stain (LifeTech) was used to measure 
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viability of the cells. The cells were incubated at RT in the dark for 20 min. The cells 
were washed 3 times with 2 ml complete DMEM and pellet d by centrifugation at 
300 x g for 5 min. After the final wash step, each aliquot of cells was re-suspended in 
2 ml complete DMEM and filtered through a 35 μm filter using a 12 x 75 sterile 
polypropylene tube with built-in sieve top (Becton Dickinson) to create a single cell 
suspension for FACS. The sorted cells were eluted into complete DMEM and 
pelleted by centrifugation at 300 x g for 15 min. The cell pellets were re-suspended 
in 500 μl complete DMEM and pooled together for a viable cell ount using Trypan 
blue and a haemocytometer. Data analysis was performed using FACSDiva software. 
2.11.2 Magnetic-activated cell sorting (MACS) 
Lymphocytes were isolated over Histopaque 1.077 from the spleens of 7-9-week-old 
J line birds, washed and re-suspended in 5 ml complete DMEM, as described in 
section 2.7.1, before performing a viable cell count sing Trypan blue and a 
haemocytometer. The cells were pelleted by centrifugation at 300 x g at 4°C for 10 
min and re-suspended in 12.5 ml MACS buffer (2.5 ml per 108 cells). Mouse anti-
chicken CD4 Ab (unconjugated, Southern Biotech) wasused for immunostaining at a 
1/500 dilution. The cells were incubated at 4°C for 30 min in the dark, washed with 
50 ml MACS buffer and pelleted by centrifugation as before. The cells were then re-
suspended in 4 ml MACS buffer (800 μl per 108 cells) and 500 μl of goat anti-mouse 
IgG MACS® MicroBeads (Miltenyi Biotec) were added (200 µl per 108 cells), which 
bind to the Fc domains of the mouse anti-chicken monoclonal CD4 Ab. The cell 
solution was incubated at 4°C for 15 min in the dark with continuous mixing. The 
cells were washed again as before and the cell pellet r -suspended in 2.5 ml MACS 
buffer. 
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Magnetic separation of cells was performed using an LS Column and a 
MidiMACS™ Separator (Miltenyi Biotec).  After attaching an LS Column to the 
MidiMACS™ Separator, 3 ml of MACS buffer were allowed to run through the LS 
Column to equilibrate it. The cell solution was applied to the LS Column, 3 ml at a 
time, and allowed to run through. The flow-through fraction contained the negatively 
depleted labelled cells. To collect the CD4+ cells, the LS Column was removed from 
the MidiMACS™ Separator and the retained cells were eluted with MACS buffer as 
the positively selected cell fraction. Five millilitres of MACS buffer were applied to 
the LS Column and the plunger used to apply force through the syringe. This was 
repeated a second time. A viable cell count was performed using Trypan blue and a 
haemocytometer. The sorted cells were washed in 10 ml complete DMEM and 
pelleted by centrifugation at 300 x g for 10 min. The cell pellet was re-suspended in 
complete DMEM at 5 x 106 cells/ml.  
Post-MACS, cells were analysed by flow cytometry using a FACSCaliber (Becton 
Dickinson) by Lonneke Vervelde (The Roslin Institute). Data analysis was 
performed using FlowJo software (TreeStar Inc., Ashland, USA). 
2.11.3 Stimulation of CD4 + cells towards a Th17 phenotype 
CD4+ T cells from splenocytes isolated from 7-9-week-old J line birds were 
positively or negatively sorted by FACS or MACS as described in sections 2.11.1 
and 2.11.2.  
U-bottomed 96-well plates were coated with mouse anti-chicken CD3 and CD28 
monoclonal Abs (mAbs) to activate CD4+ T cells (50 μl/well). Antibodies were used 
at 1 μg/ml and a 1/250 dilution respectively and diluted in PBS. The Ab-coated 
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plates were incubated at 41°C, 5% CO2 for 3 h. Plates were washed 3 times in sterile 
PBS to remove unbound Ab. 
The cell suspension of CD4+ cells (1-5 x 106 cells/ml dependent on total cell number 
after sorting) was added to 96-well U-bottomed plates (50 µl/well) coated with 
mouse anti-chicken CD3 and CD28 mAbs in a final volume of 100 µl/well with 
rchTGF-β4, rchIL-6 and rchIL-12 as a positive control, diluted 1/125, 1/250 and 
1/500 in complete DMEM. ConA (1 μg/ml) was also used as a positive control and 
medium alone was used as the negative control. Assays were conducted in duplicate. 
Cells were incubated at 41°C, 5% CO2 for 3-5 d. RNA was isolated as described in 
section 2.3.2.1 to measure expression of chIL-17F transcripts by TaqMan® assay. 
2.12 Statistical Analyses 
All statistical analyses were carried out using Minitab 17. Statistical significance was 
determined with a P value of < 0.05. 
2.12.1 t test 
A standard one-sample t test was performed on normally distributed data to 
determine if there was a significant up- or down-regulation in fold change of 
cytokine mRNA expression compared to a fold change of one at each time point. The 
residuals were checked for normality and all cytokine responses required log 
transformation to normalise the residuals. 
2.12.2 Mann-Whitney U test 
A Mann-Whitney U test was performed on abnormally distributed data from the S. 
aureus experiment to determine if there was a significant difference in chIL-17A 
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mRNA expression in the bone marrow between wild-type, mutant and control groups 
at 11 dpi. 
2.12.3 ANOVA (1-way) 
A one-way analysis of variance (ANOVA) was performed on data from the IBDV 
experiment to determine if there was a significant difference between cytokine 
mRNA levels at different time points. The residuals were checked for normality and 
all cytokine responses required log transformation t  normalise the residuals. If 
overall differences were found, a standard post-hoc Tukey test was used as a multiple 
comparison method to determine the time points at which cytokine mRNA 
expression was significantly different to each other. 
2.12.4 ANOVA (2-way) 
A two-way ANOVA with interactions was performed on data from the S. aureus 
experiment to determine if there was a significant difference in fold change of 
cytokine mRNA expression of the mutant and wild-type groups compared to 
uninfected controls and also a significant differenc  in mRNA expression between 
the time points. The interaction between infected group and time was also 
statistically analysed for significance. The residuals were checked for normality and 
all cytokine responses required log transformation o ormalise the residuals. If the 
most complicated interaction of time and infected group was not significant, it was 
removed from the model and the model re-run to analyse the lesser complicated 
interactions of time and infected group alone. This step-wise approach elucidated the 
final minimal model and any significant interactions between groups of data. 
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2.12.5 Regression analysis 
Standard linear regression was used to show the relationship between cytokine 
mRNA expression and time during H. meleagridis infection. The residuals were 
checked for normality and required no further normalisation. Examination of the raw 
data revealed the possibility of a non-linear relationship between cytokine mRNA 
expression and time. The regression model (linear, quadratic or cubic) which best 
described the relationship was chosen. Initially, a cubic relationship was applied, if 
the cubic term was not significant, a more simple quadratic relationship was applied. 
If the quadratic term was not significant, the simplest linear relationship was applied 
and tested for significance. Significance values, R² values and 95% confidence 
intervals (CI) were calculated for each model. 
2.12.6 Linear mixed effect model 
A linear mixed effect model was used to show the relationship between cytokine 
mRNA expression and time in stimulated spleen, thymus and bursal cells. This 
analysis accounted for the random effect of the repated use of individual birds. The 
residuals were checked for normality and all cytokine responses required log 
transformation to normalise the residuals. Examinatio  of the raw data revealed the 
possibility of a non-linear relationship between cytokine mRNA expression and time. 
Initially, a quadratic relationship was applied, if the quadratic term was not 
significant, the simpler linear relationship was applied and tested for significance. 
The regression model (linear or quadratic) which best d scribed the relationship was 
chosen. 
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2.12.7 Mixed effect model 
A mixed effect model was used to show the relationships between concentration of 
IL-23-stimulation and time of stimulation on cytokine mRNA expression in rchIL-
23-stimulated splenocytes. This analysis accounted for the random effect of the 
repeated use of individual birds as well as considering an interaction effect between 
IL-23-stimulation and the addition of IL-2. The residuals were checked for normality 
and all cytokine responses required log transformation to normalise the residuals. 
Examination of the raw data revealed the possibility of a non-linear relationship 
between cytokine mRNA expression and both concentration of IL-23-stimulation and 
time of IL-23-stimulation. Initially, a quadratic relationship was applied and an 
interaction effect of IL-23 and IL-2 co-stimulation was tested for. If there was no 
significant interaction effect in the quadratic relationship, the simpler linear 
relationship and an interaction effect of IL-23 and IL-2 co-stimulation was analysed. 
If there was no interaction effect of the addition f IL-2, the quadratic term was 
tested for significance and if not significant, the simpler linear relationship applied 
and tested for significance. The regression model (linear or quadratic) which best 
described the relationship was chosen. 
2.12.8 Analysis of variance 
Analysis of variance was used to analyse data from the MD experiment. A 
multivariate approach was used whereby the maximum co plicated model was 
applied to the data and the most complicated interac ion (days post infection, line of 
bird and infected/uninfected samples) was tested for significance. The residuals were 
checked for normality and the data required no further normalisation. If the most 
complicated interaction was not significant, it was removed from the model and the 
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model re-run to analyse the next least complicated interactions. The same rules were 
subsequently applied to the data, using a step-wise approach, to elucidate the final 
minimal model and any significant interactions betwen groups of data. 
To graphically display the MD data, boxplots were us d. The interquartile range box 
represents the middle 50% of the data (first and thir  quartiles) and the band inside 
the box is the median (second quartile). If the sample has more than 3 data points, 
then the upper whisker represents the upper 25% of the distribution and the lower 
whisker represents the lower 25% of the distribution. 
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Chapter 3 Cloning and biological characterisation 
of chIL-23 p19 
3.1 Introduction 
IL-23 is a member of the IL-12 family of cytokines and is a heterodimer of the p19 
and p40 subunits (Oppmann et al., 2000). In humans, the IL-23 p19 gene is located 
on chromosome 12 (Flicek et al., 2014) and with p40 forms a pro-inflammatory 
cytokine with a key role in the development of Th17 cells. IL-23 is expressed as a 
disulphide-linked heterodimer, primarily by DCs and tissue-resident macrophages 
(Basso et al., 2009). The main focus of research on the role of IL-23 in mice and 
humans has been its involvement with Th17 cell differentiation and consequently its 
role in autoimmunity. 
The formation of biologically active IL-23 requires the synthesis of both subunits 
within the same cell. As a result, purified IL-23 p19 is biologically inert in vitro and 
is poorly secreted in the absence of IL-23/IL-12 p40 (Wiekowski et al., 2001). 
Several factors are known to regulate the expression of IL-23 in mammals but the 
exact mechanisms that control IL-23 production remain incompletely understood. 
However, the stimuli to induce mammalian IL-23 expression are somewhat 
characterised. PRR activation leads to preferential expression of IL-23 at mucosal 
surfaces (Yannam et al., 2012) while TLR2 agonists, such as peptidoglycan, are 
powerful inducers of IL-23 expression (Re and Strominger, 2001). In addition, 
stimulation of TLR3 and TLR7 augment the expression of IL-23 p19 in macrophages 
(Al-Salleeh and Petro, 2007). LPS is also an inducer of IL-23 in human monocytes, 
macrophages and DCs (Roses et al., 2008). The interaction of CD40 and CD40L 
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increases production of IL-23 and generates a positive feedback loop, further 
augmenting IL-23 production (Sender et al., 2010). 
IL-23 exerts its biological effects through its interaction with the IL-23R, (which is 
discussed in more detail in Chapter 5), which is expr ssed on innate and adaptive 
immune cells. In addition to Th17 cells, IL-23R expression is also found on γδ T 
cells and ILCs (Buonocore t al., 2010; Sutton et al., 2009). The differentiation of 
Th17 cells is not dependent on IL-23 (Korn et al., 2009; McGeachy et al., 2009) but 
it is fundamental for maintenance of Th17 cells in vitro and in vivo (Chen et al., 
2011). In mammals, IL-23 drives expression of the eff ctor cytokines IL-17A, IL-
17F, IL-22 and GM-CSF in Th17 cells (Aggarwal et al., 2003; Codarri et al., 2011; 
Ivanov et al., 2006; Liang et al., 2006). 
IL-23 p19 has been identified in the sheep (Gossner et al., 2012), horse (Tompkins et 
al., 2010), cattle (Chen et al., 2009) and pig (Kokuho et al., 2012) as well as 
zebrafish (Holt et al., 2011). The biological role of IL-23 is predicted to be the same 
in these species but this is yet to be demonstrated.  
For biological analysis of IL-23 in birds, nt and aa sequences of the ligands and 
receptors in the IL-23 system are required, however, until this study, no data were 
available on the primary structures of chIL-23 p19 and the chIL-23R. This is because 
the IL-23 p19 subunit is “missing” from, and the IL-23R gene is misannotated, in the 
chicken genome. As a result, the initial aim of this Chapter was to identify the gene 
for IL-23 p19 in the chicken and consequently investigate its expression and 
bioactivity compared to mammals. Using bioinformatic analysis, the chIL-23 p19 
protein-coding cDNA sequence was identified and its mRNA expression measured in 
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chicken tissues and stimulated lymphoid cells using RT-qPCR. To study the 
biological role of chIL-23 compared to mammals, a chIL-23 flexi-construct was 
designed to express full-length rchIL-23 and its bioactivity demonstrated. Because of 
the shared p40 subunit of IL-23 and IL-12, chIL-12 p40 mAbs, which recognise 
chIL-12 p70 (Balu et al., 2011), were used to investigate if they also recognise rchIL-
23. 
To summarise, the aims of this Chapter were to ident fy and clone chIL-23 p19, 
explore the structural and functional similarities and differences between avian and 
mammalian IL-23 p19 as well as investigate the mRNA expression patterns of chIL-
23 p19 in chicken tissues and stimulated cells. 
3.2 Methods 
General methods are outlined in Chapter 2. Additional methods and alterations are 
detailed here. 
3.2.1 Cloning of chIL-23 p19 cDNA 
Chicken IL-23 p19 is not currently annotated in thechicken genome (Galgal 4.0, 
Ensembl). Forward and reverse primers were designed to a partial nt sequence of 
chIL-23 p19 (Table 2.1 IL-23_F1 and IL-23_R1). This was an expressed sequence 
tag (EST) of chIL-23 p19 (Accession Number CK613546.1) previously identified in 
the data that was not included in the genome build by Mark Gibson (Institute for 
Animal Health). A platypus IL-23 aa sequence was used in a Protein Basic Local 
Alignment Search Tool (BLASTP) (www.ncbi.nlm.nih.gov/blast) search of the 
National Centre for Biotechnology Information (NCBI) EST database, identifying a 
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chicken EST (Accession Number CK613546.1), which represented a putative novel 
chicken IL-23 p19 gene. Following successful PCR amplification (section 2.4.3.2) of 
cDNA, corresponding to the EST sequence, from stimulated chicken splenocyte 
RNA (section 2.7.1), a partial length chIL-23 p19 cDNA clone was TA-cloned into 
pGEM®-T Easy and sequenced as described in section 2.5.  
The chIL-23 p19 EST sequence was used as a probe to screen the NCBI nt database 
and located a predicted nt sequence (LOC100858964) recently added to the database. 
Primer design for amplification of chIL-23 p19 (Table 2.1 IL-23F_F2 and IL-23_R3) 
was based on the predicted sequence (LOC100858964) and RNA isolated from 
chicken DCs stimulated with LPS for 4 h was used to generate cDNA for PCR 
(section 2.7.5). The cDNA clone was TA-cloned into pGEM®-T Easy and 
sequenced. Further bioinformatic characterisation of chIL-23 p19 nt and aa 
sequences was carried out to confirm the gene’s similar ty to mammalian IL-23 p19 
sequences. 
3.2.2 chIL-23 flexi-construct design 
A single chain chIL-23 molecule (chIL-23 flexi-construct) was designed (Figure 
3.1), based on the mammalian IL-12 and IL-23 flexi-constructs (Belladonna et al., 
2002; Lieschke et al., 1997) for recombinant protein expression. Dundee Cell 
Products generated the chIL-23 flexi-construct, which was cloned into the vector 
pcDNA3.1 (Appendix 2) and purified recombinant protein expressed in a 
mammalian cell line (COS-7). 




Figure 3.1. Chicken IL-23 flexi-construct design.  The mouse CD8α signal peptide is identified by 
the red arrow. The V5HIS6 tag is indicated in the yellow wave. A precision protease site is 
represented by the black lightening symbol. The p40mature protein follows the precision protease 
site, flexi-linked to the p19 mature protein sequence, followed by a stop codon. 
3.3 Results 
3.3.1 Identification and cloning of chIL-23 p19 
The EST (Accession Number CK613546.1) was a 229 nt sequence, which was 
lacking both a start and stop codon and a polyadenylation (polyA) (AATAAA) 
signal. Translation and alignment, using ClustalX, of this EST to human, mouse and 
cattle aa sequences showed high identity across a number of residues, including 3 
conserved cysteine residues (Figure 3.2). 




Figure 3.2. Amino acid (aa) alignment of the chIL-23 EST with human, mouse and cattle IL-23 
p19 aa sequences.  Shaded areas represent conservation of aa similarity, the darker the shading the 
more conserved the residue is across the species. Conserved cysteine residues are identified by an 
asterisk. 
Using the predicted chIL-23 p19 EST as a probe in the NCBI nt database, a predicted 
nt sequence for full-length chIL-23 p19 (LOC100858964) was identified. The 
predicted nt sequence for chIL-23 p19 is located in an unmapped area of the chicken 
genome. Translation and alignment to human, mouse and c ttle IL-23 p19 showed 
the EST sequence had an identity of 24.1% (Figure 3.3), and was much longer than 
its mammalian counterparts. 




Figure 3.3. Comparison of the predicted chIL-23 p19 (LOC100858964) aa sequence with human, 
mouse and cattle IL-23 p19 aa sequences.  Shaded areas represent conservation of aa similarity, the 
darker the shading the more conserved the residue is across the species. Conserved cysteine residues 
are identified by an asterisk. 
Based on the predicted nt sequence (LOC100858964), primers IL-23_F2 and IL-
23_R3 (Table 2.1) were designed to clone cDNA encodi g the predicted full-length 
chIL-23 p19, using cDNA prepared from LPS-stimulated BMDCs as a template. The 
predicted length of the amplified chIL-23 p19 cDNA product was 801 nt. However, 
mammalian IL-23 p19 nt sequences are approximately 500 nt in length. Figure 3.4 
shows the product amplified with primers IL-23_F2 and IL-23_R3. It is 
approximately 500 nt in size and was TA-cloned into pGEM®-T Easy and 
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transformed into E. coli JM109 competent cells for subsequent plasmid isolation and 
sequencing. 
 
Figure 3.4. RT-qPCR amplification of predicted chIL-23 p19 cDNA. Lane 1: cDNA from LPS-
stimulated (2 h) BMDCs. Lane 2: cDNA from LPS-stimulated (4 h) BMDCs. Lane 3: negative control 
(H2O). Lane L: GeneRuler™ 10 kb DNA Ladder (Thermo Scientific). Red box highlights PCR 
product selected for TA cloning and sequencing. 
Sequencing of multiple clones confirmed the nt sequence of chIL-23 p19 (Figure 
3.6). Comparison of the confirmed and predicted (LOC100858964) chIL-23 p19 nt 
sequence, using the intron splicing consensus (GT/A), identified the extra sequence 
in LOC100858964 as incorrectly predicted, and likely to be intronic sequence 
(Figure 3.5). 




Figure 3.5. Nucleotide sequence alignment of the predicted chIL-23 p19 (LOC100858694) and 
confirmed chIL-23 p19.  Identical nt sequence is red. Incorrectly annotated (presumed) intronic nt 
sequence is black. 
3.3.2 Structural features of chIL-23 p19 
The full-length chIL-23 p19 nt sequence was translated and the aa sequence further 
characterised in silico. The chIL-23 p19 cDNA encodes a predicted protein of 180 aa 
(Figure 3.6), with a putative 23 aa signal peptide ntified using SignalP3.0, 
resulting in a predicted secreted mature protein of 157 aa. The signal peptide of 
human IL-23 p19 is 19 aa, resulting in a secreted mature protein of 170 aa and 
identifying the predicted chIL-23 p19 signal sequence cleavage site to be similar to 
that of mammals. When aligned with mammalian IL-23 p19 sequences, chIL-23 p19 
has an aa identity of 42.8%. Chicken IL-23 p19 is very similar in length to the 
mammalian IL-23 p19 sequences. Further, there is 41.6%, 38.9%, 53.3%, 40.6%, 
41.1%, 42.2% and 23.9% aa similarity between chIL-23 p19 and human, mouse, pig, 
sheep, cattle, horse and zebrafish IL-23 p19 respectively. There are seven cysteine 
residues in chIL-23 p19, four of which are conserved with mammals. A cysteine 
residue in human IL-23 p19, which interacts with p40, and a tryptophan residue, 
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which interacts with the IL-23R, are both conserved between the chicken and 
mammals. The location of four α-helices (A, B, C and D) determined for human and 
mouse IL-23 p19 are shown above the sequences. 
 
Figure 3.6. Comparison of the chIL-23 p19 aa sequence with mammalian and zebrafish IL-23 
p19 aa sequences.  Shaded areas represent conservation of aa similarity, the darker the shading the 
more conserved the residue is across the species. Th  vertical black line indicates the signal sequence 
cleavage site of mammalian IL-23 p19. The vertical red arrow is the predicted signal sequence 
cleavage site of zebrafish IL-23 p19. The vertical black arrow is the predicted signal sequence 
cleavage site of chIL-23 p19. Chicken-only cysteine residues are identified by a triangle. Conserved 
cysteine residues are identified by an asterisk. The red box highlights C76 (chIL-23 p19), the cysteine 
residue which interacts with p40 in mammals. The gren box highlights W149 (chIL-23 p19), the 
tryptophan that engages with the IL-23R in mammals. Horizontal black arrows highlight the 4 α-
helices, A, B, C & D, in human and mouse IL-23 p19. 
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3.3.3 Gene organisation of chIL-23 p19 
Nucleotide BLAST analysis against the chicken genome (Galgal 4.0, Ensembl) 
shows that chIL-23 p19 is encoded by four exons (Figure 3.7). In the genomic 
sequence, the intron splicing consensus (GT/AG) is conserved at the 5’ and 3’ ends 
of the introns. In the 3’ UTR, 4 mRNA instability motifs (ATTTA) were present 
upstream of the polyA signal (AATAAA). 
 
Figure 3.7. Compiled genome sequence of the chicken IL-23 p19 gene. Exons are in red and 
introns are in black. Intron splice sites are boxed. Instability motifs (ATTTA) and the polyadenylation 
signal (AATAAA) are underlined. 
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3.3.4 chIL-23 flexi-construct design 
A chIL-23 flexi-construct (Figure 3.1), based on the mammalian IL-12 flexi-
construct (Lieschke t al., 1997) and the chIL-12 flexi-construct (Degen t al., 2004) 
was designed for recombinant protein expression and subsequent comparison of the 
biological activity of chIL-23 with mammalian IL-23. The chIL-23 flexi-construct is 
a single chain heterodimeric construct in which the mature proteins of the chicken 
p40 and p19 subunits are linked to each other by an in-frame glycine-serine-linker 
(flexi-linker) (Figure 3.8). This flexi-linker ensures both subunits are expressed 
together. The chIL-23 flexi-construct contains the mouse CD8α signal peptide 
sequence to direct the recombinant protein for secretion from the transfected cell. An 
N-terminal V5HIS6 tag is included for purification of the recombinant protein. In 
addition, a precision protease site after the V5HIS6 tag allows easy cleavage, should 
the tag interfere with expressed protein function. 
 




Figure 3.8. chIL-23 flexi-construct nt and aa sequence alignment.  The mouse CD8α signal 
peptide is shown in italics. The V5HIS6 tag is indicated in red. The precision protease site is 
highlighted in bold. The p40 mature protein sequence follows the precision protease site in blue. The 
flexi-linker sequence is underlined with the p19 mature protein sequence, followed by a stop codon, in 
green. 
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3.3.5 Bioactivity of recombinant chIL-23 
In mammals, IL-23 stimulation of memory T cells drives expression of IL-17A 
(Aggarwal et al., 2003). The chIL-23 flexi-construct was used to transiently express 
recombinant protein in COS-7 cells and rchIL-23 was also expressed and purified by 
Dundee Cell Products. Using both ex-COS and purified rchIL-23, a bioassay was 
developed and optimised to demonstrate bioactivity of rchIL-23 (section 2.9.2). The 
bioassay was based on the previously described IL-23 bioassay in mammals 
(Aggarwal et al., 2003), measuring the expression of chIL-17A mRNA by
splenocytes in response to chIL-23. In mammals, IL-17A and IL-17F mRNA and 
protein expression were measured over time by RT-qPCR and enzyme-linked 
immunosorbent assay (ELISA) respectively. The measurement of Th17 cytokine 
protein expression is not possible in the chicken as Abs have not been raised to all of 
the cytokines. Therefore, mRNA expression of Th17 effector cytokine transcripts 
was measured by RT-qPCR (TaqMan®). 
Chicken splenocytes, when stimulated with purified rchIL-23, with or without the 
presence of rchIL-2, initially up-regulated chIL-17A mRNA expression compared to 
levels in unstimulated controls, with chIL-17A mRNA expression then decreasing 
with decreasing concentrations of IL-23-stimulation (Figure 3.9). This quadratic 
decline of chIL-17A mRNA levels was enhanced in thepr sence of rchIL-2 (p = 
0.007). 




Figure 3.9. Chicken IL-17A mRNA levels in purified rchIL-23-stimulated splenocytes. Cells 
were stimulated for 1 d with serial dilutions of purified rchIL-23 or purified rchIL-23 and ex-COS 
rchIL-2. Data are expressed as fold change compared to levels in age-matched unstimulated controls ± 
SEM. A mixed effect model was used to determine if there was a relationship between mRNA levels 
over time. A standard one-sample t test was performed to determine if cytokine levels were 
significantly up or down-regulated relative to a fold change of one as indicated by a single asterisk (p 
< 0.05) or double asterisk (p < 0.01). The positive control (+ ve) was ConA-stimulated splenocytes (1 
μg/ml) and ex-COS rchIL-2 was used at a 1/500 dilution. Medium alone was used on the unstimulated 
cells. Assays were carried out in triplicate and each value is the mean of 3 birds. 
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As chIL-17A mRNA levels induced by IL-23-stimulation were not that high, mRNA 
expression of the other Th17 effector cytokines, chIL-17F, chIL-21 and chIL-22, 
were investigated. 
Following stimulation of splenocytes with purified rchIL-23 for 6 h, 1, 2, 3, 4 and 6 
d, chIL-17F mRNA levels were significantly up-regulated at all time-points (p < 
0.026) compared to levels in unstimulated controls (Figure 3.10).  
 
Figure 3.10. Chicken IL-17F mRNA levels in splenocytes stimulated with purified rchIL-23 (10 
ng/ml).  Data are expressed as fold change compared to levels in age-matched unstimulated controls ± 
SEM. A mixed effect model was used to determine if there was a relationship between mRNA levels 
over time. A standard one-sample t test was performed to determine if cytokine levels were 
significantly up or down-regulated relative to a fold change of one as indicated by a single asterisk (p 
< 0.05) or double asterisk (p < 0.01). Medium alone was used on the unstimulated cells. Assays were 
carried out in triplicate and each value is the mean of 6 birds. 
Chicken IL-17F mRNA levels increased initially over time, before declining at 3-6 d 
of stimulation. The quadratic decline of chIL-17F mRNA levels over time was 
demonstrated at 1000 and 10 ng/ml of IL-23-stimulation (p < 0.045). However, at 
concentrations of 100 and 1 ng/ml, the decline of chIL-17F mRNA levels over time 
was linear (p < 0.006). 
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Figure 3.11 shows the effect of titrating purified rchIL-23 on chIL-17F mRNA 
expression from splenocytes at 2 d post-stimulation. Concentrations of rchIL-23 from 
1-1000 ng/ml significantly up-regulated chIL-17F mRNA levels (p < 0.014). A dose-
dependent effect was seen, with a typical prozoan effect, with highest concentrations 
giving less than maximal stimulation and effects titra ng out, with increasing 
dilution, to background levels. This quadratic decline (p < 0.015) in chIL-17F 
mRNA expression was seen from 6 h to 4 d post-stimulation. By 6 d post-stimulation 
the decline in chIL-17F mRNA levels was linear (p < 0.001). 
 
Figure 3.11. Chicken IL-17F mRNA levels in purified rchIL-23-stimulated splenocytes.  Data are 
expressed as fold change compared to levels in unstimulated controls ± SEM. A mixed effect model 
was used to determine if there was a relationship between mRNA levels over time. A standard one-
sample t test was performed to determine if cytokine levels were significantly up or down-regulated 
relative to a fold change of one as indicated by a single asterisk (p < 0.05) or double asterisk (p < 
0.01). Cells were stimulated for 2 d. The positive control (+ ve) was ConA-stimulated splenocytes (1 
µg/ml). Medium alone was used on the unstimulated cells. Assays were carried out in triplicate and 
each value is the mean of 6 birds. 
The original mammalian IL-23 bioassay investigated the effect of IL-23 and IL-2 co-
stimulation on expression of IL-17A and IL-17F (Aggarwal et al., 2003). IL-2 drives 
the proliferation of T cells (Smith, 1984). However, Laurence et al. (2007) showed 
IL-2 could inhibit the differentiation of Th17 cells. The cytokines which drive or 
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inhibit Th17 immune responses in the chicken have not been studied to date, 
therefore, for completeness, the effect of rchIL-2 (ex-COS) stimulation on chicken 
splenocytes was studied. Purified rchIL-23 alone (1-1000 ng/ml), and in combination 
with rchIL-2 (ex-COS), significantly up-regulated chIL-17F mRNA levels in 
splenocytes (p < 0.002) (Figure 3.12). Purified rchIL-23 in combination with rchIL-2 
(ex-COS) significantly increased chIL-17F mRNA expression compared to 
stimulation with IL-23 alone between 6 h and 2 d post-stimulation (p < 0.001) but 
not after 3-6 d post-stimulation. 
 
Figure 3.12. Chicken IL-17F mRNA levels in purified rchIL-23-stimulated splenocytes. Cells 
were stimulated for 1 d with serial dilutions of purified rchIL-23 or purified rchIL-23 and ex-COS 
rchIL-2. Data are expressed as fold change compared to levels in age-matched unstimulated controls ± 
SEM. A mixed effect model was used to determine if there was a relationship between mRNA levels 
over time. A standard one-sample t test was performed to determine if cytokine levels were 
significantly up or down-regulated relative to a fold change of one as indicated by a single asterisk (p 
< 0.05), double asterisk (p < 0.01) or triple asteri k (p < 0.001). The positive control (+ ve) was 
ConA-stimulated splenocytes (1 μg/ml) and ex-COS rchIL-2 was used at a 1/500 dilution. Medium 
alone was used on the unstimulated cells. Assays were carried out in triplicate and each value is the 
mean of 6 birds. 
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Chicken IL-17A and chIL-17F mRNA expression was up-regulated in splenocytes 
after stimulation with purified rchIL-23. Levels ofchIL-21 and chIL-22 mRNA from 
splenocytes stimulated with purified rchIL-23 were also investigated. Chicken IL-21 
mRNA was not up- or down-regulated following rchIL-23 stimulation compared to 
levels in unstimulated controls (Figure 3.13). However, the addition of rchIL-2 (ex-
COS) significantly increased mRNA levels of chIL-21 compared to rchIL-23-
stimulation alone (p = 0.016). 
 
Figure 3.13. Chicken IL-21 mRNA levels in purified rchIL-23-stimulated splenocytes. Cells 
were stimulated for 1 d with serial dilutions of purified rchIL-23 or purified rchIL-23 and ex-COS 
rchIL-2. Data are expressed as fold change compared to levels in age-matched unstimulated controls ± 
SEM. A mixed effect model was used to determine if there was a relationship between mRNA levels 
over time. A standard one-sample t test was performed to determine if cytokine levels were 
significantly up or down-regulated relative to a fold change of one. The positive control (+ ve) was 
ConA-stimulated splenocytes (1 μg/ml) and ex-COS rchIL-2 was used at a 1/500 dilution. Medium 
alone was used on the unstimulated cells. Assays were carried out in triplicate and each value is the 
mean of 3 birds. 
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Lastly, chIL-22 mRNA levels were measured in splenocytes stimulated with purified 
rchIL-23. Chicken IL-22 mRNA expression was significantly up-regulated by rchIL-
23 stimulation compared to unstimulated controls at all concentrations of purified 
rchIL-23-stimulation (p < 0.027) (Figure 3.14). Recombinant chIL-23 also had a 
prozoan effect on chIL-22 mRNA levels in splenocytes. The highest chIL-22 mRNA 
levels were measured at 100 ng/ml of rchIL-23-stimulation, and chIL-22 mRNA 
levels then declined as rchIL-23 was titrated. This quadratic relationship was seen 
from 6 h to 4 d (p < 0.007). By 6 d post-stimulation, the decline in chIL-22 mRNA 
levels was linear (p < 0.001). 
 
Figure 3.14. Chicken IL-22 mRNA levels in purified rchIL-23-stimulated splenocytes. Data are 
expressed as fold change compared to levels in age-matched unstimulated controls ± SEM. A mixed 
effect model was used to determine if there was a rel tionship between mRNA levels over time. A 
standard one-sample t test was performed to determine if cytokine levels were significantly up or 
down-regulated relative to a fold change of one as indicated by a single asterisk (p < 0.05), double 
asterisk (p < 0.01) or triple asterisk (p < 0.001). Cells were stimulated for 6 h. The positive control (+ 
ve) was ConA-stimulated splenocytes (1 µg/ml). Medium alone was used on the unstimulated cells. 
Assays were carried out in triplicate and each value is the mean of 6 birds. 
In summary, stimulation of chicken splenocytes with purified rchIL-23 has a prozone 
effect on chIL-17A, chIL-17F and chIL-22 mRNA expression. In contrast, chIL-21 
mRNA expression in splenocytes was not changed by stimulation with purified 
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rchIL-23. The addition of rchIL-2 (ex-COS) generally enhanced mRNA expression 
of chIL-17A, chIL-17F and chIL-21. These data demonstrate purified rchIL-23 is 
bioactive. 
3.3.6 Recombinant chIL-23-stimulated dendritic cell s do not express 
chIL-12 p35 
IL-23-stimulated murine splenic DCs express IL-12 p70 and IFN-γ (Belladonna et 
al., 2002). It is currently not possible to differentiate splenic DCs in vitro in the 
chicken, therefore, using an established method (Wuet al., 2010), chicken BMDCs 
were differentiated and stimulated with a series of dilutions of rchIL-23 (ex-COS) 
(sections 2.7.4 and 2.7.5) and mRNA expression of chIL-12 p35 measured using RT-
qPCR (TaqMan®). 
Chicken BMDCs stimulated with rchIL-23 (ex-COS) did not up-regulate mRNA 
levels of chIL-12 p35 (Figure 3.15). 
 
Figure 3.15. Chicken IL-12 p35 mRNA expression levels in BMDCs stimulated with rchIL-23 
(ex-COS). Data are expressed as corrected 40-Ct values ± SEM. BMDCs were stimulated with rchIL-
23 (ex-COS) diluted 1/100, LPS 200 ng/ml (+ve contrl), pcDNA3 (ex-COS) diluted 1/100 and 
medium alone (-ve control) for 3 h (blue bars), 6 h (red bars) and 24 h (green bars) respectively. 
Assays were carried out in triplicate and each value is the mean of 5 birds. 
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After differentiating, the BMDCs were stimulated for 3, 6 and 24 h with ex-COS 
rchIL-23 diluted 1/100 and 1/250. Figure 3.15 shows results from BMDCs stimulated 
with 1/100 ex-COS rchIL-23. Similar results were seen with a 1/250 dilution of 
rchIL-23 (data not shown). Altering the concentration of rchIL-23 used to stimulate 
BMDCs had no effect on chIL-12 p35 mRNA expression. 
3.3.7 Chicken anti-IL-12 p40 monoclonal antibodies bind recombinant 
chIL-23 protein 
IL-23 is composed of the subunits p19 and p40, the latt r of which it shares with IL-
12 (Oppmann et al., 2000). Monoclonal antibodies specific for chIL-12 have been 
generated and characterised in this laboratory (Balu et al., 2011). Dot-blot analysis 
was used to determine if mouse anti-chicken IL-12 p40 mAbs recognise purified 
rchIL-23. 
Three mouse anti-chIL-12 p40 mAbs (AV134, AV135 and AV136), which recognise 
rchIL-12 p40 and rchIL-12 p70, were used against a dilution series of purified rchIL-
23. All three mAbs detected purified rchIL-23 (Figure 3.16). Recombinant chIL-12 
p40 and rchIL-7 (both ex-COS) were used as positive and negative controls 
respectively. Monoclonal Ab AV134 detected purified rchIL-23 at concentrations of 
12 and 60 μg/ml (1/25 and 1/5 dilutions respectively) but not diluted 1/125 at a 
concentration of 2.4 µg/ml. Monoclonal Abs AV135 and AV136 detected all 
concentrations of purified rchIL-23. All three mouse anti-chIL-12 p40 mAbs 
detected rchIL-12 p40 (ex-COS) but not the negative control, rchIL-7 (ex-COS). The 
experiment was repeated three times. 




Figure 3.16. Dot-blot analysis demonstrating specificity of mouse anti-chicken IL-12 p40 
monoclonal antibodies (A) AV134, (B) AV135 and (C) AV136 against a series of dilutions of 
purified rchIL-23, rchIL-12p40 (ex-COS) and rchIL-7 (ex-COS). Purified rchIL-23 was diluted (1) 1:5 
(60 μg/ml), (2) 1:25 (12 μg/ml) and (3) 1:125 (2.4 μg/ml). Recombinant chIL-12 p40 and rchIL-7 
were used (1) neat, and at (2) 1:10 and (3) 1:100 dilutions. 
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3.3.8 Expression of chIL-23 mRNA in tissues 
Having confirmed the chIL-23 p19 nt sequence, it was now possible to measure 
mRNA levels of chIL-23 in various tissues, stimulated cells and during infection of 
the chicken. Attempts to design TaqMan® primers and probe for use in a RT-qPCR 
assay to measure mRNA expression of chIL-23 p19 were unsuccessful. Further 
attempts to design SYBR® Green primers by eye and to op imise a SYBR® Green 
RT-qPCR assay, including 1-step and 2-step systems, were also unsuccessful. The 
high GC content of the chIL-23 p19 nt sequence proved insurmountable. Therefore, a 
custom assay was designed by Applied Biosystems (Table 2.4). 
As shown in Figure 3.17, chIL-23 p19 mRNA is widely xpressed in all immune and 
non-immune tissues investigated at moderate levels. The highest mRNA levels in the 
non-lymphoid tissues were in the kidney and in lymphoid tissues in the spleen, with 
very similar levels seen in the thymus, Meckel’s diverticulum and bone marrow. 




Figure 3.17. Expression patterns of chIL-23 p19 mRNA in tissues as measured by RT-qPCR.  
Results are expressed as corrected 40-Ct values ± SEM. Assays were carried out in triplicate and each 
value is the mean of 3 birds. 
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3.3.9 Expression of chIL-23 mRNA in stimulated sple nocytes, 
thymocytes and bursal cells across a time course 
Chicken IL-23 p19 mRNA levels were measured in stimulated lymphoid cells and 
compared to levels in unstimulated controls. Splenocytes were stimulated with 
ConA, thymocytes with PHA and bursal cells with PMA and ionomycin over a time 
course of 2-24 h. Chicken IL-23 p19 mRNA levels were significantly down-
regulated at 18 h (p = 0.042) post-stimulation in ConA-stimulated splenocytes 
(Figure 3.18 (A)). Expression of chIL-23 p19 mRNA compared to unstimulated 
controls decreased over time in a linear relationship (p = 0.004). Chicken IL-23 p19 
mRNA levels in stimulated thymocytes was up-regulated at 2 h post-stimulation but 
there was no relationship in chIL-23 p19 mRNA levels in stimulated thymocytes 
over time (Figure 3.18 (B)). Expression of chIL-23 p19 mRNA in stimulated bursal 
cells significantly decreased over time in a linear relationship (p < 0.009) (Figure 
3.18 (C)). Chicken IL-23 p19 mRNA levels were significantly down-regulated at 12 
h (p = 0.049) post-stimulation. 




Figure 3.18. Expression patterns of chIL-23 p19 mRNA in stimulated (A) splenocytes, (B) 
thymocytes and (C) bursal cells.  Data are expressed as fold change compared to levels in age-
matched unstimulated controls ± SEM. A linear mixed effect model was used to determine if there 
was a relationship between mRNA levels over time. A standard one-sample t test was performed to 
determine if cytokine levels were significantly up or down-regulated relative to a fold change of one 
as indicated by a single asterisk (p < 0.05). Chicken splenocytes, thymocytes and bursal cells were 
stimulated with ConA, PHA and PMA and ionomycin resp ctively. Assays were carried out in 
triplicate and each value is the mean of 3 birds. 




Interleukin-23 was first identified in mammals nearly 15 years ago through its 
similarity to members of the IL-6 cytokine family (Oppmann et al., 2000). 
Detectable levels of the p19 subunit combined with the p40 subunit of IL-12, 
forming a biologically active cytokine, were shown to be secreted by activated DCs. 
Uniquely at the time, IL-23 induced strong proliferation of mouse memory T cells. 
Subsequently, Aggarwal et al. (2003) showed IL-23 promoted differentiation of a 
new subset of CD4+ T cells that produce IL-17A. More than 10 years on, the 
extensive role of IL-23 in driving both the innate and adaptive immune responses in 
mammals is still being elucidated. This Chapter describes the identification and 
initial characterisation of IL-23 in the chicken. 
The initial aim of this Chapter was to identify the chicken IL-23 p19 gene. The 
chicken IL-12/IL-23 p40 subunit was identified in the chicken in 2003 (Balu and 
Kaiser, 2003) and a functional recombinant chIL-12 protein expressed in 2004 
(Degen et al.) but version 4 of the chicken genome (Galgal 4.0, Ensembl) still does 
not have an annotated chIL-23 p19 gene. Because of low sequence homology to 
mammalian cytokines, classical molecular approaches to characterise avian cytokine 
homologues are not usually successful. The protein coding sequence (CDS) for chIL-
23 p19 was identified using in silico and in vitro methods. Several unsuccessful 
attempts were made to amplify the 5’ and 3’ ends of the chIL-23 p19 cDNA by 5’and 
3’ RACE-PCR to elucidate its full-length sequence. Subsequently, a predicted nt 
sequence for full-length chIL-23 p19 (LOC100858964) was located in the NCBI nt 
database. Using primers based on this predicted sequence, the full-length nt sequence 
of chIL-23 p19 was cloned by PCR. On sequencing the PCR product, the predicted 
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nt sequence (LOC100858964) was found to be incorrectly predicted. The precise 
genome location is yet to be determined as the predicted chIL-23 p19 nt sequence 
was identified in an unmapped area of the chicken gome. Therefore, it is not 
possible to say if the chIL-23 p19 gene demonstrates conserved synteny with 
mammals. However, the gene organisation of chIL-23 p19 has 4 exons and 3 introns, 
and is similar to that of human and mouse IL-23 p19. 
Following identification of the chIL-23 p19 gene, the aa sequence was compared to 
its mammalian counterparts. Chicken IL-23 p19 is similar in aa sequence length to 
mammalian IL-23 p19 proteins and has a moderately high aa identity, for an avian 
cytokine, of 35.5% compared to mammalian IL-23 p19 (Kaiser et al., 2005). The aa 
identity is lower than that of chIL-12 p40, which has an aa identity of 46% and 41% 
respectively with huIL-12 p40 and mIL-12 p40 (Balu and Kaiser, 2003). The 
predicted signal sequence cleavage site in chIL-23 p19 is similar to the known signal 
sequence cleavage sites in mammalian IL-23s. Human IL-23 is a heterodimeric four-
alpha-helical bundle cytokine, expressed as a disulphide-linked complex of the 
helical cytokine p19 and its binding protein p40 (Lupardus and Garcia, 2008). Four-
alpha helical bundle cytokines, such as IL-23, share a common structural motif made 
up of a central core of four α-helices (A, B, C and D), arranged in an up-up-down-
down helical topology (Sprang and Bazan, 1993). It is clear from the aa alignment 
that there is good homology and conservation of heptad repeat structures between 
human and chicken aa sequences within the regions where the α-helices are predicted 
to be, suggesting the α-helical structures are the same in the chicken. The cysteine 
residues important for disulphide bond formation within the huIL-23 p19 subunit 
(Oppmann et al., 2000) are conserved in the chicken and will likely form disulphide 
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bonds. Also, the cysteine residue which forms a disulphide bond with mammalian 
p40, and the tryptophan which interacts with the IL-23R in mammals (Lupardus and 
Garcia, 2008), are both conserved in the chicken, suggesting a likely conservation of 
function between mammalian and avian IL-23. 
To investigate the biological function of chIL-23, a chIL-23 flexi-construct was 
designed for recombinant protein expression. Similar to mammalian IL-12, the two 
subunits, p35 and p40, of chicken IL-12 need to heterodimerise to exert bioactivity 
(Degen et al., 2004). Therefore, it was assumed that chIL-23 would be similar to 
mammalian IL-23 and require expression of both subunits in the same cell for the 
recombinant protein to be biologically active. To this end, the design of the chIL-23 
flexi-construct ensures the p40 and p19 subunits are expressed simultaneously in the 
same cell at the same level. Almost all of the key molecules in the immune system 
are glycosylated (Shirouzono et al., 2012). Therefore, to compare biological activity 
of chIL-23 with mammalian IL-23, mammalian expression systems were used to 
express rchIL-23 to allow for post-translational modifications and hopefully generate 
a functional protein. The chIL-23 flexi-construct also contains a mouse CD8α signal 
peptide to direct recombinant protein secretion from the cell. 
To establish the biological function of rchIL-23, we sought to replicate the initial 
bioassay used in mice to investigate the biological function of IL-23 (Aggarwal et 
al., 2003). Following the discovery of mammalian IL-23, in experiments using 
knockout mice deficient in either the p19 or p40 subunits, its involvement in the 
autoimmune disease MS was elucidated in the mouse mod l, EAE (Cua et al., 2003). 
An IL-23 knockout model in the chicken to establish c IL-23 function, whilst 
potentially possible in the not-to-distant future, is unavailable in the chicken at 
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present. We therefore sought to generate bioactive rchIL-23 as a useful tool to begin 
to elucidate the functions of chIL-23 in vitro and in vivo. 
In mammals, IL-23 drives expression of IL-17A and IL-17F from splenocytes 
(Aggarwal et al., 2003). Chicken splenocytes were cultured in the pr sence of 
various concentrations of purified rchIL-23 alone and in combination with rchIL-2 
for up to 6 d. Measurement of all Th17 cytokines at the protein level is not yet 
possible in the chicken so mRNA levels of chIL-17A, chIL-17F, chIL-21 and chIL-
22 were measured. Recombinant chIL-23-stimulated splenocytes up-regulated 
expression of chIL-17A, chIL-17F and chIL-22 mRNA levels compared to 
unstimulated controls but there was no effect on mRNA levels of chIL-21.  
As mammalian IL-23 drives expression of IL-17A, this cytokine was chosen as the 
initial readout to determine if rchIL-23 is biologically active. Chicken IL-17A 
expression declined as rchIL-23-stimulation decreased, particularly in the presence 
of rchIL-2. However, the positive control (ConA) failed to increase chIL-17A mRNA 
expression and the expression of chIL-17A mRNA from rchIL-23-stimulated 
splenocytes was low (< 5 fold change), suggesting the data should be interpreted 
cautiously. Therefore, the mRNA levels of the other Th17 effector cytokines, chIL-
17F, chIL-21 and chIL-22, were also measured in therchIL-23-stimulated 
splenocytes, using ConA as a positive control. ConA successfully increased mRNA 
expression of these cytokines (also shown in Chapter 4) but highest cytokine mRNA 
expression varied between 2-18 h post-stimulation. This is discussed further in 
section 4.4.2 but it may be that chIL-17A expression requires higher concentrations 
of ConA stimulation than was used here and highest expression may be seen earlier 
than 24 h post-stimulation. 
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Purified rchIL-23-stimulation of splenocytes up-regulated chIL-17F mRNA 
expression from 6 h to 6 d compared to levels in unstimulated controls. Chicken IL-
17F mRNA levels declined over time. A dose-dependent ffect of rchIL-23-
stimulation was also seen, with the highest concentration of rchIL-23 (1000 ng/ml) 
giving less than maximal chIL-17F mRNA levels and effects titrating out, with 
decreasing concentration of rchIL-23-stimulation. This prozone, or hook effect, is a 
common biological response whereby the maximum response is achieved at less than 
maximal stimulation levels. 
Chicken IL-22 mRNA levels were also up-regulated in rchIL-23-stimulated 
splenocytes, in a similar pattern to chIL-17F, whereas rchIL-23-stimulation had no 
effect on chIL-21 mRNA expression. Expression of IL-21 and IL-22 was not 
investigated in the original murine IL-23 bioassay. However, as discussed before 
(section 1.3.2), IL-23 is critical for IL-22 expression in mammals, both in vitro and 
in vivo (Liang et al., 2006; Zheng et al., 2007). IL-21 expression in mammalian Th17 
cells acts via an autocrine loop, further enhancing expression of IL-21 and the IL-
23R, thus augmenting responsiveness to IL-23 (Nurieva t al., 2007). It is not 
surprising then that rchIL-23-stimulation increases expression of chIL-22 but does 
not up-regulate chIL-21 mRNA in splenocytes. 
In mammals, IL-2 supports proliferation and survival of T cells (reviewed by Smith, 
1984) but, contrary to this, is a negative regulator of Th17 development (Laurence et 
al., 2007). In the original IL-23 bioassay outlined by Aggarwal et al. (2003), and 
subsequently by Kokuho et al. (2012) to demonstrate bioactivity of swine IL-23, IL-
2 and IL-23 stimulation increased expression of IL-17 in splenocytes. The results 
here are in line with the mammalian bioassay and indicate that the addition of rchIL-
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2 has a synergistic effect on mRNA levels of chIL-17A and chIL-17F and also 
increases chIL-21 mRNA levels alone. It is possible that rchIL-23-stimulation of 
splenocytes drives expression of chIL-17A and chIL-17F from innate cells in a 
similar manner to IL-23-driven expression of IL-17A in ILC3s in mammals (Spits et 
al., 2013; Takatori et al., 2009). Further elucidation of the cell types in the chicken 
spleen expressing chIL-17A, chIL-17F and chIL-22 is required to answer this. In 
mammals, IL-23 drives expression of IFN-γ and GM-CSF in Th17 cells (El-Behi et 
al., 2011; Ivanov et al., 2006). It would be interesting to further expand the 
biological role of chIL-23 to investigate whether it can also drive expression of 
chIFN-γ and chGM-CSF. Bioactivity of rchIL-23 has been demonstrated by the up-
regulation of expression of three signature Th17 cytokines chIL-17A, chIL-17F and 
chIL-22, similarly to mammalian IL-23s (Aggarwal et al., 2003), confirming its 
functionality and its usefulness as a tool to investigate the role of chIL-23 and Th17 
immune responses in the chicken. 
A further measure of IL-23 bioactivity in mammals is the induction of IL-12 protein 
expression by splenic DCs in mice (Belladonna et al., 2002). Therefore, in addition 
to activating splenocytes, the biological effect of rchIL-23 on BMDCs was 
investigated and compared to mammals. Isolation and differentiation of splenic DCs 
in vitro in the chicken is not currently possible. With limited scope for an alternative, 
the established method of BMDC differentiation was used (Wu et al., 2010). Bone 
marrow-derived DCs were differentiated and then stimulated with rchIL-23, and the 
mRNA levels of chIL-12 p35 measured. Expression of chIL-12 p35 mRNA was not 
detected in the rchIL-23-stimulated BMDCs despite LPS-stimulated positive controls 
indicating the cells could be stimulated to express chIL-12 p35. This result contrasts 
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with original mammalian studies (Belladonna et al., 2002) but is in line with a very 
recent study by Chognard et al. (2014) where by IL-23R expression was not detected 
on mice DCs, suggesting these cells do not respond t  IL-23. Despite the 
contradictory nature of the mammalian studies, it is not surprising chicken BMDCs 
do not express chIL-12 when stimulated with rchIL-23 as BMDCs compared to 
splenic DCs in vitro have different biological activities (Garrigan et al., 1996). If a 
method for isolating and differentiating splenic DCs in the chicken were available, 
investigating the biological effect of rchIL-23-stimulation on splenic DCs would 
perhaps shed more light on the similarities and differences of mammalian IL-23 and 
chIL-23. 
As discussed before, IL-23 and IL-12 share the p40 subunit. Monoclonal Abs 
developed by this group (Balu et al., 2011) which recognise chIL-12 have been 
characterised. Specifically, the mAbs recognise the p40 subunit of chIL-12 and, 
therefore, should recognise the p40 subunit of chIL-23. To further investigate this, 
three anti-chicken IL-12 p40 mAbs, AV134, AV135 and AV136 were used in a dot-
blot analysis to determine if they recognise purified rchIL-23. All three mAbs detect 
purified rchIL-23. It is now no longer possible to use the chIL-12 p40 mAbs for 
definitive detection of chIL-12 p70. 
Chicken IL-23 p19 mRNA levels were measured in a broad range of chicken tissues 
and stimulated cells. The expression of chIL-23 p19was ubiquitous and constitutive 
in the range of cells and tissues examined. Similar constitutive expression of huIL-23 
p19 in a range of unstimulated tissues was seen in several genome-wide human tissue 
expression studies (Shmueli et al., 2003; Yanai et al., 2005), supporting the 
conclusion that chIL-23 may have a similar function t  mammalian IL-23. Chicken 
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IL-12 p40 is ubiquitously expressed in a variety of tissues (Balu and Kaiser, 2003), 
whilst expression of chIL-12 p35 is more tightly controlled (Degen et al., 2004), thus 
regulating the expression of functional IL-12. This is in contrast to mammals where 
IL-12 p35 is ubiquitously expressed and the expression of the p40 subunit is more 
tightly regulated, determining whether a cell produces functional IL-12 (Gately et al., 
1998). The co-expression of the IL-23 subunits, p19and p40, would be expected in 
tissues as it would potentially allow the formation f IL-23. However, the ubiquitous 
expression of both subunits at the mRNA level suggests regulation of chIL-23 
expression may be post-translational. The high mRNA levels seen in non-lymphoid 
tissues may in part be explained by the chicken’s lack of lymph nodes and their 
development of diffuse lymphoid aggregates in organs (Michael and Hodges, 1974). 
Consequently, tissues defined in mammals as non-lymphoid contain more lymphoid 
cells in the chicken. 
In contrast to being ubiquitously and highly expressed in a range of tissues, chIL-23 
p19 mRNA expression was not up-regulated in stimulated splenocytes or bursal 
cells, and  chIL-23 p19 expression in these cells declined over 24 h. Chicken IL-23 
p19 was only up-regulated in stimulated thymocytes at 2 h post-stimulation. The 
predominant cell type in the thymus and bursa of Fabricius are T and B cells 
respectively, whereas the cell population in the spleen is more heterogeneous and 
includes APCs such as DCs and macrophages. IL-23 expression in mammals is 
mainly from DCs and tissue-resident macrophages through activation with TLR 
ligands such as LPS (Kastelein et al., 2007). ConA, PHA and PMA and ionomycin 
were used to stimulate splenocytes, thymocytes and bursal cells respectively. These 
stimulants activate lymphocytes (Abb et al., 1979; Dutton, 1972; Nowell, 1960), 
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resulting in expression of cytokines but there is no evidence to suggest they also 
stimulate DCs. ConA can activate macrophages to produce pro-inflammatory 
cytokines (Nugent et al., 1985; Wang and Basch, 1979) but the expression of IL-23 
in mammalian macrophages stimulated with ConA has not been investigated. Holt et 
al. (2011) showed in vitro stimulation of zebrafish leucocytes with LPS for 1 h 
increased expression of IL-23 p19. As the stimulants used here do not up-regulate 
expression of chIL-23 p19, one of the next steps would be to investigate the effects 
of stimulation with LPS or other mitogens on chicken splenocytes. In addition, 
stimulation of chicken bone marrow-derived macrophages with TLR ligands and 
subsequent measurement of chIL-23 p19 mRNA expression would be interesting. 
Finally, the development of a mAb which recognises chIL-23 p19 would also allow 
identification of cells expressing chIL-23 p19 and distinguish between the expression 
of chIL-12 p70 and chIL-23. 
To summarise, IL-23 p19 has been identified and cloned in the chicken. Purified 
rchIL-23 was expressed from an IL-23 flexi-construc and the bioactivity of the 
recombinant protein demonstrated by increased mRNA levels of chIL-17A, chIL-
17F and chIL-22 in splenocytes stimulated with rchIL-23. The rchIL-23 was 
recognised by chIL-12 mAbs against the chIL-12/chIL-23 p40 subunit. Chicken IL-
23 p19 was expressed in a wide range of tissues but was not consistently up-
regulated in stimulated splenocytes, thymocytes or bursal cells. The identification of 
IL-23 in the chicken and expression of purified rchIL-23 provides useful tools to 
further investigate the role of IL-23 and Th17 immune responses in the chicken.
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Chapter 4 Th17 effector cytokine expression 
4.1 Introduction 
Th17 cells in mammals are characterised by the expression of the cytokines IL-17A, 
IL-17F, IL-21 and IL-22 (Korn et al., 2009). The roles of the mammalian Th17 
cytokines are discussed in Chapter 1. The Th17 effector cytokines IL-17A (Min and 
Lillehoj, 2002), IL-17F (Kim et al., 2012b), IL-21 (Rothwell et al., 2012) and IL-22 
(Kim et al., 2012a) have now been identified in the chicken. Relatively little is 
known about what cells express these cytokines and their anatomical location. 
Further, the expression and biological function of these Th17 effector cytokines 
during infection has not been investigated in the chicken. In mammals, the 
expression of Th17 cytokines is driven by cytokines, such as IL-23. The role of 
mammalian IL-23, and the influence it has on the immune response, particularly 
during persistent infections, has been well studied (Reviewed by Tato and Cua 
(2008)). However, expression of IL-23 in the chicken has not been studied to date. 
Of the Th17 effector cytokines, the most studied outside of biomedical model species 
is IL-17A. However, despite being identified in several mammalian species (Katoh et 
al., 2004; Riollet et al., 2006; Tompkins et al., 2010), birds (Min and Lillehoj, 2002; 
Yoo et al., 2009) and fish (Gunimaladevi et al., 2006; Kono et al., 2011), 
information on the role of IL-17A in these species r mains limited (reviewed by 
Mensikova et al., 2013). Chicken IL-17A was identified by Min and Lillehoj (2002). 
Its role in the immune response has primarily been investigated in Salmonella and 
Eimeria infections. Chicken IL-17A mRNA levels are increasd during Salmonella 
enteritidis infection (Matulova et al., 2013). Further, mRNA expression of chIL-17A 
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is higher in non-vaccinated chickens compared to vaccin ted birds following 
infection with Salmonella enteritidis (Matulova et al., 2012). In Eimeria tenella-
infected birds, chIL-17A is associated with increased immunopathology (Zhang et 
al., 2013). Infected birds treated with chIL-17A showed xacerbated lesion scores 
and reduced body weight gain compared to untreated birds. The converse was seen in 
chIL-17A-neutralised birds (Zhang et al., 2013). Infected birds treated with chIL-
17A Ab showed reduced caecal lesion scores and increased body weight gain 
compared to untreated, infected birds. These studies suggest IL-17A in chickens 
plays a role in mucosal immunity and associated gut pathology as in mammals. 
Chicken IL-17F was cloned from ConA-stimulated splenocytes (Kim et al., 2012b). 
Increased chIL-17F mRNA expression was seen in Eimeria-infected birds compared 
to uninfected controls up to 10 dpi (Kim et al., 2012b). Fish species possess genes 
with homology to mammalian IL-17A and IL-17F, which have been termed IL-
17A/F (reviewed by Kono et al., 2011). The functional role of IL-17F in other 
species remains to be investigated. 
IL-21 has pleiotropic effects on both innate and adaptive immune responses. Beyond 
biomedical model species, it has been identified in cattle (Muneta et al., 2003), pig 
(Muneta et al., 2004) and fish (Wang et al., 2011). Chicken IL-21 was cloned 
(Rothwell et al., 2012) and, similarly to mammals, synergistically enhances T cell 
proliferation and inhibits maturation of DCs. Its expression and potential role in 
chicken immune responses, particularly Th17 immune responses, remains to be 
elucidated. 
Chapter 4 Th17 effector cytokine expression  
128 
 
IL-22 has been identified in cattle and is expressed by αβ and γδ T cells (Ma et al., 
2010). Identification and demonstration of bioactivity of recombinant IL-22 in a non-
mammalian species was initially made in fish (Igawa et al., 2006; Monte et al., 
2011). IL-22 was identified in the chicken genome by Kaiser et al. (2005) and 
subsequently Kim et al. (2012a) demonstrated recombinant chIL-22 induced pro-
inflammatory cytokines and anti-microbial peptides in epithelial cells and 
hepatocytes, similarly to mammalian IL-22. 
The aims of this Chapter are to characterise Th17 immune responses in the chicken 
during infection by measuring mRNA levels of Th17 effector cytokines and IL-23 in 
various tissues, stimulated cells and during infection. The four disease models used 
in this Chapter to investigate Th17 immune responses in the chicken are discussed in 
Chapter 1. 
4.2 Methods 
General methods are outlined in Chapter 2. Additional methods and alterations are 
detailed here. 
4.2.1 Cloning of chIL-17F cDNA 
At the beginning of this study, the chIL-17F cDNA sequence was incorrectly 
annotated in the chicken genome (WASHUC2, Ensembl). The annotated sequence 
for chIL-17F in Ensembl (ENSGALT00000026912) appeared to be missing the first 
exon (Figure 4.1), suggesting the correct chIL-17F sequence to be the GenScan 
prediction (GENSCAN00000013648). 




Figure 4.1. Ensembl (WASHUC2) showing the genetic location (red box) of chIL-17F 
(GENSCAN00000013648) on chromosome 3 of the chicken genome. The annotated gene for 
chicken IL-17F in Ensembl is located just below (ENSGALT00000026912). 
Using the GenScan prediction for chIL-17F (GENSCAN000 0013648) (Figure 4.1), 
forward and reverse primers (Table 2.1) were designd to amplify the full-length 
chIL-17F cDNA. RNA isolated from chicken splenocytes stimulated with ConA for 
2 h was used as a template to amplify chIL-17F cDNA by PCR (section 2.4.3.1). The 
chIL-17F cDNA clone was TA-cloned into pGEM®-T Easy and sequenced to 
confirm the identity of chIL-17F and its similarity o mammalian IL-17F. 
4.2.2 RT-qPCR (TaqMan ®) primer and probe design 
Having confirmed the full-length nt sequence of chIL-17F, primers and probe for use 
in RT-qPCR (TaqMan®) were designed using Primer Express v3 (Applied 
Biosystems) (Table 2.4). TaqMan® primers and probes w re also designed for chIL-
17A using Primer Express v3. Primers and probes to de ect mRNA expression of 
chIL-21 (Rothwell et al., 2012) and chIL-22 (Pathania, 2008) were designed 
previously. For all TaqMan® primer and probe sequences see Table 2.4. 




4.3.1 Identification and cloning of chIL-17F 
Based on the predicted chIL-17F nt sequence (GENSCAN00000013648), primers 
IL-17F_F3 and IL-17F_R2 (Table 2.1) were designed to clone the predicted full-
length chIL-17F cDNA, using cDNA prepared from ConA-stimulated splenocytes as 
a template. Figure 4.2 shows the product amplified with primers IL-17F_F3 and IL-
17F_R2. It is approximately 500 nt in size and was then TA-cloned into pGEM®-T 
Easy and transformed into E. coli JM109 competent cells for subsequent plasmid 
isolation and sequencing. 
 
Figure 4.2. RT-qPCR amplification of the predicted chIL-17F cDNA.  Lane L: GeneRuler™ DNA 
Ladder Mix (Thermo Scientific). Lane 1: cDNA from ConA-stimulated (2 h) splenocytes. Lane 2: 
negative control. Red box highlights PCR product select d for TA cloning and sequencing. 
Multiple cloned plasmids were sequenced to confirm the nt sequence of chIL-17F, 
which also confirmed the misannotation of the chIL-17F gene 
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(ENSGALT00000026912) in the Ensembl database (WASHUC2). Alignment of the 
misannotated chIL-17F aa sequence and the cloned and tr slated chIL-17F aa 
sequence (Figure 4.3), confirmed that the additional 5’ exon of the chIL-17F 
GenScan prediction (GENSCAN00000013648) encodes a start codon and 8 
additional aa. 
 
Figure 4.3. Comparison of the annotated chIL-17F aa sequence (ENSGALT00000026912) and 
the GenScan prediction for chIL-17F (GENSCAN00000013648). The GenScan prediction encodes 
an additional start codon and 8 aa. 
4.3.2 Structural features of chIL-17F 
The chIL-17F cDNA encodes a predicted protein of 169 aa (Figure 4.4), which 
contains a predicted 25 aa signal peptide with a resultant mature protein of 144 aa. 
This has 39.6% identity at the predicted aa level (67/169 differences) compared with 
human, mouse and cattle IL-17F. Further, there are 49.1%, 50.3% and 50.8% 
similarity between chIL-17F and human, mouse and cattle IL-17F respectively. 
There are seven cysteine residues in chIL-17F, of which six are conserved with 
mammals, in which there are two disulphide bonds (indicated by solid light grey 
lines). Positively charged arginine residues involved in the interaction with the IL-
17-RA are conserved in the chicken. The location of an α-helix and five β-strands in 
human IL-17F are shown as an open arrow and dark grey arrows respectively above 
the aa sequences. Mammalian IL-17s display a cysteine knot structure. There are two 
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conserved serine residues which replace the cysteine r sidues in the position of the 
third disulphide bond, within the cysteine knot. One of these serine residues (Ser126) 
is conserved in the chicken but the other is not (Ala86). 
 
Figure 4.4. Comparison of the chIL-17F aa sequence with human, mouse and cattle IL-17F.  
Shaded areas represent conservation of aa similarity, the darker the shading, the more conserved the 
residue is across the species. The vertical black arrow indicates the predicted signal sequence cleavage 
site of chIL-17F. Cysteine residues conserved across all species are indicated by asterisks. The 
chicken-specific cysteine residue is identified by a triangle. Conserved positively charged arginine 
residues involved in the interaction with IL-17-RA are indicated by small circles. An α-helix is shown 
by an open arrow, β-strands by dark grey arrows. Disulphide bonds are indicated by solid grey lines 
connecting the relevant cysteines. In mammalian IL-17s there are two conserved serines which replace 
the cysteines in the position of the third disulphide bond in the cysteine knot. The serine residue 
conserved in the chicken is highlighted in green and that conserved only in mammals is highlighted in 
red. 
4.3.3 Analysis of chicken Th17 effector cytokine mR NA expression in 
tissues and stimulated cells 
The mRNA expression of chicken IL-17A, IL-17F, IL-21 and IL-22 was studied in a 
wide range of chicken tissues and stimulated cells in order to compare it to cytokine 
expression in mammals and fish. 




As shown in Figure 4.5, chIL-17A mRNA is widely expressed in all immune and 
non-immune tissues investigated at moderate levels. The highest mRNA levels in 
non-lymphoid tissues were seen in the kidney and in lymphoid tissues in the spleen, 
with very similar levels seen in the thymus and Meckel’s diverticulum. 
 
Figure 4.5. Expression patterns of chIL-17A mRNA in tissues as measured by RT-qPCR.  Data 
are expressed as corrected 40-Ct values ± SEM. Assays were carried out in triplicate and each value is 
the mean of 3 birds. 
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Levels of chIL-17A mRNA were also measured in stimulated lymphoid cells and 
compared to those in unstimulated controls. Splenocytes were stimulated with ConA, 
thymocytes with PHA and bursal cells with PMA and ionomycin over a time-course 
of 2-24 h. As seen in Figure 4.6 (A), ConA stimulation significantly up-regulated (p 
= 0.002) chIL-17A mRNA expression in splenocytes after 6h of stimulation. There is 
a significant negative linear relationship (p = 0.018) in fold change over time of 
chIL-17A mRNA levels in stimulated splenocytes. Chicken IL-17A mRNA levels 
decreased from 2-24 h. There was no difference in mRNA expression between 
control and stimulated cells in the thymus at any time-point observed (Figure 4.6 
(B)). Chicken IL-17A mRNA levels in stimulated bursal cells were significantly up-
regulated at 2 h post-stimulation (Figure 4.6 (C)), and showed a significant negative 
linear decline (p < 0.001) in fold change over time, d creasing from 2-24 h post-
stimulation. 




Figure 4.6. Expression patterns of chIL-17A mRNA in stimulated (A) splenocytes, (B) 
thymocytes and (C) bursal cells.  Data are expressed as fold change compared to levels in age-
matched unstimulated controls ± SEM. A linear mixed effect model was used to determine if there 
was a relationship between mRNA levels and time. A standard one-sample t test was performed to 
determine if cytokine levels were significantly up or down-regulated relative to a fold change of one 
as indicated by a single asterisk (p < 0.05) or double asterisk (p < 0.01). Chicken splenocytes, 
thymocytes and bursal cells were stimulated with ConA, PHA and PMA and ionomycin respectively 
for between 2-24 h. Assays were carried out in triplicate and each value is the mean of 3 birds. 
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4.3.3.2 Chicken IL-17F 
As shown in Figure 4.7, chIL-17F mRNA is widely expressed in tissues albeit at a 
low level and also at slightly lower levels compared to chIL-17A (Figure 4.5). The 
highest levels of chIL-17F mRNA expression in non-lymphoid tissues were in the 
lung and in lymphoid tissues were in the caecal tonsil and the bursa of Fabricius. 
 
Figure 4.7. Expression patterns of chIL-17F mRNA in tissues as measured by RT-qPCR.  Data 
are expressed as corrected 40-Ct values ± SEM. Assays were carried out in triplicate and each value is 
the mean of 3 birds. 
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Chicken IL-17F mRNA levels were also measured in stimulated lymphoid cells and 
compared to those in unstimulated controls. Chicken IL-17F mRNA was 
significantly up-regulated at 6-18 h (p < 0.034) post-stimulation in ConA-stimulated 
splenocytes (Figure 4.8 (A)). However, there was no ignificant relationship in chIL-
17F mRNA expression in stimulated splenocytes over time. Chicken IL-17F mRNA 
in control and stimulated thymocytes was extremely low and there was no difference 
in mRNA levels between control and stimulated cells in the thymus at any time-point 
(Figure 4.8 (B)). There was no significant relationship in chIL-17F mRNA 
expression in stimulated thymocytes over time. Expression of chIL-17F mRNA in 
stimulated bursal cells was significantly up-regulated between 2-6 h (p < 0.026) post-
stimulation (Figure 4.8 (C)). Chicken IL-17F mRNA levels also showed a significant 
negative quadratic relationship (p = 0.041) in fold change over time. Levels of chIL-
17F mRNA compared to unstimulated controls initially decreased over time (2-18 h) 
before increasing at 24 h. 




Figure 4.8. Expression patterns of chIL-17F mRNA in stimulated (A) splenocytes, (B) 
thymocytes and (C) bursal cells.  Data are expressed as fold change compared to levels in age-
matched unstimulated controls ± SEM. A linear mixed effect model was used to determine if there 
was a relationship between mRNA levels and time. A standard one-sample t test was performed to 
determine if cytokine levels were significantly up or down-regulated relative to a fold change of one 
as indicated by a single asterisk (p < 0.05) or double asterisk (p < 0.01). Chicken splenocytes, 
thymocytes and bursal cells were stimulated with ConA, PHA and PMA and ionomycin respectively 
for between 2-24 h. Assays were carried out in triplicate and each value is the mean of 3 birds. 
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4.3.3.3 Chicken IL-21 
Figure 4.9 shows low levels of chIL-21 mRNA detected in a variety of tissues. The 
highest chIL-21 mRNA levels in non-lymphoid tissues were measured in the gut and 
no expression was detected in muscle or skin. In lymphoid tissues, the highest chIL-
21 mRNA levels were in Meckel’s diverticulum, bursa of Fabricius and caecal tonsil. 
 
Figure 4.9. Expression patterns of chIL-21 mRNA in tissues as measured by RT-qPCR.  Data are 
expressed as corrected 40-Ct values ± SEM. Assays were carried out in triplicate and each value is the 
mean of 3 birds. 
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Messenger RNA levels of chIL-21 were also measured in unstimulated and 
stimulated lymphoid cells by RT-qPCR. Chicken IL-21 mRNA in stimulated 
splenocytes was significantly up-regulated compared to unstimulated controls at 2-6 
h (p < 0.048) post-stimulation (Figure 4.10 (A)). Chicken IL-21 mRNA expression in 
stimulated splenocytes also showed a significant positive linear relationship (p = 
0.023) over time, increasing from 2-24 h post-stimulation. Chicken IL-21 mRNA 
expression in stimulated thymocytes was only measured at 2 h post-stimulation; the 
increase in chIL-21 mRNA levels was not significant (Figure 4.10 (B)). Stimulated 
bursal cells showed a significant increase in chIL-21 mRNA compared to 
unstimulated controls at 2, 6 and 12 h (p < 0.008) post-stimulation (Figure 4.10 (C)). 
Further, there was a significant negative quadratic relationship in fold change of 
chIL-21 mRNA expression compared to unstimulated controls over time (p = 0.049). 
Chicken IL-21 mRNA levels in stimulated bursal cells increased from 2-6 h post 
stimulation and then decreased from 6-24 h post stimulation. 




Figure 4.10. Expression patterns of chIL-21 mRNA in stimulated (A) splenocytes, (B) 
thymocytes and (C) bursal cells.  Data are expressed as fold change compared to levels in age-
matched unstimulated controls ± SEM. A linear mixed effect model was used to determine if there 
was a relationship between mRNA levels and time. A standard one-sample t test was performed to 
determine if cytokine levels were significantly up or down-regulated relative to a fold change of one 
as indicated by a single asterisk (p < 0.05) or double asterisk (p < 0.01). Chicken splenocytes, 
thymocytes and bursal cells were stimulated with ConA, PHA and PMA and ionomycin respectively 
for between 2-24 h. Assays were carried out in triplicate and each value is the mean of 3 birds. 
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4.3.3.4 Chicken IL-22 
RT-qPCR was used to measure mRNA levels of chIL-22 in various tissues and 
stimulated lymphoid cells. As shown in Figure 4.11, chIL-22 mRNA is widely 
expressed in tissues but at very low levels. The highest mRNA levels in non-
lymphoid cells were measured in muscle, heart and kidney. The highest mRNA 
expression of chIL-22 in lymphoid cells was in caecl tonsil. 
 
Figure 4.11. Expression patterns of chIL-22 mRNA in tissues as measured by RT-qPCR.  Data 
are expressed as corrected 40-Ct values ± SEM. Assays were carried out in triplicate and each value is 
the mean of 3 birds. 
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Chicken IL-22 mRNA was measured in stimulated lymphoid tissues and compared to 
unstimulated controls. Chicken IL-22 mRNA levels were measured in stimulated 
splenocytes at all time-points but there was no significant up-regulation in stimulated 
cells compared to levels in unstimulated controls, nor was there a significant 
relationship in fold change of chIL-22 mRNA expression compared to unstimulated 
controls over time (Figure 4.12 (A)). No chIL-22 mRNA was detected in control or 
stimulated thymocytes (Figure 4.12 (B)). Stimulated bursal cells expressed increased 
levels of chIL-22 mRNA compared to those in unstimulated controls at 2, 4, 6 and 12 
h stimulation but the levels were not significant (Figure 4.12 (C)). Chicken IL-22 
mRNA levels were not measured at 18 or 24 h post-stimulation. There was not a 
significant relationship in fold change of chIL-22 mRNA levels compared to 
unstimulated controls over time in stimulated bursal cells. 




Figure 4.12. Expression patterns of chIL-22 mRNA in stimulated (A) splenocytes, (B) 
thymocytes and (C) bursal cells. Data are expressed as fold change compared to levels in age-
matched unstimulated controls ± SEM. A linear mixed effect model was used to determine if there 
was a relationship between mRNA levels and time. A standard one-sample t test was performed to 
determine if cytokine levels were significantly up or down-regulated relative to a fold change of one. 
Chicken splenocytes, thymocytes and bursal cells were stimulated with ConA, PHA and PMA and 
ionomycin respectively for between 2-24 h. Assays were carried out in triplicate and each value is the 
mean of 3 birds. 
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4.3.4 Analysis of chicken Th17 cytokine mRNA expres sion in vivo 
following bacterial, viral and parasitic challenge 
To further investigate whether chickens mount Th17 immune responses, mRNA 
levels of the Th17 effector cytokines: chIL-17A, chIL-17F, chIL-21 and chIL-22 
were measured during Marek’s disease, Infectious bur al disease and histomoniasis 
infections. The cytokines chIL-17A, chIL-17F and chIL-23 p19 were measured 
during S. aureus infection (section 2.2). 
4.3.4.1 Marek’s disease 
The Th17 effector cytokines, chIL-17A, chIL-17F, chIL-21 and chIL-22 as well as 
chIL-23 p19 mRNA expression was measured in the splen from a resistant and 
susceptible MDV-infected chicken line and compared to uninfected, age-matched 
controls. 
Figure 4.13 (A) shows there was a significant interaction (p = 0.001) between the 
line of chicken and the infected/uninfected group in chIL-23 p19 mRNA expression. 
Infected resistant line 61 birds expressed lower levels of chIL-23 p19 mRNA 
compared to uninfected line 61 resistant birds, whereas infected susceptible line 72 
birds expressed higher levels of chIL-23 p19 mRNA compared to uninfected line 72 
birds at all time points. This significant interaction between the line of chicken and 
the infected/uninfected group and subsequent relationship was also measured in 
chIL-17A (p < 0.001) and chIL-21 (p = 0.003) mRNA levels (Figure 4.13 (B) & 
(C)). 
Further, there was also a significant main effect of dpi (p = 0.01) and line (p = 0.001) 
on expression of chIL-21 mRNA (Figure 4.13 (C)). At 4 dpi, chIL-21 mRNA levels 
were higher compared to 2 and 3 dpi, irrespective of gr up (infected/uninfected) and 
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line of bird. Resistant line 61 birds expressed higher levels of chIL-21 mRNA 
compared to susceptible line 72 birds, irrespective of group (uninfected/infected) and 
dpi. 
 
Figure 4.13. Quantification of A) chIL-23 p19, B) chIL-17A and C) chIL-21 mRNA levels in 
spleens during MDV infection.  Data are expressed as corrected 40-Ct of infected and uninfected 
resistant (R) line 61 and susceptible (S) line 72 birds at 2, 3 and 4 days post-infection. Dark grey boxes 
represent infected birds (I) and light grey boxes represent uninfected birds (U). Significant interactions 
(p < 0.05) between groups of data were determined using analysis of variance. Assays were carried 
out in triplicate. 
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There was also a significant interaction (p = 0.023) between the dpi and the 
infected/uninfected group in chIL-17A mRNA expression (Figure 4.14). At 2 dpi, 
chIL-17A mRNA in MDV-infected birds was lower compared to mRNA levels in 
MDV-uninfected birds, whereas at 3 and 4 dpi, chIL-17A mRNA expression in 
MDV-infected birds was higher compared to those in age-matched, uninfected 
controls. 
 
Figure 4.14. Quantification of chIL-17A mRNA levels in spleens during MDV infection. Data are 
expressed as corrected 40-Ct of infected and uninfected birds at 2, 3 and 4 days post-infection. Dark 
grey boxes represent infected birds (I) and light grey boxes represent uninfected birds (U). Significant 
interactions (p < 0.05) between groups of data were determined using analysis of variance. Assays 
were carried out in triplicate. 
Chicken IL-17F mRNA levels showed a significant main effect (p < 0.001) between 
uninfected and infected birds, irrespective of the lin of bird or the dpi (Figure 4.15). 
Expression of chIL-17F mRNA was higher in uninfected birds compared to MDV-
infected birds. 




Figure 4.15. Quantification of chIL-17F mRNA levels in spleens during MDV infection. Data are 
expressed as corrected 40-Ct of infected and uninfected resistant (R) line 61 and susceptible (S) line 72
birds at 2, 3 and 4 days post-infection. Dark grey boxes represent infected birds (I) and light grey 
boxes represent uninfected birds (U). Significant interactions (p < 0.05) between groups of data were 
determined using analysis of variance. Assays were carried out in triplicate. 
Expression of chIL-22 mRNA did not show any significant interactions between the 
line of bird, the sample type (infected/uninfected) or the dpi (Figure 4.16). 
 
Figure 4.16. Quantification of chIL-22 mRNA levels in spleens during MDV infection.  Data are 
expressed as corrected 40-Ct of infected and uninfected resistant (R) line 61 and susceptible (S) line 72
birds at 2, 3 and 4 days post-infection. Dark grey boxes represent infected birds (I) and light grey 
boxes represent uninfected birds (U). Significant interactions (p < 0.05) between groups of data were 
determined using analysis of variance. Assays were carried out in triplicate. 
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4.3.4.2 Infectious bursal disease 
Using previously archived RNA samples, chIL-17A, chIL-17F, chIL-21 and chIL-22 
mRNA levels were measured in caecal tonsils from IBDV-infected chickens and 
compared to uninfected, age-matched controls at 1, 3 and 4 dpi. 
Chicken IL-17A mRNA levels were significantly up-regulated at 1 dpi (p = 0.036) 
but then down-regulated at 3 dpi (p = 0.024) (Figure 4.17 (A)). There was a 
significant decrease in chIL-17A mRNA expression at 3 and 4 dpi (p < 0.03) 
compared to 1 dpi. Messenger RNA levels of chIL-17F were significantly increased 
at 3 dpi compared to 1 dpi (p = 0.019) (Figure 4.17 (B)). Chicken IL-21 mRNA 
levels were significantly down-regulated at 4 dpi ( = 0.033) and significantly 
decreased at 4 dpi compared to 1 dpi (p = 0.035). Chicken IL-22 mRNA expression 
was significantly up-regulated at 4 dpi (p = 0.026) and chIL-22 mRNA expression at 
1 and 3 dpi was significantly reduced compared to 4dpi (p < 0.03) (Figure 4.17 (C) 
and (D)). 




Figure 4.17. Quantification of A) chIL-17A, B) chIL-17F, C) chIL-21 & D) chIL-22 mRNA 
levels in caecal tonsils during IBDV infection.  Data are expressed as fold change compared to 
levels in age-matched uninfected controls ± SEM at 1, 3 and 4 days post-infection (dpi). A 1-way 
ANOVA and post-hoc standard Tukey test were used to etermine if the mRNA levels at each dpi 
were significantly different to each other. A standrd one-sample t test was performed to determine if 
cytokine levels were significantly up or down-regulated relative to a fold change of one (p < 0.05) as 
indicated by a single asterisk (p < 0.05). Each infected value is the mean of 3 birds. Control values ar  
from 1 bird. Assays were carried out in triplicate. 




Chicken IL-17A, chIL-17F, chIL-21 and chIL-22 mRNA expression was measured 
in caecal tonsils from H. meleagridis-infected chickens and compared to uninfected, 
age-matched controls over a time course from 1-30 dpi. 
Chicken IL-17A and chIL-21 mRNA levels (Figure 4.18 (A) & (C)) were high at 1 
dpi, decreasing until 12 dpi and then increasing from 18-30 dpi, demonstrating a 
quadratic relationship over time. This relationship is stronger for chIL-17A mRNA 
expression with an R2 value of 34.4% for chIL-17A compared to 24% for chIL-21 
mRNA expression. Chicken IL-17F and chIL-22 mRNA levels (Figure 4.18 (B) & 
(D)) were highest at 1 dpi, decreasing over time until 30 dpi, demonstrating a linear 
relationship over time. All relationships were significant (p < 0.05). 




Figure 4.18. mRNA levels of (A) chIL-17A, (B) chIL-17F, (C) chIL-21 & (D) chIL-22 in caecal 
tonsils during H. meleagridis infection.  Data are expressed as fold change compared to the mean 
value of 2 age-matched uninfected controls at 1, 2, 3, 4, 6, 8, 10, 12, 18, 24 and 30 days post-
infection. Regression analysis was used to statistically analyse the data. Chicken IL-17A and chIL-21 
mRNA expression show a quadratic relationship over time. Chicken IL-17F and chIL-22 mRNA 
expression show a linear relationship over time. The red line represents the regression analysis and the 
green dashed lines indicate the 95% confidence intervals. R² values and p values for each cytokine are 
indicated in the top right hand corner of each figure. All relationships have a significance value of less 
than 0.05 (p < 0.05). 
4.3.4.4 Staphylococcus aureus pilot study 
A S. aureus in vivo challenge experiment pilot study was carried out in collaboration 
with Ross Fitzgerald and Andreas Lengeling. RT-qPCR (TaqMan®) was used to 
measure mRNA expression of chIL-17A, chIL-17F and chIL-23 p19 from the 
spleens and bone marrow of S.aureus-infected chickens. 
The mRNA expression of chIL-17A, chIL-17F and chIL-23 p19 was measured in the 
spleen and bone marrow at 6 and 11 dpi. There was no difference in fold change of 
chIL-17A mRNA in the spleen or chIL-17F mRNA in the spleen and bone marrow 
between the wild-type and mutant groups compared to unstimulated controls at any 
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time-point (Figure 4.19 (A) and (B)). Chicken IL-23 p19 mRNA levels were 
significantly decreased in the wild-type and mutant infected groups at 11 dpi 
compared to 6 dpi in the spleen and the bone marrow (p < 0.026) (Figure 4.19 (C)). 
 
Figure 4.19. Quantification of (A) chIL-17A, (B) chIL-17F and (C) chIL-23 p19 mRNA in the 
spleen and bone marrow during S. aureus infection.  Data are expressed as fold change in cytokine 
mRNA levels of wild-type infected birds (light grey bars) and mutant infected birds (dark grey bars) 
compared to uninfected age-matched controls ± SEM at 6 nd 11 days post-infection. A 2-way 
ANOVA with interactions was used to determine if there were significant differences between group 
and dpi for each cytokine (p < 0.05) as indicated by an asterisk. Control values at 6 days are the mean 
of 2 birds and at 11 days, the mean of 3 birds. Wild-type values at 6 days are the mean of 3 birds and 
at 11 days are the mean of 4 birds. Mutant values at 6 and 11 days are the mean of 3 birds. Assays 
were carried out in triplicate. 
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Chicken IL-17A mRNA expression measured in the bone marrow showed bird-to-
bird variation between the groups and dpi (Figure 4.20). Individual birds responded 
by expressing chIL-17A mRNA or not at all. As no chIL-17A mRNA was measured 
in the control group at 6 dpi, it was not possible to analyse fold change. With the 
exception of one bird (WT2), there was higher mRNA expression in the wild-type 
and mutant groups compared to uninfected controls at 6 dpi. At 11 dpi, there was no 
difference in chIL-17A mRNA expression between the wild-type, mutant or 
uninfected control groups. 
 
Figure 4.20. Chicken IL-17A mRNA levels in the bone marrow of S. aureus infected birds.  Data 
are expressed as corrected 40-Ct cytokine mRNA levels in uninfected control birds (C1-C5) (white 
bars), wild-type infected birds (WT1-WT7) (light grey bars) and mutant infected birds (M1-M7) (dark 
grey bars) at 6 and 11 dpi. A Mann-Whitney U test was used to determine if there were significant 
differences between the wild-type, mutant and uninfected control groups. Assays were carried out in 
triplicate. 




Th17 cells were identified in mammals by Harrington et al. (2005) and are 
characterised by the production of IL-17A, IL-17F, IL-21 and IL-22 (Korn et al., 
2009). They are a CD4+ T cell subset that have not been described in the chicken to-
date despite chickens expressing the characteristic cytokines. Therefore, to study the 
possible involvement of Th17 immune responses in the c icken, mRNA expression 
of Th17 cytokines (IL-23, IL-21, IL-17A, IL-17F and IL-22) was measured in 
various tissues, stimulated cells and during infection by RT-qPCR (TaqMan®). At 
the beginning of this study, IL-17F had not been positively identified and cloned in 
the chicken. The gene was incorrectly annotated in the chicken genome. In order to 
study the expression of Th17 effector cytokines in the chicken, the chIL-17F nt 
sequence was confirmed. TaqMan® primers and probes were designed against chIL-
17A and chIL-17F. This Chapter describes the cloning of chIL-17F and its structural 
features, as well as measurement of chIL-17A, chIL-17F, chIL-21 and chIL-22 
mRNA levels in a wide range of tissues, stimulated c lls and during infection in the 
chicken. Additionally, mRNA expression of chIL-23 p19 was measured during MD 
and S. aureus infection in the chicken to establish if there is al o a role for chIL-23 
during infection. 
4.4.1 Identification of chIL-17F 
Chicken IL-17F has high aa identity (39.6%) compared to mammalian IL-17Fs 
(Kaiser et al., 2005) and is similar in aa sequence length to its mammalian 
counterparts. Mammalian IL-17A and IL-17F have the highest identity of the IL-17 
family of cytokines at approximately 50% (Weaver et al., 2007). This is very similar 
to chIL-17A and chIL-17F, which share 53% aa sequence identity (Kim et al., 
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2012b). Mammalian IL-17 family cytokines, in their homodimeric form, display a 
cysteine knot structure with two disulphide bonds (Liu et al., 2013). This is made up 
of two pairs of anti-parallel β-strands bundled through two disulphide bonds and a 
third disulphide bond being replaced by two conserved serine residues (Zhang et al., 
2011).  The cysteine residues important for disulphide bond formation are conserved 
in chIL-17F and may be involved in the formation of 2 disulphide bonds. However, 
only one of the two conserved serine residues is pre ent. Mammalian IL-17A and IL-
17F form homodimers (IL-17A/A and IL-17F/F) and a heterodimer (IL-17A/F) 
(Chang and Dong, 2007). The high aa conservation between chIL-17A and chIL-17F 
and their mammalian counterparts, particularly within the regions important for 
secondary structure formation, imply chIL-17A and chIL-17F may also form 
functional homo- and heterodimers. The positively charged arginine residues that 
interact with the mammalian IL-17RA (Zhang et al., 2011) are also conserved in the 
chicken, suggesting chIL-17F may interact with its receptor as in mammals. The 
cloning of chIL-17F provides an analytical tool for investigating Th17 immune 
responses in the chicken, and is the first step towards establishing if chIL-17F 
biological function is similar to mammals. 
4.4.2 Chicken IL-17A expression 
To begin to elucidate whether chickens mount Th17 immune responses, mRNA 
expression of the Th17 effector cytokines chIL-17A, chIL-17F, chIL-21 and chIL-22 
was measured using RT-qPCR (TaqMan®) in a wide range of tissues and in 
stimulated splenocytes, thymocytes and bursal cells. Chicken IL-17A was widely 
expressed in all immune and non-immune tissues measur d. These data contradict 
Min and Lillehoj’s (2002) findings where Northern blot analysis of a series of normal 
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chicken tissues did not detect chIL-17A mRNA. However, more recent findings from 
Kim et al. (2012b) detected chIL-17A mRNA, using RT-qPCR, at low levels in 
thymus, bursa of Fabricius, small and large intestin , liver, lung, brain and fat but not 
in spleen, kidney, heart or skin. In Rainbow trout, similarly to chicken, mRNA 
expression of the IL-17A/F2 molecule was detected in 14 tissues of healthy fish by 
RT-qPCR (Monte et al., 2013). Early studies in mammals using Northern blot-
analysis did not detect IL-17 transcript in normal tissues (Kennedy et al., 1996; Yao 
et al., 1995b) but pig IL-17A mRNA is detected in heart, skin and jejunum by RT-
qPCR (Katoh et al., 2004). These reports suggest that the expression and detection of 
IL-17A in tissues varies across species but is perhaps more dependent on the 
detection method used. It is possible that RT-qPCR is a more sensitive detection 
method than Northern blot analysis used in the published data. Alternatively, chIL-
17A mRNA tissue expression may also vary between individual chickens due to 
breed and age. Min and Lillehoj (2002) used (SPF) white Leghorn chickens (15 
weeks old) and Kim et al. (2012b) used a Ross line of chicken (10 days old), both of 
which differ in breed and age from J line birds at 6 weeks old. 
Chicken IL-17A mRNA levels were up-regulated in ConA-stimulated splenocytes 
after six hours. However, over time, chIL-17A mRNA expression declined between 
2-24 h post-stimulation. ConA is a polyclonal T cell stimulus, which has similar 
effects on mammalian and chicken T cells (Stobo, 1972; Toivanen and Toivanen, 
1973). Previous reports detected chicken and duck IL-17A expression 24-48 h post-
stimulation (Min and Lillehoj, 2002; Yoo et al., 2009). However, both of these avian 
studies used higher concentrations of ConA to stimulate splenocytes, suggesting 
higher levels of ConA-stimulation maybe required to measure up-regulation of chIL-
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17A mRNA levels in stimulated splenocytes. There was up-regulation of chIL-17A 
mRNA in stimulated bursal cells but chIL-17A mRNA levels declined between 2-24 
h post-stimulation. Chicken IL-17A mRNA levels have not been reported in 
stimulated thymocytes or bursal cells before this study. In trout, mRNA expression 
of the IL-17A/F2 molecule was up-regulated by several mitogens including PHA and 
PMA and calcium ionophore in the head kidney, a major lymphoid organ in the fish 
(Monte et al., 2013). However, the specific cell types expressing the IL-17A/F2 
molecule were not investigated. In humans, stimulated B cells express IL-17A 
(Vazquez-Tello et al., 2012). The majority (98%) of bursal lymphocytes are B cells 
(Schat et al., 2012) so it is unsurprising that stimulated bursal cells up-regulate chIL-
17A mRNA expression. 
Measuring chIL-17A mRNA in stimulated primary cells i  the first step to 
investigate how IL-17A expression in the chicken compares to mammals. To further 
this study, investigation of appropriate polyclonal stimuli that drive chIL-17A 
expression in stimulated cells, and at what concentrations, would be useful as a 
possible indicator of what drives chIL-17A expression in vivo. In humans, IL-17A is 
expressed by CD4+ and CD8+ T cells, γδ T cells, NKT cells and ILC3’s (Reynolds et 
al., 2010). It would be interesting to investigate thebiological and immunological 
properties of chIL-17A by comparing the cells expressing IL-17A in the chicken and 
mammals. There are mouse Abs to chicken CD4+, CD8+ and γδ T cells (Davidson 
and Boyd, 1992; Sowder et al., 1988), which could be used with an Ab to rchIL-17 
(Yoo et al., 2008) to investigate the cells that express IL-17A in the chicken. 
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4.4.3 Chicken IL-17F expression 
The expression of chIL-17F mRNA was ubiquitous in the range of tissues examined. 
Chicken IL-17F mRNA levels were lower and more variable in the tissues measured 
compared to chIL-17A. These data correlate with previous studies in the chicken, 
where chIL-17F was detected widely in tissues but at low levels (Kim et al., 2012b), 
and with studies in fish, where the IL-17A/F2 molecul  was detected in all tissues 
examined (Monte et al., 2013). In mammals, IL-17A and IL-17F have similar 
structures and properties and signal through the same receptors (Toy et al., 2006; 
Weaver et al., 2007; Wright et al., 2008). However, the distinct functions of IL-17A 
and IL-17F, particularly in mucosal infection and autoimmune disease, have only 
begun to be elucidated (Ishigame et al., 2009; Iwakura et al., 2011). Further 
investigation of the possible overlapping and distinct cellular expression, and 
biological functions of chIL-17A and chIL-17F is needed, to establish similar roles to 
mammals. 
Chicken IL-17F mRNA levels were up-regulated compared to unstimulated controls 
in ConA-stimulated splenocytes. There was no relationship in chIL-17F mRNA 
levels over time. This contrasts with recently published data showing chIL-17F 
mRNA to generally increase in a time-dependent manner, peaking after 24 h, 
following mitogen stimulation of splenocytes (Kim et al., 2012b). This could be due 
to the variation in chIL-17F mRNA expression found i  different chicken lines and 
tissues sampled (Kim et al., 2012b). There was no difference in chIL-17F mRNA 
levels between control and stimulated cells in the ymus suggesting PHA-
stimulation of thymocytes does not increase chIL-17F mRNA expression. 
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Chicken IL-17F mRNA in stimulated bursal cells was up-regulated but overall chIL-
17F mRNA levels decreased until 18 h post-stimulation. These data suggest chicken 
B cells are capable of expressing and increasing expression of chIL-17F upon 
stimulation, similarly to human B lymphocytes (Vazquez-Tello et al., 2012), despite 
human IL-17F mainly being expressed by CD4+ and CD8+ T cells, γδ T cells, 
epithelial cells and other innate cells (Reynolds et al., 2010). To-date, there is no 
chIL-17F Ab but the development of one would be usef l to further investigate the 
cells that express chIL-17F. Further molecular tools are required to shed light on the 
biological function of chIL-17F, both in relation to chIL-17A function and within 
Th17 immune responses in the chicken. 
4.4.4 Chicken IL-21 expression 
Chicken IL-21 mRNA was widely expressed in a range of tissues at low levels. 
However, chIL-21 mRNA was not detected in muscle or skin. IL-21 tissue 
expression has been investigated in cattle and fish (Muneta et al., 2003; Wang et al., 
2011). Bovine IL-21 was only detected in the spleen by RT-PCR (Muneta et al., 
2003), in contrast to fish, where IL-21 was measured by RT-qPCR in all tissues 
examined (Wang et al., 2011). Similarly to fish, higher chIL-21 mRNA levls were 
seen in the gut compared to other non-lymphoid tissue , probably due to the high 
levels of lymphoid cells found in this tissue. In SPF birds, the highest levels of chIL-
21 mRNA were detected in lymphoid tissues rich in plasma cells, specifically 
Meckel’s diverticulum, the spleen and the Harderian gland (Rothwell et al., 2012), 
which is corroborated here. 
Chicken IL-21 mRNA levels in stimulated splenocytes were up-regulated, with chIL-
21 mRNA expression increasing over time. In chickens, IL-21 is expressed by CD4+ 
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and TCRαβ+ cells and expression is up-regulated by mitogen stimulation (Rothwell 
et al., 2012). In mammals, IL-21 is expressed by CD4+ T cells and NKT cells 
(Coquet et al., 2007; Parrish-Novak et al., 2000). The increased chIL-21 mRNA 
levels in splenocytes compared to unstimulated controls may represent induction of 
chIL-21 mRNA in these cell types. 
Stimulated bursal cells increased expression of chIL-21 mRNA from 2-6 h and then 
chIL-21 mRNA levels decreased between 6-24 h post-stimulation. It is unclear why 
increased expression of chIL-21 mRNA was detected in stimulated bursal cells. The 
bursa of Fabricius is 98% B cells (Schat et al., 2012) and in SPF birds, B cells 
stimulated with PMA expressed higher levels of chIL-21 mRNA compared to 
unstimulated controls (Rothwell et al., 2012). However, the low levels detected were 
attributed to contaminating CD4+ T cells. The chIL-21 mRNA levels measured in 
stimulated bursal cells in this study are likely to be too high to be justified by 
contamination of T cells. Therefore, contrary to mammals, these data suggest that 
chicken B cells when stimulated with PMA and ionomycin express increased levels 
of chIL-21 mRNA. 
4.4.5 Chicken IL-22 expression 
Expression of chIL-22 mRNA was measured in various tis ues using RT-qPCR 
(TaqMan®) and was detected at very low levels in all tissues. Chicken IL-22 mRNA 
was also measured in stimulated lymphoid tissues and compared to unstimulated 
controls. There was no up- or down-regulation of chIL-22 mRNA expression, or 
relationship over time, in any of the stimulated cells. Previous studies in mammals 
have shown that mitogen-activated human and mouse αβ T cells, NK cells and 
monocytes express IL-22 (Dumoutier t al., 2001; Wolk and Sabat, 2006; Xie et al., 
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2000). Chicken IL-22 mRNA expression from these cells types would explain the 
low detection of chIL-22 mRNA in the spleen but not in the bursa of Fabricius. 
Mammalian IL-22 expression in B cells has not been reported. Mammalian IL-22 is 
primarily expressed by activated Th17 cells (Liang et al., 2006). The thymus is 
predominantly made up of developing and naïve T cells, which these data suggest are 
not capable of expressing chIL-22 mRNA. 
To summarise, all chicken Th17 effector cytokines were constitutively expressed in 
normal tissues. Chicken IL-17F, chIL-21 and chIL-22 mRNA levels were up-
regulated in stimulated splenocytes and bursal cells, with higher expression 
compared to unstimulated controls seen at earlier time-points, but chIL-17A mRNA 
was not. Th17 effector cytokine mRNA expression in different lymphoid cells of the 
chicken can be modulated in vitro by a range of stimulants. It would be interesting to 
investigate the cell types in the chicken expressing Th17 effector cytokines to further 
compare and contrast avian Th17 immune responses with mammals. Identification of 
the cell types which express the Th17 effector cytokines may also explain why it was 
not possible to induce expression of chIL-17A, chIL-17F, chIL-21 or chIL-22 in 
stimulated thymocytes. 
4.4.6 Infection models 
In addition to investigating whether mRNA expression of Th17 effector cytokines 
could be modulated in primary cells in the chicken, further investigation of whether 
chickens mount Th17 immune responses was carried out by measuring mRNA of 
chIL-17A, chIL-17F, chIL-21 and chIL-22 during MD, Infectious bursal disease and 
histomoniasis infection. MD and Infectious bursal disease are recognised as being 
controlled by Th1 immune responses (Liu et al., 2010; Xing and Schat, 2000) 
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whereas histomoniasis is controlled by Th2 immune responses (Powell et al., 2009). 
Messenger RNA expression of chIL-17A, chIL-17F and chIL-23 were also measured 
during S. aureus infection of chickens. In mammals, S. aureus induces Th17 immune 
responses (Cho et al., 2010) and is already established as a disease modl in poultry 
(Daum et al., 1990). Archived RNA samples from previous in vivo challenge 
experiments were examined, with the exception of S. aureus. Tissues which 
expressed higher mRNA levels of Th1/Th2 effector cytokines during the course of 
infection were selected for measurement of Th17 effector cytokine expression. 
Sampling time points were restricted by the original experiment and were selected on 
availability of sample. 
4.4.6.1 Marek’s disease 
The mRNA levels of the Th17 effector cytokines and IL-23 p19 were measured in 
the spleens of MDV-infected chickens. Chicken IL-23 p19, chIL-17A and chIL-21 
mRNA levels were decreased in infected resistant line 61 chickens and increased in 
infected susceptible line 72 chickens compared to uninfected controls. Chicken IL-
17A is a pro-inflammatory cytokine and its elevated expression early in cytolytic 
infection may simply represent a response to increased pathology in susceptible 
birds. However, the early involvement of IL-17 immune responses appears to be 
associated with susceptibility to MDV infection. Resistance in line 61 birds has been 
mapped to a genetic locus outside of the MHC (MDV-1) (Bumstead, 1998). It has 
been postulated this resistance resides at the level of target cell number and their 
susceptibility to MDV (evident during the lytic phase) (Lee et al., 1981). The 
apparent reduction in Th17 immune responses in resistant line 61 birds early in MDV 
infection raises the question is the reduction in Th17 cytokine expression in infected 
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resistant birds because of reduced pathology or does it potentially effect the numbers 
of activated B and T cell numbers during MDV-infection? 
Chicken IL-17A mRNA levels were higher in MDV-infected birds compared to 
mRNA levels in age-matched, uninfected controls at 3 nd 4 dpi, irrespective of the 
line of bird. These data suggest innate levels of chIL-17A increase over time from 
the point of MDV-infection, regardless of resistance or susceptibility to MD. Further 
study is required to investigate if, or indeed when, this IL-17 response declines and 
whether MDV strain alters this response. The early differences in chIL-17A, chIL-21 
and chIL-23 p19 mRNA levels between susceptible and resistant genotypes indicate 
these cytokines may play a role in adaptive immune responses that in susceptible 
lines result in tumour formation and in resistant li es result in lesion regression. 
Chicken IL-17F mRNA expression was decreased in MDV-infected chickens 
compared to uninfected chickens irrespective of the lin  of bird or the time point 
measured. Interestingly, chIL-17A and chIL-17F mRNA levels demonstrated 
differential expression patterns during MDV-infection. Chicken IL-17A mRNA 
levels were dependent on the line of bird and the dpi but chIL-17F mRNA expression 
was dependent on MDV-infection. As discussed previously, the distinct biological 
functions of IL-17A and IL-17F in mammals are not clear. The data here suggests 
potentially different roles for chIL-17A and chIL-17F during MDV infection. 
IFN-γ expression is up-regulated during MDV infection at 3-10 dpi in both 
susceptible and resistant lines of chicken, associated with increasing MDV loads 
(Kaiser et al., 2003). IFN-γ is expressed by Th17 cells in mammals but also acts to 
inhibit Th17 immune responses, depending on the context and amount of IFN-γ 
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expressed (Harrington et al., 2005; Hirota et al., 2011). Therefore, expression of the 
Th17 effector cytokines and IL-23 in MDV-infected chi kens after 3 dpi needs 
further study to investigate if chIFN-γ expression alters Th17 effector cytokine 
expression. The role of Th17 cytokines in MDV pathogenesis remains unclear and 
further investigation over a longer time course is needed to fully elucidate the 
complex adaptive immune responses mounted in response t  MDV infection. 
4.4.6.2 Infectious bursal disease 
Messenger RNA levels of the Th17 effector cytokines were also measured during 
IBDV infection. IBDV targets the chicken immune system in a complex and poorly 
understood manner (Ingrao et al., 2013). The molecular basis of pathogenicity is 
unclear, however, new studies highlight the role of an exacerbated innate immune 
response during early infection, up-regulating pro-inflammatory mediators and 
inducing a cytokine storm (Rauw et al., 2007). The expression of Th17 cytokines 
during IBDV infection has not been reported to-date. Interestingly, chIL-17A and 
chIL-17F mRNA levels were differentially expressed during the acute phase of 
IBDV infection. At 1 dpi, chIL-17A mRNA levels were up-regulated and chIL-17F 
mRNA levels reduced. By 3 dpi, chIL-17A mRNA levels were down-regulated, and 
the reverse was true of chIL-17F mRNA levels, which were increased. As previously 
discussed, the distinct expression of mammalian IL-17A and IL-17F during disease 
is only just beginning to be revealed (Dubin and Kolis, 2009); why chIL-17A and 
chIL-17F mRNA expression is different in the early stages of IBDV infection needs 
to be investigated further. Chicken IL-21 mRNA levels were reduced at later time 
points, whereas chIL-22 mRNA levels were up-regulated. Overall, all Th17 cytokine 
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mRNA levels detected were low, suggesting these cytokines are not induced as part 
of a cytokine storm during the innate response to IBDV infection. 
This study measured Th17 cytokines in caecal tonsil from SPF birds infected with a 
very virulent IBDV (vvIBDV) strain. Rauw et al. (2007) reported high levels of 
systemic chIFN-γ during the acute phase of vvIBDV infection. Despite reports of 
Th17 cells able to express IFN-γ (Lee et al., 2009), high levels of IFN-γ inhibit Th17 
immune responses (Villarino et al., 2010; Yeh et al., 2014). IFN-γ is up-regulated 
during IBDV infection (Rautenschlein et al., 2002; Ruby et al., 2006), which could 
explain the low mRNA levels of Th17 cytokines measured. Other cytokines shown to 
be up-regulated during IBDV infection are the pro-inflammatory cytokines IL-2 
(Rautenschlein et al., 2002), IL-18 and IL-6 (Ruby et al., 2006), suggesting 
activation of T cells, particularly Th1 cells. IL-2 and Th1 immune responses also 
inhibit Th17 immune responses (Laurence et al., 2007; Lazarevic et al., 2011). Kim 
et al. (1998) reported the down-regulation of TGF-β4 during IBDV infection. TGF-
β4 is the avian homologue of mammalian TGF-β (Jakowlew et al., 1997), which is 
required for Th17 cell differentiation (Veldhoen t al., 2006), further suggesting the 
inhibition of Th17 immune responses during IBDV infection. The possible 
involvement of Th17 immune responses during both the early and the later stages of 
IBDV infection in the chicken require further investigation. 
4.4.6.3 Histomoniasis 
The mRNA levels of Th17 effector cytokines were also measured in the caecal tonsil 
during H. meleagridis infection in the chicken. All cytokine mRNA levels were 
initially up-regulated. Chicken IL-17A and chIL-21 mRNA levels decreased over 
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time until 12 dpi and then increased from 18-30 dpi. Messenger RNA levels of chIL-
17F and chIL-22 decreased over the time course. 
The original study by Powell et al. (2009) demonstrated increased expression of 
chIL-1β, chIL-6 and chTGF-β4 and low levels of chIFN-γ, chIL-13 and chIL-4 early 
in infection in broiler chickens. The increased expr ssion of IL-1β drives expression 
of IL-17A and IL-22 from innate cells during early infection in mammals (Coccia et 
al., 2012), possibly explaining the up-regulated mRNA levels of chIL-17A and chIL-
22 cytokines measured initially. It may be that therelease of chIL-17A is important 
in the initial innate immune responses in the caecal tonsil to limit movement of 
protozoa to the liver. The innate immune response is activated immediately upon 
encountering a pathogen and continues for approximately 4 days, at which point 
infection is either effectively overcome or the adaptive immune response is triggered. 
All Th17 effector cytokine mRNA levels decreased up to 4 dpi, suggesting a decline 
in innate immune responses. By 5 dpi, there was increased mRNA expression of 
chIFN-γ as well as up-regulation of chIL-13, a signature Th2 cytokine (Powell et al., 
2009). Th1 and Th2 cytokines inhibit Th17 immune responses in mammals (Cooney 
et al., 2011; Lazarevic et al., 2011) so may explain the continued decreasing levels of 
Th17 cytokine mRNA levels seen at this time. From 12 dpi, there was evidence of 
caecal healing occurring at a gross level and sustained elevation of chIL-13 mRNA 
levels (Powell et al., 2009). At this time, all Th17 effector cytokine mRNA levels 
were down-regulated, possibly due to elevated Th2 cytokine expression. The 
reduction in gross pathology in the caeca may be attributed to the down-regulation of 
the pro-inflammatory cytokines chIL-17A and chIL-17F. The importance of IL-17 in 
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the context of gut inflammation is highlighted by the expression of IL-17A and IL-
17F in humans with IBD (Fujino et al., 2003). 
Two Th17 effector cytokines, chIL-17A and chIL-21, showed a decline and then an 
increase in mRNA levels whereas chIL-17F and chIL-22 mRNA expression 
decreased over time. Why chIL-17A and chIL-21 mRNA showed different 
expression patterns to chIL-17F and chIL-21 during H. meleagridis infection is 
unclear. IL-17A is the signature cytokine of Th17 immune responses (Aggarwal et 
al., 2003), and by the recruitment of neutrophils, is involved in overcoming infection 
with extracellular pathogens in mammals. The relationship of chIL-17A mRNA 
expression with time suggests involvement of IL-17 immune responses during 
infection with the extracellular pathogen H. meleagridis. Therefore, chIL-17A and 
chIL-23 p19 mRNA levels in additional tissues, and more time points between 12 
and 30 dpi, should be investigated to elucidate the ext nt of Th17 involvement in the 
immune response to H. meleagridis infection. 
4.4.6.4 Staphylococcus aureus 
Finally, mRNA levels of chIL-17A, chIL-17F and chIL-23 p19 were measured in a 
S. aureus infection model in the chicken. Measurement of these cytokines was based 
on studies in mammals. IL-17A and IL-17F-deficient mice are more susceptible to 
opportunistic infections with S. aureus (Ishigame et al., 2009) and S. aureus 
peptidoglycan preferentially induces IL-23 expression (Smits et al., 2004). BCO 
pathogenesis requires haematogenously distributed bacteria and lesions are most 
commonly found associated with the growth plates of the long bones, particularly the 
femur (McNamee and Smyth, 2000; Wideman and Prisby, 2012). Therefore, the 
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spleen and bone marrow of the femur were sampled for cytokine mRNA 
measurement. This was a pilot study to identify an optimal infection dosage of S. 
aureus, which would allow measurement of disease symptoms for the longest 
possible time course. All three cytokines were detect d in the spleen and bone 
marrow at all time-points. There was no difference in chIL-17A mRNA expression in 
the spleen or chIL-17F mRNA expression in the spleen and bone marrow. However, 
chIL-17A mRNA expression in the bone marrow varied from bird-to-bird within the 
groups. There was higher mRNA expression of chIL-17A in the wild-type and 
mutant groups at 6 dpi, suggesting the possibility of a local chIL-17A response to S. 
aureus infection. 
During the study, the birds appeared to be overcoming the initial infection. 
Therefore, half of the birds from each group were culled and sampled after 6 dpi, and 
the remainder sampled at 11 dpi, to detect any changes in cytokine mRNA levels 
between infected and recovered birds. As the only variation in cytokine mRNA 
levels between infected and control groups was seenin chIL-17A mRNA expression 
in the bone marrow, it is possible cytokine levels were already returning to normal 
levels following resolution of the S. aureus infection. The bird-to-bird variation in 
chIL-17A mRNA levels in the bone marrow requires further investigation and may 
suggest early local involvement of IL-17A in response to S. aureus infection. 
Because of the lack of response detected in the tissues sampled and cytokines 
measured, it was decided not to investigate mRNA levels in the additional tissues 
sampled or, indeed of the other Th17 effector cytokines, chIL-21 and chIL-22. 
The S. aureus study was a pilot study and due to time constraints, further 
investigation of Th17 immune responses during S. aureus infection of the chicken 
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was not possible. The apparent recovery from S. aureus infection suggests a higher 
infective dose of bacteria is required to establish BCO in this breed of chicken. Also, 
a time course over which to sample infected birds would hopefully highlight any 
relationship between chIL-17A, chIL-17F and chIL-23 p19 mRNA expression and S. 
aureus infection. Measuring cytokine expression in additional lymphoid and non-
lymphoid tissues such as the bursa of Fabricius, thymus and liver may also indicate 
any systemic involvement of S. aureus during BCO. 
4.4.7 Summary 
The aims of this chapter were to investigate Th17 immune responses in the chicken 
by measuring mRNA levels of Th17 effector cytokines and IL-23 in various tissues, 
cells and during infection of the chicken and compare to mammals. The development 
of Th17 reagents in the chicken, such as chIL-17A and chIL-17F TaqMan® primers 
and probes, permit investigation of how and where Th17 immune response 
components are expressed and their potential role during infection. Th17 mRNA 
levels were detected in nearly all tissues sampled although at low levels. The 
cytokine most highly expressed in tissues was chIL-17A. Stimulated lymphoid cells 
generally up-regulated expression of chicken Th17 effector cytokine mRNA, with 
levels decreasing over time. These data warrant further investigation of the specific 
cell types expressing the Th17 cytokines in these lymphoid tissues. The infection 
model experiments used archived samples, or were initial pilot studies, and 
investigation of Th17 effector cytokine levels, using additional tissue samples and 
longer time course studies, is required to fully investigate the role of Th17 immune 
responses in the chicken. However, confirmation that chicken Th17 effector 
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cytokines are expressed is highly suggestive of the involvement of Th17 immune 
responses in the bird. 
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Chapter 5 Identifying the chIL-23R 
5.1 Introduction 
T helper cells are functionally distinguished on their patterns of cytokine secretion 
(Mosmann et al., 1986). Th1 cells express high levels of IFNγ, Th2 cells express IL-
4 and Th17 cells predominantly express IL-17A (Bruckla her-Waldert et al., 2009). 
Additionally, Th cells can be phenotypically distinguished by the expression of cell 
surface markers and transcription factors. The master regulator for transcription of 
Th1 cells is T-bet and for Th2 cells is GATA3 (Rengarajan et al., 2000). Th17 cells 
universally express IL-23R (McGeachy et al., 2009), RORC, RORγt (Ivanov et al., 
2006) and CCR6 (Acosta-Rodriguez t al., 2007b), and can additionally express a 
number of chemokine receptors to regulate the migration of Th17 cells to peripheral 
tissues (Lim et al., 2008). As a result, mammalian Th17 cells are prima ly identified 
by expression of these molecules, using antibodies for intracellular staining of IL-
17A in CD4+ T cells and detecting cell surface expression of IL-23R (Harrington et 
al., 2005; Veldhoen et al., 2006; Wilson et al., 2007). However, due to the low 
expression of IL-23R (Chognard et al., 2014) and a lack of appropriate antibody 
reagents to identify and track IL-23R-bearing cells in vivo (Awasthi et al., 2009), 
both knock-in and knock-out IL-23R-reporter mice have been developed to 
investigate mammalian IL-23R (Awasthi et al., 2009).  
In mammals, the generation of normal Th17 cell effector responses requires IL-23R-
dependent signalling (McGeachy et al., 2009) as IL-23 is required for the 
stabilisation of the Th17 phenotype during an immune response. IL-23R is a member 
of the haemopoietin receptor superfamily and is made up of two subunits, IL-23R 
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and IL-12Rβ1 (Parham et al., 2002). In humans, IL-23R is expressed on activated 
and memory T cells as well as γδ and CD8 T cells and B cells. It is also expressed by 
innate lymphoid cells (Chognard et al., 2014; Parham et al., 2002). The role of the 
IL-23R in cell-mediated inflammatory processes in conjunction with IL-23, during 
autoimmune diseases, as well as in the pathogenesis of many cancers, is well-
established in mammals (Cargill et al., 2007; Duerr et al., 2006; Yao et al., 2014). 
Therefore, genetic polymorphisms of the mammalian IL-23 pathway are strongly 
associated with susceptibility to inflammatory disea  (Duvallet et al., 2011). There 
are 24 splice variants of the human IL-23R, suggesting the potential for considerable 
biological diversity in the IL-23R gene (Kan et al., 2008; Zhang et al., 2006). 
The IL-23R has been successfully identified in the pig (Kokuho et al., 2012) and 
cattle (Chen et al., 2009) but not yet in the chicken. Three single nucleotide 
polymorphisms (SNP) have been identified in cattle, with the potential to alter gene 
expression and protein function but further study is required with respect to their 
biological and practical relevance (Skelding et al., 2010). 
The identification of IL-23 and its receptor in mammals initiated the discovery of a 
third Th subset, Th17, which is yet to be confirmed in the chicken. Chicken IL-23 
p19 has not been identified in the chicken genome (Chapter 3) and the chIL-23R is 
misannotated in the current chicken genome build. To enable biological analysis of 
the chIL-23R, similarly to chIL-23 p19, basic genetic information about the chIL-
23R molecule is required. The aims of this Chapter w re to identify and clone the IL-
23R in the chicken and investigate the structural similarities and differences between 
avian and mammalian IL-23R. Further, to measure mRNA expression of the chIL-
23R in tissues and stimulated cells. The longer term goal of this study was to be able 
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to positively identify Th17 cells in the chicken and, therefore, confirm the presence 
of Th17 immune responses in birds. 
5.2 Methods 
General methods are outlined in Chapter 2. Additional methods and alterations are 
detailed here. 
5.2.1 Cloning of the chIL-23R 
At the beginning of this study, the chIL-23R cDNA sequence was incorrectly 
annotated in the chicken genome (WASHUC2, Ensembl). The annotated sequence 
for the chIL-23R in Ensembl (ENSGALT00000018285) appeared to be missing 
several exons (Figure 5.1), suggesting the correct chIL-23R sequence to be the 
GenScan prediction (GENSCAN00000023581) located on the same chromosome as 
the misannotated chIL-23R gene and the annotated chIL-12Rβ2 gene. 




Figure 5.1. Ensembl (WASHUC2) showing the genetic location of the chIL-23R 
(GENSCAN00000023581) on chromosome 8 of the chicken genome. Red boxes highlight the 
predicted chIL-23R (GENSCAN00000023581), and the annotated genes for chIL-23R 
(ENSGALT00000018285) and chIL-12Rβ2 (ENSGALT00000018300), located downstream on the 
same chromosome. 
Using the GenScan prediction for the chIL-23R (GENSCAN00000023581) (Figure 
5.1), multiple forward and reverse primer sets (Appendix 5) were designed to 
amplify the full-length chIL-23R, of varying lengths and GC content, as well as 
covering different parts of the predicted sequence. In addition to multiple primer sets, 
oligo(dT)20 and gene-specific reverse primers were used to generate cDNA from 
RNA extracted from chicken splenocytes stimulated with mitogen (ConA and PHA). 
These cDNA templates were then used in subsequent PCR reactions, using all 
possible combinations of forward and reverse primers, as well as testing different 
annealing temperatures and extension times for the various primer combinations. 
Optimisation of the GC-Rich PCR System (Roche), which allows for improved 
amplification of sequence with a high GC content, using primers IL-23R_F10 and 
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IL-23R_R1b (Table 2.1), increased amounts of RNA in cDNA synthesis and a high 
MgCl2 concentration, amplified the full-length sequence of the chIL-23R. The chIL-
23R cDNA clone was TA-cloned into pGEM®-T Easy and sequenced. Bioinformatic 
characterisation of the chIL-23R nt and aa sequences was carried out to confirm the 
identity of chIL-23R and similarity to mammalian IL-23R sequences. 
5.2.2 RT-qPCR (TaqMan®) primer and probe design 
Having confirmed the full-length nt sequence of the c IL-23R, primers and probe for 
use in RT-qPCR (TaqMan®) were designed using Primer Express v3 (Applied 
Biosystems) to detect chIL-23R mRNA expression (Table 2.4). 
5.3 Results 
5.3.1 Identification and cloning of the chIL-23R 
Based on the predicted chIL-23R nt sequence (GENSCAN00000023581), primers 
IL-23R_F10 and IL-23R_R1b (Table 2.1) were designed to clone cDNA encoding 
the predicted full-length chIL-23R, using cDNA prepared from ConA-stimulated 
splenocytes as a template. Figure 5.2 shows the product amplified with primers IL-
23R_F10 and IL-23R_R1b. It is approximately 2.5 kb nt in size and was TA-cloned 
into pGEM®-T Easy and transformed into E.coli JM109 competent cells for 
subsequent plasmid isolation and sequencing. 




Figure 5.2. RT-qPCR amplification of the predicted chIL-23R.  Lane L: GeneRuler™ DNA 
Ladder Mix (Thermo Scientific). Lane 1: cDNA from ConA-stimulated (2 h) splenocytes. Lane 2: 
cDNA from ConA-stimulated (4 h) splenocytes. Lane 3: negative control. Red box highlights PCR 
product selected for TA cloning and sequencing. 
Multiple cloned plasmids were sequenced to confirm the nt sequence of the chIL-
23R, which also confirmed the misannotation of the chIL-23R gene 
(ENSGALT00000018285) in the Ensembl database (WASHUC2). Further 
bioinformatic characterisation of the chIL-23R nt ad aa sequences was carried out 
to confirm the gene’s similarity to mammalian IL-23R sequences. 
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5.3.2 Structural features of the chIL-23R 
The full-length chIL-23R nt sequence was translated an  the aa sequence further 
characterised in silico. The chIL-23R encodes a predicted protein of 816 aa, with a 
putative 55 aa signal peptide (Figure 5.3). The human IL-23R cDNA encodes a 
predicted protein of 629 aa, with a putative 23 aa signal peptide, resulting in a 
predicted protein of 606 aa. When aligned with mammlian IL-23R sequences, the 
chIL-23R has an identity of 27.1% at the predicted aa level compared to the human, 
mouse, pig and cattle IL-23Rs. The chIL-23R aa sequence is much longer than the 
mammalian IL-23R sequences. Further, there is 33.5%, 31.6%, 32.8% and 32.7% aa 
similarity between the chIL-23R and human, mouse, pig and cattle IL-23Rs 
respectively. There are 19 cysteine residues in the c IL-23R, 11 of which are 
conserved between the chicken and mammals. There ar 11 N-linked glycosylation 
sites in the chIL-23R. Two of these are conserved in all the mammalian IL-23R’s and 
one is conserved in just the mouse IL-23R. The transmembrane domain of the chIL-
23R contains a sequence (WSAWG) similar to the cytokine receptor signature 
WSXWS-like motif, which is characteristic of the mamalian type I cytokine 
receptor superfamily. In the intracellular domain of the chIL-23R, there are 6 
tyrosine residues, only one of which is conserved (Tyr718) between the chicken and 
mammals.  




For figure legend, see page 180 




Figure 5.3. Comparison of the chIL-23R aa sequence with human, mouse, pig and cattle IL-23R 
aa sequences.  Shaded areas represent conservation of aa similarity, the darker the shading the more 
conserved the residue is across the species. The vertical black and red arrows indicate the predicted 
signal sequence cleavage site of mammalian and chicken IL-23R respectively. Red boxes indicate 
mammalian N-linked glycosylation sites. Blue boxes indicate chicken N-linked glycosylation sites. 
Conserved cysteine residues are identified by a black asterisk. The horizontal black line indicates the
WSXWS-like motif. The green box highlights the transmembrane domain. In the cytoplasmic domain, 
red asterisks indicate conserved mammalian tyrosine residues and the red circles highlight chicken 
tyrosine residues. 
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5.3.3 Alignment of the chIL-23R CDS with predicted chIL-23R nt 
sequences 
As the annotated chIL-23R nt sequence (Ensembl) appeared to be incorrectly 
annotated, and the confirmed chIL-23R nt sequence was based on the GenScan 
prediction (GENSCAN00000023581), the three nt sequences were aligned for 
comparison. This confirmed that the annotated chIL-23R (ENSGALT00000018285) 
in Ensembl is incorrect and that the chIL-23R nt sequence is shorter than the 
GenScan prediction (GENSCAN00000023581), suggesting it is over predicted 
(Figure 5.4).  




Figure 5.4. Nucleotide sequence alignment of the predicted chIL-23R (GENSCAN00000023581), 
the confirmed chIL-23R and the incorrectly annotated chIL-23R (ENSGALT00000018285).  
Identical nt sequence is red, partial nt alignment is blue and no alignment is black. 
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5.3.4 Gene organisation of the chIL-23R 
Nucleotide BLAST analysis against the chicken genome (Galgal 4.0, Ensembl) 
shows that the chIL-23R is encoded by 15 exons (Figure 5.6) spanning 11 kb of 
chicken genomic DNA and is located on chromosome 8, 1138 nt upstream of the 
current annotated chIL-23R (ENSGALT00000018285) (Figure 5.5). The location of 
the gene for IL-12Rβ2 (ENSGALT00000018300) in the chicken is also included, as 
it is found downstream on the same chromosome as in mammals, demonstrating 
conserved synteny in the chicken. In the genomic sequence of the chIL-23R, the 
intron splicing consensus (GT/AG) is conserved at the 5’ and 3’ ends of the introns 
(Appendix 6). 
 
Figure 5.5. Ensembl (Galgal 4.0) showing the genetic location of the incorrectly annotated chIL-
23R (ENSGALT00000018285) on chromosome 8 of the chiken genome.  Red boxes highlight the 
incorrectly annotated chIL-23R (ENSGALT00000018285), and the annotated gene for chIL-12Rβ  









Figure 5.6. Exon-intron organisation of the chicken IL-23R (chIL-23R) compared to the human IL-23R (huIL-23R).  Exons are represented by open boxes and 
introns are represented by black lines. The number of nucleotides in each exon is shown above the genestructure and the number of nucleotides in each intron is shown 
below the gene structure. The chIL-23R is encoded by 15 exons and the huIL-23R is encoded by 10 exons. 
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5.3.5 Expression of chIL-23R mRNA in tissues 
Having confirmed the chIL-23R nt sequence, it was now possible to measure mRNA 
levels of the chIL-23R in various tissues. The chIL-23R is constitutively expressed in 
all tissues at moderate levels (5-15 corrected 40-Ct) (Figure 5.7). The highest mRNA 
levels in non-lymphoid tissues were in the heart, lung and gut and in lymphoid 
tissues were in the caecal tonsil. 
 
Figure 5.7. Expression patterns of chIL-23R mRNA in tissues as measured by RT-qPCR.  Data 
are expressed as corrected 40-Ct values ± SEM. Assays were carried out in triplicate and each value is 
the mean of 3 birds. 
Chapter 5 Identifying the IL-23R in the chicken 
186 
 
5.3.6 Expression of chIL-23R mRNA levels in stimula ted splenocytes, 
thymocytes and bursal cells across a time course 
Chicken IL-23R mRNA levels were measured in stimulated lymphoid cells and 
compared to levels in unstimulated controls. Splenocytes were stimulated with 
ConA, thymocytes with PHA and bursal cells with PMA and ionomycin over a time 
course of 2-24 h. Chicken IL-23R mRNA levels in stimulated splenocytes were 
significantly up-regulated compared to unstimulated controls at 12 h post-stimulation 
(p = 0.014) (Figure 5.8 (A)). However, there was no significant relationship in chIL-
23R mRNA expression in stimulated splenocytes over time. In stimulated 
thymocytes, chIL-23R mRNA levels were significantly up-regulated compared to 
unstimulated controls at 18-24 h post-stimulation (p < 0.021) (Figure 5.8 (B)). 
Further, there was a significant positive linear relationship (p = 0.040) in chIL-23R 
mRNA fold change over time, with chIL-23R mRNA levels increasing from 2-24 h 
post-stimulation. In stimulated bursal cells, chIL-23R mRNA levels were 
significantly up-regulated at 4-12 (p < 0.031) and 24 h (p = 0.002) post-stimulation 
(Figure 5.8 (C)) but there was no significant relationship in chIL-23R mRNA 
expression over time. 




Figure 5.8. Expression patterns of chIL-23R mRNA in stimulated (A) splenocytes, (B) 
thymocytes and (C) bursal cells.  Data are expressed as fold change compared to levels in age-
matched unstimulated controls ± SEM. A linear mixed effect model was used to determine if there 
was a relationship between mRNA expression levels over time. A standard one-sample t test was 
performed to determine if cytokine levels were signif cantly up or down-regulated relative to a fold 
change of one as indicated by a single asterisk (p < 0.05) or double asterisk (p < 0.01). Chicken 
splenocytes, thymocytes and bursal cells were stimulated with ConA, PHA and PMA and ionomycin 
respectively for between 2-24 h. Assays were carried out in triplicate and each value is the mean of 3
birds. 




In humans and mice Th17 cells require IL-23 for stabilisation of the Th17 phenotype 
(McGeachy et al., 2009). The expression of IL-23R is driven by STAT3 activation 
by IL-1β and IL-6 (Durant et al., 2010; Ivanov et al., 2006). In addition, IL-23 also 
markedly increases expression of the IL-23R, in an autocrine manner (Ghoreschi et 
al., 2010). The IL-23R in mice and humans was identified shortly after IL-23 was 
discovered, by expression cloning e.g. screening a cDNA library with a bioassay 
(Parham et al., 2002). IL-23R pairs with IL-12Rβ1 to confer responsiveness to IL-23 
in cells expressing both receptor subunits. As Th17 cells universally express the IL-
23R (McGeachy et al., 2009), it is used as a cell-surface marker for identification of 
Th17 cells. The IL-23R is currently incorrectly annotated in the chicken genome. 
Therefore, this Chapter describes the identification and initial characterisation of the 
chIL-23R, in order to facilitate the identification of Th17 cells in the chicken in the 
future. 
The initial aim of this Chapter was to identify the correct chicken IL-23R gene. As 
previously discussed (Chapter 3), classical molecular approaches to characterise 
avian cytokines and their receptors are not usually successful due to low sequence 
homology with mammalian orthologues. The CDS for chIL-23R was identified using 
in silico and in vitro methods. Due to the GC-rich areas of the chIL-23R nt sequence, 
the chIL-23R CDS was difficult to amplify by PCR. Multiple primer sets of varying 
lengths and GC content, covering different parts of the predicted sequence were used 
to amplify the chIL-23R. Different cDNA templates, using all possible combinations 
of forward and reverse primers, as well as different a nealing temperatures and 
extension times for the various primer combinations were also used to confirm the 
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chIL-23R CDS. Subsequently, using increased amounts of RNA in cDNA synthesis 
and a high MgCl2 concentration, the full-length sequence of the chIL-23R was 
confirmed. This also confirmed the predicted nt sequence for chIL-23R 
(GENSCAN00000023581) to be over predicted and the annot ted nt sequence for 
chIL-23R to be under predicted (ENSGALT00000018285). However, the genome 
location of the chIL-23R is correct (chromosome 8) and demonstrates conserved 
synteny with mammals, the chIL-23R being located upstream of the chIL-12Rβ2 on 
the same chromosome. The gene organisation of the chIL-23R is different to 
mammalian IL-23Rs. The chIL-23R is encoded by 15 exons spanning 11 kb of 
chicken genomic DNA. This was confirmed by comparison of the chIL-23R nt 
sequence and the chicken genome sequence identifying the intron splicing consensus 
(GT/AG) at the 5’and 3’ ends of the introns (Appendix 6). The human IL-23R was 
originally thought to be encoded by 10 exons spanning 92 kb of human genomic 
DNA (Parham et al., 2002). However, it is now evident that the human IL-23R 
mRNA is comprised of 11 exons (Kan et al., 2008). The cattle and pig IL-23Rs are 
encoded by 10 exons and 11 exons respectively. Multiple splice forms of the human 
IL-23R have been identified (Kan et al., 2008; Zhang et al., 2006) so it is possible 
that the identified chIL-23R is not a functional protein, and a shorter splice variant is 
expressed as the functional isoform of the chIL-23R. Further investigation by using 
restriction enzyme digestion and sequence analysis is required to establish if there 
are multiple splice variants of the chIL-23R as in humans. 
Following identification of the chIL-23R gene, the aa sequence was compared to its 
mammalian counterparts. Chicken IL-23R is longer in aa sequence length compared 
to mammalian IL-23R proteins. The intracellular and transmembrane domains of 
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mammalian and chIL-23R are of similar aa length but the aa sequence of the chIL-
23R extracellular domain is longer than its mammalian counterparts. A functional 
reason for this is unclear at the moment. The crystal structure of human IL-23 is 
available (Beyer et al., 2008; Lupardus and Garcia, 2008) but the crystal structure of 
mammalian IL-23R has not been investigated. Elucidating the crystal structure of the 
chIL-23R and comparing to mammals would be interesting and may shed light on 
potential functional differences in the IL-23R betwen birds and mammals, as well as 
a reason for the longer aa sequence of the chIL-23R. 
Despite the chIL-23R aa sequence being longer, there is an expected level of aa 
identity (27.1%) between the chIL-23R and mammalian IL-23R aa sequences. The 
predicted signal sequence cleavage site in the chIL-23R is similar to the known 
signal sequence cleavage site in the mammalian IL-23R. Eleven of the 19 cysteine 
residues in the chIL-23R are conserved between chicken and mammals, and there is 
one conserved potential N-linked glycosylation site. N-linked glycosylation is an 
important post-translational modification during protein expression and is important 
in protein folding and the stability of expressed proteins (Mitra et al., 2006). It is also 
important for ligand binding and stability of cytokine receptors (Ding et al., 1995). 
The transmembrane domain of the chIL-23R contains a sequence (WSAWG) similar 
to the cytokine receptor signature WSXWS-like motif, which is characteristic of the 
mammalian type I cytokine receptor superfamily (haemopoietin receptor family). In 
the intracellular domain of the chIL-23R, there aretwo tyrosine residues, which are 
conserved with mammals. The number of tyrosine residues (six) in the chIL-23R 
suggests a role in the signal transduction process of the receptor as in mammals. It is 
difficult to discern a proline-rich area in the transmembrane domain of the chIL-23R 
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that would be predicted to bind a Jak. To summarise, the IL-23R has been identified 
in the chicken genome but the possibility of additional isoforms of this receptor 
requires further investigation. 
To investigate the potential role of IL-23 and the IL-23R in the chicken, expression 
of the chIL-23R was investigated in a broad range of tissues and stimulated cells. 
Chicken IL-23R mRNA was measured in all tissues. In humans, IL-23R mRNA 
expression is primarily restricted to the lymph nodes, the gut and the lungs (Shmueli 
et al., 2003; Yanai et al., 2005). In IL-23R-eGFP mice, gut-associated lymphoid 
tissue exhibited the highest number of IL-23R+ cells (Chognard et al., 2014). The 
mRNA levels of the chIL-23R were also higher in thegut and the lung compared to 
other non-lymphoid tissues measured. IL-23 is produce  early in response to 
pathogenic challenge and is essential for driving early local immune responses 
(McKenzie et al., 2006). Therefore, it is not surprising to find increased expression 
of IL-23R in the mucosal tissues of the gut, allowing a rapid immune response in 
those tissues to expression of IL-23. The increased mRNA levels of the chIL-23R in 
the gut and lung suggests a similar role for the chIL-23R to mammals. 
Messenger RNA levels of the chIL-23R were also measured in stimulated lymphoid 
tissues and compared to unstimulated controls, to fur her outline the potential role of 
the IL-23R during immune responses in the chicken. ConA stimulation of 
splenocytes increased mRNA expression of the chIL-23R but there was no 
relationship in chIL-23R expression over time. Expression of the IL-23R in 
stimulated cells has never been examined over a time course in vitro in any other 
species so it is difficult to draw comparisons. However, PHA-stimulated PBMCs 
showed enhanced expression of the IL-23R in the pig (Kokuho et al., 2012). In 
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humans and mice, the IL-23R is expressed predominantly o  T cells (γδ T cells and 
Th17 cells) (Chognard et al., 2014). Compared to mice and humans, chickens 
possess a higher number of γδ T cells (Su et al., 1999), which comprise 
approximately 20% of the total splenocyte population (Pieper et al., 2008). ConA 
stimulation of splenocytes may be increasing mRNA expr ssion of the chIL-23R in 
γδ T cells. In mice and humans, IL-23R is quite lowly expressed on cells and there 
are a lack of Ab reagents to identify and track IL-23R-positive cells in vivo (Awasthi 
et al., 2009). Development of a chIL-23R monoclonal Ab would potentially allow for 
investigation of the specific cell types which express the chIL-23R and a comparison 
of these cells to humans, therefore, confirming if chicken T cells also express the 
chIL-23R. 
Expression of chIL-23R mRNA in stimulated thymocytes and bursal cells was 
increased compared to unstimulated controls. Chicken IL-23R mRNA expression 
increased over time in stimulated thymocytes but this relationship was not seen in 
stimulated bursal cells. As the IL-23R is expressed predominantly on mature T cells 
in mammals, it is unclear which cell types in the chicken thymus are expressing the 
chIL-23R following stimulation. The IL-23R is expressed by a small number of B 
cells in mice (Chognard et al., 2014), which were identified using the IL-23R-eGFP 
mouse (Awasthi et al., 2009). Also, IL-23 has been identified in the human tonsillar 
B cell response through expression of the IL-23R on plasma cells (Cocco et al., 
2011). These data suggest chicken B cells express the chIL-23R. However, the 
specific cell types which express the chIL-23R need to be identified in order to 
investigate the biological role of chIL-23 on B cells. These data suggest thymocytes 
and bursal cells are potentially capable of responding to IL-23-stimulation. Further 
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investigation of the specific cell types involved and whether these cells co-express 
chIL-12Rβ1 is required. 
In mammals, the IL-23R is made up of 2 subunits, IL-23R and IL-12Rβ1, and co-
expression of both subunits allows a cell to respond t  IL-23. The mRNA expression 
of chIL-12Rβ1 has not been investigated in the chicken. Further study is needed to 
investigate if cells which co-express the chIL-23R and chIL-12Rβ1 respond to chIL-
23 similarly to mammals. In mammals, IL-12Rβ1, the sub-unit common to both IL-
12 and IL-23R, is expressed in all sorted populations f PBMCs (Chognard et al., 
2014), whereas the expression of IL-23R and IL-12Rβ2 is restricted and defines the 
cell types responding to either IL-23 or IL-12 signalling. The IL-23 and IL-12 
receptors are not expressed on the same cell types in mammals and show a strong 
dichotomy in the cells which express the IL-12R or the IL-23R. Most notably, the 
receptors for IL-12 and IL-23 only appear to be co-expressed in γδ T cells, of which 
the chicken has high circulating numbers. It would be interesting to investigate the 
specific cell types expressing the chIL-23R and the c IL-12R for comparison to 
mammals, as the cell populations that express either the IL-12R or the IL-23R are 
well-conserved between mouse and man (Chognard et al., 2014). 
Whilst expression of mRNA is informative as to which ells express IL-12R or IL-
23R, it does not necessarily correspond to expression of functional protein. 
Therefore, in order to identify specific cells expressing the functional IL-23R, the 
development of a monoclonal antibody to the chIL-23R is needed. It was hoped that 
development of a chIL-23R monoclonal antibody would be possible during my PhD, 
unfortunately due to time constraints, it has not been and development of this useful 
reagent remains the remit of future work. A chIL-23R monoclonal Ab would 
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potentially allow identification of Th17 cells in the chicken. Positively identifying 
Th17 cells in the chicken would confirm that chickens mount Th17 immune 
responses in a manner similar to mammals. Th17 cells in mammals can also be 
identified by expression of IL-17A, RORγt and CCR6 (Acosta-Rodriguez et al., 
2007b; Harrington et al., 2005; Ivanov et al., 2006). IL-17A and CCR6 are expressed 
in the chicken (Min and Lillehoj, 2002; Munoz et al., 2009) but RORγt is not 
currently annotated in the chicken genome. Identifyi g RORγt in the chicken and 
development of monoclonal Ab for chRORγt and chCCR6, as well as using the chIL-
17A Abs (Yoo et al., 2008), would allow for thorough investigation and 
identification of the chicken cell types co-expressing these molecules and a 
comparison to mammals. 
To summarise, the IL-23R has been identified and cloned in the chicken. The chIL-
23R was expressed in a wide range of tissues and was up-regulated in stimulated 
splenocytes, thymocytes and bursal cells. Confirmation that the chIL-23R is in the 
chicken genome, and is expressed in tissues and stimula ed cells in the bird, is highly 
suggestive of Th17 immune responses in the chicken. The identification of the chIL-
23R is the beginning to developing useful tools to further identify Th17 cells in the 
chicken and confirming that chickens mount Th17 immune responses in similar 
manner to mammals. 
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Chapter 6 Differentiating Th17 cells in the chicken  
6.1 Introduction 
Th cells are distinguished into different lineages based on their pattern of cytokine 
secretion, transcription factor expression, and functio s, which are responsible for 
different immune responses to specific pathogens as well as immunopathology. The 
original Th1/Th2 paradigm as proposed by Mosmann and Coffman (1989) defined 
Th1 cells as producing IFN-γ, and protecting against intracellular infections, and Th2 
cells as producing IL-4, IL-5 and IL-13, and protecting against extracellular 
infections. By this definition, the Th1/Th2 paradigm applies in the chicken (Degen t 
al., 2005; Powell et al., 2009). However, the repertoire of mammalian CD4+ T cell 
subsets has now expanded beyond the original paradigm to include regulatory 
subsets and other effector subsets (reviewed by Kara et al., 2014). The understanding 
of CD4+ cellular subsets and the responses in which they are involved in the chicken 
naturally lags behind that in biomedical model species (Kaiser, 2010), expanding 
beyond the Th1/Th2 paradigm to include the recent identification of Tregs in the 
chicken (Shanmugasundaram and Selvaraj, 2010; 2011). 
The concept of an IL-17/IL-23 pro-inflammatory axis n mammals was first 
suggested by Aggarwal et al. (2003) but it was Harrington et al. (2005) who 
described the Th17 cell. The Stockinger group were first to differentiate Th17 cells 
in vitro from naïve CD4+ T cells using TGF-β and IL-6 (Veldhoen et al., 2006). 
Th17 cell differentiation can be split into 3 stages: the differentiation stage mediated 
by TGF-β and IL-6, the self-amplification stage by IL-21, and the stabilisation stage 
by IL-23 (Luckheeram et al., 2012). However, whilst the addition of TGF-β and IL-6 
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into naïve CD4+ T cell cultures does indeed drive Th17 cell differentiation, the in 
vivo requirements of Th17 cell differentiation are far more complex than these in
vitro conditions. A detailed description of mammalian Th17 differentiation is 
discussed in Chapter 1. In vitro studies in mammals using Th17 cells differentiated 
ex vivo from naïve CD4+ T cells commonly use CD3 and CD28 antibodies to mimic 
the two-signal activation of naïve T cells required for T cell expansion (Trickett and 
Kwan, 2003). Specific stimulation for a Th17 phenotype is provided by the 
recombinant cytokines TGF-β and IL-6 with or without the addition of IL-1β, IL-23 
and IL-2 (Lee et al., 2012; Mangan et al., 2006; Veldhoen et al., 2006; Wilson et al., 
2007). Further, antibodies against IL-12, IFN-γ, and IL-4 can also be used to prevent 
cells differentiating towards a Th1 or Th2 phenotype (Ivanov et al., 2006; Zhou et 
al., 2008). Th17 cells are identified by the expression of the T cell marker CD4 as 
well as IL-17A and/or the IL-23R (Harrington et al., 2005; Veldhoen et al., 2006; 
Wilson et al., 2007). 
Due to a greater repertoire of reagents available in mammalian immunology, 
differentiating Th cells in vitro and identifying Th cells in vivo in mice and man is 
now commonplace. However, in vivo identification of specific cell types is still a 
challenge in the chicken and in vitro differentiation of Th cells has not been possible 
to-date. In order to answer the question are there Th17 immune responses in the 
chicken, this Thesis has identified the key missing cytokine, IL-23 and demonstrated 
a similar biological activity to mammals (Chapter 3), measured mRNA expression 
the Th17 effector cytokines in tissues, stimulated c lls and during infection in the 
chicken (Chapter 4) and identified a phenotypic marker for Th17 cells, the IL-23R 
(Chapter 5). The aim of this Chapter is to differentiate chicken Th17 cells in vitro 
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from naïve CD4+ T cells using recombinant cytokines, in a similar method to 
mammals, and measure mRNA expression of the Th17 effector cytokines and the IL-
23R to confirm a Th17 phenotype. 
6.2 Methods 
General methods are outlined in Chapter 2. Additional methods and alterations are 
detailed here. 
6.2.1 Optimisation of splenocyte co-stimulation ass ay 
Anti-chicken CD3 (AV36 and Southern Biotech clone CT-3) and CD28 antibodies 
(AV7) were immobilised on a flat-bottomed 96-well tissue culture plate. CD3 
antibodies were diluted to 1 μg/ml in sterile PBS. CD28 antibody was then diluted 
1/1000, 1/500 or 1/250 in 1 ml of 1 μg/ml CD3 antibody solution. The antibody 
solution, or sterile PBS as a control (50 μl per well) was added to each well of the 
96-well plate and incubated for 3 h at 37°C. The plate was then vigorously washed 
three times with sterile PBS to remove any unbound antibodies. Chicken splenocytes 
were isolated as described in section 2.7.1 and adjusted to a density of 5 x 106 
cells/ml. The cell suspension (100 μl/well) was added to the antibody-coated plate 
with or without the addition of ConA (0.5 μg/ml), with complete medium alone 
(Appendix 1) as a control. The cells were cultured at 41°C, 5% CO2 for 72 h. After 
72 h of culture, 20 μl of CellTiter 96 Aqueous One Solution (Promega) was added to 
each well and the plate incubated for a further 4 h. After 4 h of culture, the 
absorbance of the plate was measured at 490 nm on 96-well plate reader. 
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6.2.2 Optimisation of MACS sorted CD4 + T cell stimulation 
Further to the stimulation of CD4+ T cells outlined in section 2.11.3, CD4+ T cells 
were stimulated with ConA (1 and 2 μg/ml) for 4, 24 and 72 h. 
6.3 Results 
6.3.1 Optimisation of anti-CD3 ( αCD3) and anti-CD28 ( αCD28) 
stimulation 
To drive CD4+ T cells towards a Th17 phenotype, CD3 and CD28 antibodies were 
used, in conjunction with Th17 driving cytokines, to stimulate the cells. The optimal 
concentrations of CD3 and CD28 antibodies for maximl splenocyte proliferation 
were 1 μg/ml of CD3 antibody (AV36) and a 1/250 dilution ofCD28 antibody 
(AV7) (Figure 6.1). 
 
Figure 6.1. Measurement of splenocyte proliferation after αCD3 and αCD28 co-stimulation. 
Optical density (OD) was measured at 490 nm and corre ted for medium alone (Relative). 
Splenocytes were stimulated for 72 h with a negative control (medium), αCD3 (1 μg/ml) from 
Southern Biotech (SB) or the AV36 clone (AV36), αCD28 (1/500 dilution) the AV7 clone (AV7), 
ConA (0.5 μg/ml) or a combination of αCD3 and αCD28 (1-6). 1) αCD3 (SB) and αCD28 (1/250). 2) 
αCD3 (SB) and αCD28 (1/500). 3) αCD3 (SB) and αCD28 (1/1000). 4) αCD3 (AV36) and αCD28 
(1/250). 5) αCD3 (AV36) and αCD28 (1/500). 6) αCD3 (AV36) and αCD28 (1/1000). Highest 
splenocyte proliferation was measured in 4) αCD3 (AV36) and αCD28 (1/250). The data are 
representative of 1 bird. 




Chicken CD4+ T cells were negatively sorted from splenocytes by fluorescence-
activated cell sorting (FACS) (kindly carried out by Bob Fleming). The gating 
strategy employed is shown in Figure 6.2. Following removal of cells that stained 
positive for CD8α (CD8+ T cells), TCR1 (γδ T cells), KUL01 (macrophages) and 
Bu-1 (B cells), approximately 7% of the total cells were chicken CD4+ T cells. 
Following FACS analysis of the sorted chicken CD4+ T cells, the cells were > 80% 
pure. A total of 4.8 x 106 cells were collected from 9.6 x 107 cells.




Figure 6.2. Negative FACS of chicken CD4+ T cells. FACS dot plots for A) unstained splenocytes, 
B) live/dead staining C) pre-sort and D) post-sort chicken CD4+ T cells and E) the gating hierarchy 
applied. Analysis of the side scatter (SSC) versus the forward scatter (FSC) plot identified 
lymphocytes. Single cells were identified by the SSC plot. Cells negative for CD8α, TCR1, KUL01 
and Bu-1 Ab staining were subsequently selected for. Sytox blue staining of a sample of cells selected 
for live cells. Percentages (%) of cells are of the total cell population. The flow cytometric results here 
represent one experiment of 3 repeats. 
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Following pooling and centrifugation of all negatively sorted cells, no cell pellet was 
visible nor were any live cells visible following Trypan blue staining. The cell sort 
was repeated twice more using an identical gating strategy and all negative cells were 
collected. Using Trypan blue staining and a haemocytometer, the cells were counted 
(4.6 x 106 and 5.5 x 106 cells respectively). 
Following FACS sorting, chicken CD4+ T cells were driven towards a Th17 
phenotype by TCR activation and cytokine stimulation. To confirm the chicken 
CD4+ T cells had differentiated into a Th17 phenotype, mRNA levels of the 
reference gene 28S, and the cytokines chIL-17F and chIL-2 were measured from the 
control stimulated CD4+ T cells. Messenger RNA expression of 28S was detected 
from two experiments but chIL-17F and chIL-2 mRNA expression was not measured 
(Figure 6.3), indicating the cells did not proliferate and were not stimulated. 




Figure 6.3. Expression of A) 28S, B) chIL-17F and C) chIL-2 mRNA in stimulated CD4+ T cells. 
Data are expressed as corrected 40-Ct. Chicken CD4+ T cells were stimulated with medium alone (U), 
ConA alone (ConA), CD3 and CD28 Ab together (αCD3 αCD28) or CD3 and CD28 Ab and ConA 
together (αCD3 αCD28 ConA) for 3 days. These data are representative of 2 birds. Technical 
replicates were carried out in triplicate. No chIL-17F or chIL-2 mRNA expression was detected. 
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Following 3 unsuccessful attempts to negatively sort chicken CD4+ T cells and drive 
them towards a Th17 phenotype, chicken CD4+ T cells were positively sorted by 
FACS (kindly carried out by Bob Fleming). The gating strategy used is indicated in 
Figure 6.4. Chicken T cells that stain positively for CD4 were selected for and 
approximately 14% of the total cell population were CD4+. When the positively 
sorted chicken CD4+ T cells were analysed by FACS, they were approximately 38% 
pure. 




Figure 6.4. Positive FACS of chicken CD4+ T cells.  FACS dot plots for A) unstained splenocytes, 
B) live/dead staining C) pre-sort and D) post-sort chicken CD4+ T cells and E) the gating hierarchy 
applied. Analysis of the side scatter (SSC) versus the forward scatter (FSC) plot identified 
lymphocytes. Single cells were identified by the SSC versus PE plot. Live cells negative for Sytox 
blue staining and positive for CD4 Ab staining were subsequently selected for. Percentages (%) of 
cells are of the total cell population. The flow cytometric results here represent one experiment. 
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Following pooling and centrifugation of all positively sorted CD4+ cells, no cell 
pellet was visible nor were any live cells visible following Trypan blue staining. A 
sample of the collected cells was re-examined by FACS and the total percentage of 
chicken CD4+ T cells was reduced 7-fold (38.4% compared to 4.9% of the total cells) 
compared to immediately post-sort (Figure 6.5), indicating a substantial loss of cells. 
 
Figure 6.5. Comparison of chicken CD4+ T cells  A) immediately post-sort and B) following 
centrifugation with C) the gating hierarchy used. Percentages (%) of cells are of the total cell 
population. FACS dot plots show a 7-fold reduction n all cells after centrifugation to collect the 
sorted chicken CD4+ T cells. The flow cytometric results here represent one experiment. 




Chicken CD4+ T cells were positively sorted by magnetic-activated cell sorting 
(MACS). To assess the purity of the MACS sorted cells, they were analysed by 
FACS (kindly carried out by Lonneke Vervelde) (Figure 6.6). Chicken T cells that 
stain positively for CD4 were selected for and > 83% of the live MACS-sorted cell 
population was CD4+. These data are representative of 2 repeats. 
 
Figure 6.6. FACS analysis of MACS of chicken CD4+ cells. The SSC versus FSC plot was used to 
select for the live cell population in the unstained splenocytes (54.7%). The unstained cell population 
was confirmed CD4- and the Ab (goat anti-mouse IgG1) used as a conjugate control was also 
negative. Negative CD4 cells post-sort contained 6.7% CD4+ cells. Chicken CD4+ cells were 83% of 
the live cell population. 
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Following MACS sorting, using Trypan blue staining, the number of sorted cells  
was counted (3.5 x 107 cells) and subsequently chicken CD4+ T cells were driven 
towards a Th17 phenotype by TCR activation and cytokine stimulation. To identify 
Th17 cells, mRNA levels of the reference gene 28S, and the cytokines chIL-17F and 
chIL-2 were measured from the control stimulated CD4+ T cells after 5 d of 
stimulation (Figure 6.7). Figure 6.7 (A) shows low levels of 28S mRNA was 
measured but mRNA expression of chIL-17F and chIL-2 was not detected, indicating 
the cells did not proliferate and were not stimulated. 




Figure 6.7. Expression of A) 28S, B) chIL-17F and C) chIL-2 mRNA in stimulated CD4+ T cells. 
Data are expressed as corrected 40-Ct. Chicken CD4+ T cells were stimulated with medium alone (U), 
ConA alone (ConA), CD3 and CD28 Ab together (αCD3 αCD28) or CD3 and CD28 Ab and ConA 
together (αCD3 αCD28 ConA) for 5 days. These data are representative of 1 bird. Technical replicates 
were carried out in triplicate. No chIL-17F or chIL-2 mRNA expression was detected. 
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Additionally, the MACS sorted CD4+ T cells were also stimulated with a higher 
concentration of ConA (2 μg/ml) for 4 h and the mRNA levels of 28S, chIL-17F and 
chIL-2 also measured (Figure 6.8). Low mRNA levels of 28S were expressed (Figure 
6.8 (A)) but chIL-17F and chIL-2 mRNA expression was not detected. Data shown 
in Figure 6.8 are from 4 h of stimulation but are representative of 24 and 72 h. The 
chicken CD4+ T cells did not proliferate and were not stimulated. 




Figure 6.8. Expression of A) 28S, B) chIL-17F and C) chIL-2 mRNA in stimulated CD4+ T cells. 
Data are expressed as corrected 40-Ct. Chicken CD4+ T cells were stimulated with medium alone (U), 
ConA alone (ConA), CD3 and CD28 Ab together (αCD3 αCD28) or CD3 and CD28 Ab and ConA 
together (αCD3 αCD28 ConA) for 4 h. These data are representative of 1 bird. Technical replicates 
were carried out in triplicate. No chIL-17F or chIL-2 mRNA expression was detected. 




The aim of this Chapter was to differentiate chicken Th17 cells in vitro from naïve 
CD4+ T cells using recombinant cytokines, in a similar method to mammals, and 
measure mRNA levels of the Th17 effector cytokines and the IL-23R to confirm a 
Th17 phenotype. Ideally, antibody reagents would be available in the chicken, as 
they are in mammals, to identify Th17 cytokine expression, as well as the IL-23R on 
the cell surface in chicken cells. Further, mammalian studies use antibodies to inhibit 
Th1 and Th2 phenotypes at the same time as driving cells towards a Th17 phenotype. 
The majority of these antibody reagents are not available in the chicken so the 
established method of measuring mRNA expression by RT-qPCR was used as an 
alternative. 
In vitro mammalian studies use ex vivo naïve CD4+ T cells, which are activated by 
plate-bound CD3 and CD28 antibodies (Veldhoen t al., 2006). The optimal 
concentrations of CD3 and CD28 antibodies for maximl chicken splenocyte 
proliferation were established. The optimisation assay set out to find out which 
αCD3 (Southern Biotech or AV36), and what dilution of αCD28, were most effective 
at stimulating chicken splenocytes. The concentration of αCD3 (1 μg/ml) was 
established by previous work within the group. One μg/ml of CD3 antibody (AV36) 
and a 1/250 dilution of CD28 antibody (AV7) were optimal for stimulating chicken 
splenocytes and were used throughout the on-going study. 
A negative FACS cell sort, where unstained cells were selected for, was used to 
purify chicken CD4+ T cells from splenocytes. FACS was chosen as the purification 
method of chicken CD4+ T cells as individual cells are able to be purified based on 
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size, granularity and fluorescence. It is the prefer d method of cell sorting when a 
very high purity of the desired cell population is required. The strategy of negative 
FACS to derive chicken CD4+ T cells was used to avoid activating or stimulating the 
T cells during the sorting process. 
From the total splenocyte population, 7% were CD4+ T cells and this cell population 
had a purity of > 80%. This experiment was repeated three times with similar results. 
Sorting parameters were adjusted for the requirement of cell purity, not yield, to 
allow for a more pure CD4+ T cell population and not an increased cell number 
during the cell sort. CD4+ T cells make up approximately 15-20% of the total 
splenocyte population in the J line chicken (Figure 6.4 & Figure 6.6). Therefore, 7% 
sorted CD4+ T cells from the total splenocyte population is les than the typical CD4+ 
T cell percentage in the spleen. This lower percentage of CD4+ T cells collected may 
be because of a loss of CD4+ T cells during the sorting process as a result of non-
specific antibody staining of these cells. Despite successfully obtaining CD4+ T cells 
post-sort, following pooling and centrifugation of the sorted cell population, there 
was no cell pellet visible. Following Trypan blue staining to identify live/dead cells, 
there were no live cells visible under the microscope. It is assumed that the sorted 
population of CD4+ T cells had died between sorting and subsequent centrifugation. 
On repeating this experiment, a 9-week old bird instead of a 7-week old bird was 
used to increase the size of the spleen and, therefor , to increase the yield of 
splenocytes for cell sorting. The splenocytes were also incubated with the staining 
Abs at room temperature instead of over ice to investigate if this had a positive effect 
on cell survival post-sort. Cell viability and yield can be compromised during cell 
sorting. Viability and recovery can be improved by using a cell-dependent optimal 
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temperature and by maintaining collection tubes at an optimal temperature (Basu et 
al., 2010). A similar percentage, purity and number of CD4+ T cells were sorted a 
second time using negative FACS. The cells survived pooling and centrifugation and 
the presence of live cells were confirmed by Trypan blue staining. The CD4+ T cells 
were counted and then stimulated (1 x 105 cells/well) using recombinant chTGF-β4 
and chIL-6 for 3 days. 
The mRNA levels of chIL-2 and chIL-17F and the rRNA of 28S were measured by 
RT-qPCR. The rRNA 28S is a chicken housekeeping gene, which is expressed by all 
chicken cells at a constant rate, observed by our group and others in the field (Li et 
al., 2005). Expression of IL-2 from mammalian T cells indicates the cells have 
undergone proliferation (Reviewed by Smith, 1984) and chicken splenocytes, 
following ConA stimulation, also produce IL-2 (Sundick and GillDixon, 1997). 
Chicken IL-17F was measured as an indicator of a Th17 phenotype as this was the 
cytokine expressed by IL-23-stimulated chicken splenocytes (Chapter 3). Low 
mRNA levels of 28S and no chIL-2 or chIL-17F mRNA were measured. The low 
levels of 28S mRNA confirmed the presence of chicken RNA and indicated that the 
amount of RNA extracted from the stimulated CD4+ T cells was low. This is could 
be a result of too low a starting cell number (1 x 05 cells/well), however, this is 
comparable to similar assays in humans (Wilson et al., 2007). The normal levels of 
28S mRNA measured from stimulated cells is over 30 corrected 40-Ct. Lack of 
detection of chIL-2 mRNA suggests the cells did notproliferate whereas lack of 
chIL-17F mRNA expression suggests the CD4+ T cells were not driven towards a 
Th17 phenotype. This experiment was repeated with the same result. The inability of 
the cells to proliferate and differentiate into Th17 cells is probably due to the low 
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number of CD4+ T cells sorted from the chicken spleen and the reduc  viability of 
the cells following sorting. 
Due to the failure of negative FACS to sort chicken CD4+ T cells, a positive FACS 
was attempted. This would allow a comparison of CD4+ cell numbers obtained by 
both methods and allow investigation of the effects of different sorting methods on 
chicken CD4+ T cell survival. It is possible that the sorted CD4+ T cells would be 
activated by the sorting process. However, the advantages of potentially sorting a 
greater number of viable chicken CD4+ T cells outweighed this potential 
disadvantage. 
Following positive FACS, 14% CD4+ T cells were obtained from the total splenocyte 
population and this cell population had a purity of < 38%. There were an increased 
percentage of CD4+ T cells sorted by positive FACS compared to negative FACS but 
the cell purity was reduced. Sorting parameters for this cell sort were adjusted to 
increase cell yield, and not purity as before, to all w for collection of a greater cell 
number and not a higher purity of CD4+ T cells. However, a cell purity of < 38% is 
low. 
Following pooling and centrifugation of the sorted chicken CD4+ cell population, 
there was no cell pellet visible. Trypan blue staining confirmed the presence of dead 
cells only. The likely death of the sorted cell population was investigated by FACS 
analysis. This confirmed a large (7-fold) reduction in total CD4+ T cell numbers from 
immediately post-sort (38.4%) to after pooling and centrifugation of the sorted cells 
(4.9%). This confirmed that the majority of the sorted population of CD4+ T cells 
had died between sorting and subsequent centrifugation. Cell death and/or a reduced 
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cell recovery occurred following both negative and positive FACS. There are a 
number of accepted methods to improve the viability and recovery rate of cells 
during sorting, which were adhered to or changed accordingly to improve cell 
survival of chicken CD4+ T cells during FACS. Polypropylene tubes were used for 
cell processing and sorting through out. Collection tubes were filled with medium 
containing chicken serum. Initially, cells were kept on ice pre- and post-sort and then 
subsequently at room temperature to avoid multiple temperature fluctuations. It is 
possible that an optimal temperature between approximately 4°C and 21°C is 
required for sorting of chicken CD4+ T cells. During the sorting process, tubes 
containing cells were inverted regularly and collection tubes were processed 
immediately after they were filled and collected cells re-suspended in appropriate 
medium. The collection tubes were centrifuged for over 10 minutes to collect the 
sorted cells. It is unclear what factor/s were adversely affecting chicken T cell 
viability and subsequent survival. 
In an attempt to find a method of cell sorting that did not adversely affect chicken 
CD4+ T cell survival, a positive MACS cell sort was carried out. FACS analysis was 
used to assess the purity of the MACS sorted CD4+ T cells. The live cell percentage 
was <54% and the sorted CD4+ T cell population was < 80% pure. A total of 3.5 x 
107 live cells were counted using Trypan blue. The starting cell numbers of 
splenocytes pre-sort were similar to the cell numbers used for FACS and so the CD4+ 
T cell numbers following MACS were higher. Both FACS and MACS achieved 
purities of < 80% for sorted CD4+ T cells. 
The CD4+ T cells were stimulated using recombinant chTGF-β4 and chIL-6 for 5 
days. As before, the mRNA levels of 28S, chIL-2 and chIL-17F were measured by 
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RT-qPCR. Again, low levels of 28S were measured but chIL-2 and chIL-17FmRNA 
was not detected, indicating the CD4+ T cells were not stimulated and did not 
proliferate.  
The positive MACS cell sort was repeated and live chicken CD4+ T cells were 
stimulated by a higher concentration of ConA for a shorter period of time to 
investigate if the sorted cells were capable of being stimulated. Quantitative RT-PCR 
did not measure chIL-17F or chIL-2 mRNA expression f llowing ConA stimulation 
for 4, 24 or 72 h indicating the cells were not stimulated and did not proliferate. 
Based on the unreliable success of sorting chicken CD4+ T cells and the subsequent 
loss of chicken CD4+ T cells, it is assumed these cells did not proliferat  nor were 
able to be stimulated and driven towards a Th17 phenotype due to a reduced viability 
post-sort. CD4+ T cells have been successfully sorted from PBMCs in cattle (Flynn 
and Marshall, 2011) and the bovine CD4+ T cells were subsequently driven towards 
a Th17 phenotype (Peckham et al., 2014). Bovine cells were sorted by positive 
MACS whereas human CD4+ T cells were isolated by two rounds of magnetic bead 
depletion (Wilson et al., 2007). Chicken cells are routinely sorted by MACS in our 
group and stimulated for short periods of time (< 1 d) (Rothwell et al., 2012). It is 
unclear why in this case chicken CD4+ T cells were unreliable to sort by several 
methods and could be stimulated. Several adapted mammalian methods of sorting 
CD4+ T cells have been attempted in these experiments discussed here in the 
chicken. However, they could not been continued further due to time constraints. It is 
paramount to investigate further the issues surrounding the sorting of viable chicken 
CD4+ T cells before attempting to differentiate and identify chicken Th17 cells. A 
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suitable cell sorting method where chicken CD4+ T cells reliably survive for further 
optimisation of Th17 cell differentiation is needed. 
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Chapter 7 General discussion 
7.1 Overall perspective 
The aim of this Thesis was to identify Th17 immune responses in the chicken. The 
key cytokine, IL-23 and its receptor, at the crux of mammalian Th17 immune 
responses, were crucially missing from the chicken g ome. These genes were 
identified and cloned, and their protein structure investigated. A recombinant protein 
of chIL-23 was generated and its bioactivity demonstrated. Messenger RNA levels of 
the Th17 effector cytokines were measured in tissue, stimulated cells and in 
infection models in the chicken. Finally, in vitro differentiation of Th17 cells from 
CD4+ T cells was attempted. These studies indicated the expression of all Th17-
related cytokines in the chicken, similar biological activity of chIL-23 to mammalian 
IL-23, and a potential role of chIL-17A in Marek’s disease. 
The Th1 and Th2 paradigm proposed by Mosmann and Coffman (1989) has been 
universally used to explain how hosts elicit different adaptive immune responses to 
eradicate invading pathogens. Classically, effector CD4+ T cells have been divided 
into two distinct lineages on the basis of their cytokine profiles: IFN-γ producing Th1 
cells or IL-4-producing Th2 cells. The chicken mounts Th1 and Th2 immune 
responses to infection similarly to mammals (Degen et al., 2004; Powell et al., 
2009). It is now apparent that mammalian CD4+ cells, upon encounter of specific 
antigen, are activated, expand and differentiate ino various Th subsets expressing 
both distinct cytokine profiles and effector functions (Korn et al., 2009). Th17 cells 
are one of the newer T helper cell subsets to be describ d in mammals and are yet to 
be described in the chicken. Critically, the mammalian Th17 immune response 
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functions to clear specific types of pathogen not effectively neutralised by Th1 or 
Th2 immune responses, particularly extracellular bacterial pathogens (Korn et al., 
2009). There are a number of important pathogens within the poultry industry and 
knowledge of the avian immune response to the majority f these is basic (Wigley, 
2013). It is important to understand the potential role of Th17 immune responses in 
the chicken because a better understanding of the avian immune system is key to 
developing effective poultry disease control measure  for the future. Not only will 
this improve poultry health and welfare but also reduce, and ultimately prevent, 
zoonotic transmission of disease to humans via the food-chain. 
7.2 Cloning and analysis of chIL-23 and the chIL-23 R 
The presence of IL-23 and the IL-23R genes in the cicken genome indicates 
conservation of these genes from before the divergence of mammals and birds from a 
common ancestor over 300 million years ago. Using a EST from discarded data 
from the chicken genome build, the full-length chIL-23 p19 sequence was mined 
from the chicken genome. The predicted chIL-23R sequence in the Ensembl database 
is annotated incorrectly. Using a GenScan prediction, the full-length correct chIL-
23R cDNA was identified. Both chIL-23 and its receptor were cloned from RNA 
from ConA-stimulated splenocytes. Similarly to mammals, chIL-23 p19 is a 180 aa, 
with the cysteine residue that binds IL-23 p40, andthe tryptophan residue that binds 
the IL-23R, conserved between chickens and mammals (Chapter 3). The chIL-23R 
encodes a protein of 816 aa and demonstrates conserved synteny with mammals 
(Chapter 5). 
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Both molecules were ubiquitously expressed across a number of lymphoid and non-
lymphoid tissues in the chicken as shown by RT-qPCR, similarly to other chicken 
cytokines and their receptors (Gibson et al., 2012; Rothwell et al., 2012; van 
Haarlem et al., 2009). Primary immune cells stimulated with mitogens associated 
with the activation and proliferation of T and B cells up-regulated the chIL-23R 
mRNA levels but did not affect mRNA levels of IL-23 p19 in the chicken. 
Expression of mammalian IL-23 is primarily from APCs. Therefore, this experiment 
could be improved by using a more suitable stimulus to drive chIL-23 p19 mRNA 
expression. LPS induces IL-23 expression in human mo ocytes, macrophages and 
DCs (Roses et al., 2008) and also drives expression of IL-23 in zebrafish leucocytes 
(Holt et al., 2011). TLR2, 3 and 7 agonists augment the expression of IL-23 from 
human DCs and mouse macrophages (Al-Salleeh and Petro, 2007; Re and 
Strominger, 2001). These TLR agonists also induce anti-viral responses in chicken 
macrophages (Barjesteh et al., 2014) and may well be more applicable for 
stimulating chIL-23 p19 mRNA expression in splenocytes. 
7.3 Biological activity of rchIL-23 
Mammalian IL-23 is a heterodimeric cytokine composed of a p19 and p40 subunit 
and is a member of the IL-12 family of cytokines (Oppmann et al., 2000). The full 
differentiation and maintenance of Th17 cells is dependent on IL-23 (Korn et al., 
2009; McGeachy et al., 2009) and it is fundamental to maintain Th17 cells in vitro 
and in vivo (Chen et al., 2011). IL-23-stimulation of splenocytes drives expression of 
IL-17A and IL-17F (Aggarwal et al., 2003). Many in vitro and in vivo studies have 
investigated the biology of IL-23 in human and rodent systems, the findings of which 
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are not always applicable to cytokine function in other species, particularly the bird. 
However, mRNA levels of chIL-17A, chIL-17F and chIL-22 were up-regulated in 
splenocytes stimulated with rchIL-23, demonstrating a bioactivity of rchIL-23 
similar to mammals, and the evolutionary conserved functional importance of this 
molecule. 
7.4 Th17 cytokines in the chicken 
Th17 immune responses in mammals are mediated by the production of pro-
inflammatory effector cytokines such as IL-17A, IL-17F, IL-21 and IL-22, resulting 
in protection from invading microbial pathogens (Korn et al., 2009). The Th17 cell 
subset has not yet been described in birds but several components of Th17 immune 
responses have been identified in the chicken including the main effector cytokines 
chIL-17A, chIL-17F, chIL-21 and chIL-22. Expression of these cytokines was 
investigated in tissues, cells and during infection models in the chicken. Chicken 
Th17 mRNA levels were detected in nearly all tissue sampled although at low 
levels. It is tempting to speculate that expression of these cytokines in such a wide 
variety of tissues suggests that Th17 cytokines are more widely expressed in the 
chicken than in mammals. However, it should be noted that RT-qPCR is a sensitive 
technique. Also, as discussed previously, the high mRNA levels seen in non-
lymphoid tissues may in part be explained by the chicken’s lack of lymph nodes and 
their development of diffuse lymphoid aggregates in organs (Michael and Hodges, 
1974). Consequently, tissues defined in mammals as non-lymphoid contain more 
lymphoid cells in the chicken. Further, it must be borne in mind that expression of 
mRNA does not necessarily correlate with expression of functional protein. As 
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discussed previously, the ubiquitous expression of cytokines and their receptors in 
lymphoid and non-lymphoid tissues, using a sensitive technique such as RT-qPCR, is 
a common finding in the chicken. As such, this work is highly suggestive of the 
chicken mounting Th17 immune responses similarly to mammals and provides the 
basis for further investigation of Th17 cytokine expression in the chicken, eliciting 
which cells express Th17 cytokines under specific conditions in vitro. 
Primary immune cells in the chicken stimulated with mitogens generally up-
regulated expression of the chicken Th17 effector cytokines, with levels decreasing 
over time. These data suggest the chicken Th17 effector cytokines may be expressed 
during Th17 immune responses in the chicken. This is the first time Th17 immune 
responses have been studied in the chicken, therefor , the potential role of clearing 
infection not neutralised by Th1 or Th2 immune responses also required 
investigation. Expression of the Th17 cytokines was investigated during infection in 
the chicken, using archived samples. In chickens infected with MDV, an alphaherpes 
virus that drives Th1 immune responses in the chicken, susceptible line 72 birds 
expressed higher levels of chIL-23 p19, chIL-17A and chIL-21 mRNA compared to 
resistant line 61 birds, suggesting an early involvement of IL-17 immune responses in 
susceptibility to MDV infection (chapter 4). Of the pathogens in mammals known to 
drive Th17 immune responses and, therefore, require a Th17 adaptive response to 
overcome infection, S. aureus infection is currently the only disease model 
established in poultry. In an experimental BCO model, higher levels of chIL-17A 
mRNA were measured in the bone marrow of the wild-type and mutant groups at 6 
dpi compared to uninfected controls, suggesting the possibility of a local chIL-17A 
response to infection. These preliminary studies validate the need for further 
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investigation of Th17 immune responses in the chicken and provide a basis from 
which to do this. 
7.5 Future experiments 
7.5.1 Further understanding of the role of chIL-23 
The discovery of mammalian IL-23 and the revelation of the biology that this 
cytokine governs, led to significant new insights within mammalian immunology 
(Cua et al., 2003; Langrish et al., 2005; Oppmann et al., 2000). IL-23 plays crucial 
roles in orchestrating innate and adaptive immune responses and in the pathogenesis 
of mammalian autoimmunity (Reviewed by Gaffen t al. (2014) and Sutton et al. 
(2012)). Now that the IL-23 p19 subunit has been identified in the chicken, more 
detailed studies of its role in the avian immune response and in disease models is 
possible as well as a comparison of its role in birds compared to mammals. Recent 
work has shown that Th17-like responses appear to take place within a zebrafish 
autoimmune model, indicated by an increase in IL-17 expression, and provide 
evidence that cytokines such as IL-23 are involved in a non-mammalian species 
(Quintana et al., 2010). The development of a mAb, in conjunction with the 
biologically active recombinant protein of chIL-23, would provide reagents to fully 
understand the cells and tissues which express chIL-23. Having the chIL-23 p19 
subunit, along with many of the important cytokines that are expressed by different T 
cell subtypes, will aid future investigations into the types of Th and Treg cells that 
exist in birds. 
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7.5.2 The chIL-23R and chROR γt as potential Th17 cell markers 
T helper cells in mammals, classified as Th1, Th2 or Th17, are identified by 
expression of specific transcription factors and by the cell surface expression of 
specific receptors. Mammalian Th17 cells express IL-23R and it is used in vitro and 
in vivo to identify Th17 cells (Wilson et al., 2007). Having identified the IL-23R in 
the chicken, development of a chIL-23R mAb would further this study by identifying 
cells in the chicken which express this mammalian Th17 cell surface marker. It 
would be worth generating mAbs against chIL-23 and the chIL-23R, because IL-23 
and its receptor are so important for Th17 immune responses in mammals, and most 
of the biological roles of IL-23 and IL-23R in mammals were demonstrated by anti-
IL-23 and anti-IL-23R mAbs. RORγt is the master regulator of transcription for 
mammalian Th17 cells but is not in the current build of the chicken genome. 
Identification of this transcription factor in the chicken would provide another tool 
with which to potentially identify chicken Th17 cells. 
7.5.3 Understanding the role of Th17 immune respons es in the chicken 
This Thesis investigated the expression of Th17 effector cytokines in disease models 
already established as driving Th1 or Th2 immune responses in the chicken. From 
this preliminary data, it is clear that there are Th17 immune responses in the chicken, 
and these Th17 cytokines are possibly expressed during infections previously 
assigned as generating Th1 or Th2 immune responses. However, the role of Th17 
cytokines during infection in the chicken remains uclear. A further MD experiment 
was planned, which involved a longer time course, larger group sizes and additional 
tissue sampling, to study Th17 effector cytokine mRNA levels during MDV 
infection. Unfortunately, there was an outbreak of MD within the unit where the 
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experiment was planned and the study did not go ahead. Whilst research on the 
pathogenesis of MD has come a long way, there are details which remain elusive and 
the potential involvement of Th17 immune responses may highlight methods to 
manipulate the immune response for better protection against the disease. 
The S. aureus pilot study, whilst remaining inconclusive about Th17 involvement, 
suggests the potential role of Th17 cytokines also needs further study. S. aureus is 
known to drive Th17 immune responses in mammals and the results in the chicken 
imply the same may be true. Once an infective dose of S. aureus is established, 
increasing the number of birds, including earlier time points for sampling and 
sampling more tissues, would allow for a more thorough investigation of Th17 
cytokine expression during S. aureus infection. 
7.6 Conclusions 
In summary, IL-23 and the IL-23R, which are vital to Th17 immune responses in 
mammals, are present in the chicken. IL-23, a mammalian cytokine required for full 
differentiation and maintenance of Th17 cells, shows similar biological activity in 
the chicken. Th17 effector cytokine genes are expressed in stimulated lymphoid cells 
and during infection of the chicken. These data confirm that there are Th17 immune 
responses in the chicken. The study of chIL-23, the c IL-23R and the Th17 effector 
cytokines in the chicken, as well as the reagents ad methods established in this 
project, provide useful tools and will aid further investigation of Th17 immune 
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Appendix 1 Buffers and solutions 
QIAprep® spin miniprep kit (Qiagen) 
Buffer P1 (dissolving buffer) 50 mM Tris-Cl (pH8.0), 10 mM EDTA, 
100 μg/ml RNase A  
Buffer P2 (lysis buffer) 200 mM NaOH, 1% SDS (w/v) 
Buffer N3 (neutralising buffer) contains guanidine hydrochloride 
Buffer PB (binding buffer) contains guanidine hydrochloride 
Buffer PE (wash buffer) contains guanidine hydrochlride 
 
EndoFree® plasmid Maxi kit (Qiagen) 
Buffer P1 (dissolving buffer) 50 mM Tris-Cl (pH 8.0), 10 mM EDTA, 
100 μg/ml RNase A  
Buffer P2 (lysis buffer) 200 mM NaOH, 1% SDS (w/v) 
Buffer P3  3 M potassium acetate (pH 5.5) 
Buffer ER contains isopropanol and polyethylene 
glycol octylphenyl ether 
Buffer QBT (equilibrium buffer) 750 nM NaCl, 50 mM OPS (pH 7.0), 
15% isopropanol (v/v), 0.1% Triton®X-
100 
Buffer QC (wash buffer) 1 nM NaCl, 50 nM MOPS (pH 7.0), 15% 
isopropanol (v/v) 
Buffer QN (elution buffer) 1.6 nM NaCl, 50 nM MOPS (pH 7.0), 
15% isopropanol (v/v) 
 
QIAquick PCR purification kit (Qiagen) 
Buffer PB (binding buffer) contains guanidine hydrochloride and 
isopropanol 
Buffer PE (wash buffer) contains ethanol 
 
QIAquick gel extraction kit (Qiagen) 
Buffer QG (dissolving buffer) contains guanidine hydrochloride 
Buffer PE (wash buffer) contains ethanol 
 
RNeasy mini kit (Qiagen) 
Buffer RLT (lysis buffer) contains guanidine hydrochloride 
Buffer RW1 contains guanidine hydrochloride 





Serum-free growth DMEM 
DMEM 
1% 200 nM L-glutamine 
1% 100X Non-essential amino acids 




10% foetal bovine serum 
1% 200 nM L-glutamine 
1% 100X Non-essential amino acids 





1% 200 nM L-glutamine 




10% Chicken serum 
1% 200 nM L-glutamine 








0.5% (w/v) BSA 









Appendix 2 Vectors 
pGEM®-T Easy 
 
Figure 7.1. pGEM®-T Easy plasmid map. 
pCI-neo 
 






Figure 7.3. pTargeT™ plasmid map. 
pcDNA3 
 






Figure 7.5. pcDNA3.1 plasmid map. 
pKW08 
 




Appendix 3 Cells, recombinant protein and antibodie s 
Bacterial strains 
Escherichia coli competent cells, JM109 strain cells: e14-(McrA-) recA1 gyrA96 thi-
1 hsdR17 (rĸ
-mĸ
+) supE44 relA1 ∆(lac-proAB) [F’ traD36 proAB laclqZ∆M15] 
(Stratagene 200235) were used to clone plasmid DNA. 
COS-7 cells 
The COS-7 cell line is a fibroblast-like cell line d rived from African green monkey 
kidney tissue. The COS-7 cell line was derived by immortalising CV-1 cells with a 
defective mutant of the SV40 virus, which can produce large T antigen but has a 
defect in genomic replication itself. It is an adherent cell line that can be transiently 
transfected for high level expression of recombinant protein (Gluzman, 1981).  
Recombinant protein 




















Table 7.2. Antibodies used in this study.  ch = chicken; m = mouse. 
Antigen Species Clone/Subclass Conjugation Supplier/Source 
chCD3 Mouse AV36/IgG1 Unconjugated 
T.F. Davison (Institute for 
Animal Health, Berkshire, 
UK) 
chCD28 Mouse AV07/IgG1 Unconjugated Young et al., 1994) 
chTCR1 Mouse IgG1 FITC Southern Biotech 
Chicken 
monocytes/macrophages 
Mouse KUL01/IgG1 FITC Southern Biotech 
chCD8α Mouse IgG2b PE Southern Biotech 
chBu1 Mouse AV20/IgG1 AF647 Southern Biotech 
chCD4 Mouse CT-4/IgG1 Unconjugated Southern Biotech 
chCD4 Mouse CT-4/IgG1 PE Southern Biotech 
chIL-12p40 Mouse AV134 Unconjugated Balu et al., 2011) 
chIL-12p40 Mouse AV135 Unconjugated Balu et al., 2011) 
chIL-12p40 Mouse AV136 Unconjugated Balu et al., 2011) 













Figure 7.7 Predicted coding nucleotide sequence (2,769 nt) and amino acid sequence (922 aa) of 
chicken IL-23R (GENSCAN00000023581).  Primers designed are underlined. Primers used for 
amplification of chIL-23R cDNA sequence in colour: IL-23R F10 green and IL-23R R1b in blue. 





Table 7.3. Primer sequences for PCR amplification of chIL-23R 














































Figure 7.8. Compiled genome sequence of the chIL-23R gene. Exons are in red and introns are in 
black. Intron splice sites are boxed. Instability motifs (ATTTA) and the polyadenylation signal 
(AATAAA) are underlined. 
